University of Pennsylvania

ScholarlyCommons
Publicly Accessible Penn Dissertations
2017

Design And Synthesis Of Gold Nanoparticle Contrast Agents For
Atherosclerosis Imaging With Computed Tomography
Peter Chhour
University of Pennsylvania, pchhour@gmail.com

Follow this and additional works at: https://repository.upenn.edu/edissertations
Part of the Biomedical Commons, and the Nanoscience and Nanotechnology Commons

Recommended Citation
Chhour, Peter, "Design And Synthesis Of Gold Nanoparticle Contrast Agents For Atherosclerosis Imaging
With Computed Tomography" (2017). Publicly Accessible Penn Dissertations. 2221.
https://repository.upenn.edu/edissertations/2221

This paper is posted at ScholarlyCommons. https://repository.upenn.edu/edissertations/2221
For more information, please contact repository@pobox.upenn.edu.

Design And Synthesis Of Gold Nanoparticle Contrast Agents For Atherosclerosis
Imaging With Computed Tomography
Abstract
Cell tracking offers the opportunity to study migration and localization of cells in vivo, allowing
investigations of disease mechanisms and drug efficacy. Monocytes play a key role in the progression of
atherosclerotic plaques in the coronary arteries. While x-ray computed tomography (CT) is commonly
used to clinically assess coronary plaque burden, cell tracking with CT is mostly unexplored. The
establishment of monocyte cell tracking tools would allow for the direct investigation of gene and drug
therapies aimed at monocyte recruitment in atherosclerosis. In this thesis, we present the design and
optimization of gold nanoparticles as CT contrast agents for cell tracking of monocyte recruitment to
atherosclerotic plaques. Gold nanoparticle polymer constructs with controlled localization are evaluated
as potential monocyte labels. However, cytotoxic effects were observed at concentrations necessary for
cell labeling. Therefore, variations in physical and chemical properties of gold nanoparticles were
explored as cell labels for monocyte tracking. Each formulation was screened for effects on cell viability,
cell function and uptake in monocytes. The uptake in monocytes revealed a complex relationship with
nanoparticle size behavior dependent on the surface ligand used. This led to the selection of an optimal
size and coating for monocyte labeling, 11-mercaptoundecanoic acid coated 15 nm gold nanoparticles.
This formulation was further investigated for cell viability, function, and uptake with isolated primary
monocytes. Moreover, primary monocytes labeled with this formulation were used to observe monocyte
recruitment in atherosclerotic mice. Mice with early atherosclerotic plaques received intravenously
injections of gold labeled monocytes and their recruitment to plaques were observed over 5 days with CT.
Increases in CT attenuation in the plaque and transmission electron microscopy of plaque sections
indicated the presence of gold labeled monocytes in the plaque. These results demonstrate the feasibility
of using CT to track ex-vivo labeled cells non-invasively with CT and could further be used to investigate
drugs aimed at modulating monocyte recruitment in the treatment of atherosclerosis. This work expands
the applications of cell tracking and may lead to additional uses in other diseases.
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ABSTRACT

DESIGN AND SYNTHESIS OF GOLD NANOPARTICLE
CONTRAST AGENTS FOR ATHEROSCLEROSIS IMAGING WITH
COMPUTED TOMOGRAPHY
Peter Chhour

David P. Cormode, D.Phil.

Cell tracking offers the opportunity to study migration and localization of cells in
vivo, allowing investigations of disease mechanisms and drug efficacy. Monocytes play a
key role in the progression of atherosclerotic plaques in the coronary arteries. While xray computed tomography (CT) is commonly used to clinically assess coronary plaque
burden, cell tracking with CT is mostly unexplored. The establishment of monocyte cell
tracking tools would allow for the direct investigation of gene and drug therapies aimed
at monocyte recruitment in atherosclerosis. In this thesis, we present the design and
optimization of gold nanoparticles as CT contrast agents for cell tracking of monocyte
recruitment to atherosclerotic plaques. Gold nanoparticle polymer constructs with
controlled localization are evaluated as potential monocyte labels. However, cytotoxic
effects were observed at concentrations necessary for cell labeling. Therefore, variations
in physical and chemical properties of gold nanoparticles were explored as cell labels for
monocyte tracking. Each formulation was screened for effects on cell viability, cell
function and uptake in monocytes. The uptake in monocytes revealed a complex
relationship with nanoparticle size behavior dependent on the surface ligand used. This
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led to the selection of an optimal size and coating for monocyte labeling, 11mercaptoundecanoic acid coated 15 nm gold nanoparticles. This formulation was further
investigated for cell viability, function, and uptake with isolated primary monocytes.
Moreover, primary monocytes labeled with this formulation were used to observe
monocyte recruitment in atherosclerotic mice. Mice with early atherosclerotic plaques
received intravenously injections of gold labeled monocytes and their recruitment to
plaques were observed over 5 days with CT. Increases in CT attenuation in the plaque
and transmission electron microscopy of plaque sections indicated the presence of gold
labeled monocytes in the plaque. These results demonstrate the feasibility of using CT
to track ex-vivo labeled cells non-invasively with CT and could further be used to
investigate drugs aimed at modulating monocyte recruitment in the treatment of
atherosclerosis. This work expands the applications of cell tracking and may lead to
additional uses in other diseases.
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Chapter 1: Introduction to cardiovascular disease, computed
tomography and nanoparticle contrast agents
1.1 Introduction
The development of nanotechnology has presented new potential solutions to
biomedical problems. Via control over a nanoparticle’s physical and chemical properties,
it can be specifically tailored to a given biomedical application. These properties
influence how the nanoparticles interact with cells and the surrounding biological
environment. As a result, nanotechnology has been involved in applications for drug
delivery, gene delivery, adjuvants for cancer therapy and medical imaging. In particular,
cell tracking has emerged as a methodology to observe cell behavior in vivo. The ability
to detect migration, viability and localization of nanoparticle labeled cells has become of
interest with the emergence of stem cell and immuno-cell therapy. Additionally, cell
tracking presents an opportunity to study specific disease mechanisms in conditions
such as cardiovascular disease (CVD).
X-ray computed tomography is the most commonly used imaging modality to
detect and diagnose CVD in patients due to its high spatial and temporal resolution.
However, the current CT contrast agents used for CVD imaging have a number of
limitations including fast clearance, potential adverse reactions, and non-specific
localization. The use of iodinated nano-structures and inorganic nanocrystals has shown
initial success in mitigating the issues mentioned above. Furthermore, the use of CT
contrast agents for cell tracking remains largely unexplored, prompting the need to
develop cell tracking CT contrast agents for investigating CVD.

Herein, we propose and evaluate the design of gold nanoparticle formulations for
optimal labeling of monocytes for non-invasively tracking of their recruitment into
atherosclerotic plaques with CT. Complications from atherosclerosis remain the leading
cause of death in CVD and monocyte recruitment into plaques plays a large role in the
progression of the disease. We hypothesized that large nanoparticles with high payloads
would be effective for giving monocytes high loading, to allow their detection with CT.
We therefore developed and characterized large (~500 nm) polyphosphazene
nanospheres containing high payloads of nanocrystals including gold and iron
nanoparticles. We found loading of the nanocrystals could be selectively localized to the
core or surface without disrupting the diagnostic function of the nanoparticle (Chapter 2).
However at incubation concentrations necessary for sufficient cell loading for in vivo
detection with CT, cytotoxicity towards monocytes was observed. We next sought to
investigate the potential of gold nanoparticles that were not encapsulated in
polyphosphazene for labeling monocytes. We studied the effect of gold nanoparticle size
and coating on monocyte labeling (Chapter 3). We synthesized particles ranging from 15
to 150 nm and characterized their viability and uptake in monocytes. We found the
coating of the gold nanoparticle affected the relationship between size and gold uptake
in monocytes suggesting a unique size relationship for each coating examined. Since
maximal cell loading could be achieved with 15 nm gold nanoparticles, we chose them
for further study. We investigated the biocompatibility of 15 nm gold nanoparticle
formulations with both a monocyte cell line and primary monocytes. After selecting an
optimal formulation, we were able to detect the recruitment of gold labeled monocytes to
atherosclerotic plaques in mice using x-ray computed tomography (Chapter 4). The
results indicate the feasibility of non-invasively tracking the localization of gold labeled
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cells using computed tomography. In this chapter, we detail the progression of
atherosclerosis, the current state of CT technology, and the state of the art use of
nanoparticles as CT contrast agents.

1.2 Background
1.2.1 Cardiovascular disease
1.2.1a Overview
Cardiovascular diseases (CVD) are the leading cause of death, accounting for
nearly 1 in 3 deaths in the developed world today. Worldwide, CVD accounted for 17.3
million deaths in 2013 which is expected to increase to 23.6 million by 2030. 1 In the
United States, approximately 35.1% of adults have at least one cardiovascular disease,
and this number is expected to rise to 43.9% by 2030.2 This rise in prevalence is
expected due to increase of factors such as physical inactivity, poor nutrition, and
obesity. Cardiovascular disease is a broad definition that covers several pathologies
including stroke, high blood pressure, heart failure, and coronary artery disease (CAD).
Nearly half of the total deaths from CVD arise from CAD which includes angina pectoris
(chest pain), atherosclerosis of the coronary arteries, myocardial infarction, and ischemic
heart disease.3 These underlying causes of these conditions is the development of
atherosclerosis in the coronary arteries that lead to narrowing of the arteries and
potential blockage from rupture.
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1.2.1b Coronary arterial disease
Coronary artery disease is the progression of atherosclerosis in the coronaries
such that it leads to clinical manifestations, i.e. ischemic heart disease and myocardial
infarction. Atherosclerosis is prevalent in areas of high oscillatory flow and low
endothelial shear stress, indicating that initiation of atherosclerosis may be due to
localized mechanical stresses.4-5 These local flow conditions allow for the accumulation
of circulating low density lipoproteins (LDL) into the intima. Oxidation of these LDL
particles leads to the activation of the endothelium, increasing the expression of surface
adhesion molecules.6-7 Increased expression of vascular cell adhesion molecule (VCAM)
and intercellular adhesion molecules (ICAM) promote the adherence of circulating
leukocytes.8-10 Subsequently, a chemokine gradient drives the migration of these
adhered leukocytes into intima. Inflammatory monocytes play a key role in the
progression of atherosclerosis and have been found to be recruited into the intima
through chemokine gradients for MCP-1 (CCR2 receptor), fractalkine (CX3CR1
receptor), and CCL5 (CCR5 receptor).11-13 In the intima, monocytes differentiate into
phenotypical macrophages and begin engulfing oxidized LDL particles. These lipid
particles accumulate in the macrophages, eventually becoming foam cells, which are
thus named due to their appearance under microscopy.14 Foam cells promote the
destabilization of the surrounding extracellular matrix (ECM) through the release of
proteolytic enzymes, including matrix metalloproteinases (MMP) and cathepsins.15 The
chronic build up of foam cells and other cells, such as altered smooth muscle cells
migrating from the media, increases the chances of plaque rupture.16
The development of plaques may eventually lead to their rupture, which releases
the contents of the plaque into the circulation as depicted in Figure 1.1. The contents of
4

the plaque such as necrotic cells and cell debris induce the formation of a thrombus,
which can occlude the artery.17 Such an occlusion occurring in the coronary artery can
result in an acute myocardial infarction (MI). The myocardium downstream of the
occlusion may become ischemic, which can lead to necrosis. Resolution of the occlusion
can lead to increased incidence of a secondary cardiac event for patients resulting from
weaken structural integrity of the affected myocardium. Management of wound healing
after a MI is critical for improved prognosis for patients.

Figure 1.1 Progression of atherosclerosis in artery.
Illustration of plaque build up and progression to stabilized plaque or rupture. Continued
accumulation of lipids in the intima can lead to a thin fibrous cap, increasing risk of
rupture. Plaque rupture in the coronary artery leads to the formation of thrombus and an
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occlusion of the artery i.e. myocardial infarction. Reproduced with permission from Libby
et al. (2002).15

1.2.1c The role of monocytes in coronary arterial disease
Monocytes play a central role in both the progression of atherosclerosis in the
coronary arteries and wound healing of the myocardium after a MI as shown in Figure
1.2. In both instances, the function of the monocytes depends on their subtype.
Monocytes are frequently divided into two subtypes via differential marker expression. In
humans, classical inflammatory monocytes are described by the cell surface expression
of CD14++CD16- markers.18 Conversely, resident monocytes are characterized by their
expression CD14+CD16+.19 These two distinct monocyte subpopulations have been
found to be conserved across species, with Ly6C+ and Ly6C- cell surface markers
describing inflammatory and resident murine monocyte populations, respectively. 20
These subtypes are also classified by the relative expression of CCR2, a chemokine
receptor involved in recruitment of inflammatory cells.21-22 This receptor plays a
prominent role in the migration of inflammatory monocytes to inflamed tissue.
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Figure 1.2 The role of monocytes in atherosclerosis progression.
Monocytes are actively recruited into the arterial wall in developing plaques through
active chemokine gradients. In the arterial wall, monocytes differentiate in macrophages
and engulf LDL, becoming foam cells. Foam cells promote plaque destabilization and
rupture. After rupture and occlusion of coronary arteries, monocytes are recruited to
injured tissue for repair and wound healing. Reproduced with permission from Ghattas et
al. (2013).23

In the progression of arterial disease, the activation of the endothelium increases
the adherence of circulating leukocytes including monocytes. Inflammatory monocytes
migrate through the endothelium facilitated by the expression of surface receptors
CCR2, CX3CR1 and CCR5.24-25 The release of chemokines corresponding to these
receptors (MCP-1, fractalkine, CCL5) drives the chemokine gradients and subsequent
migration. In the intima, monocytes differentiate into macrophages and begin engulfing
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oxidized low density lipoproteins.26-27 The initial recruitment of monocytes populates
lesional macrophages early in plaque formation. However in established plaques, the
majority of the macrophages are due to local proliferation. 28-29 With the accumulated
LDL, the macrophages become phenotypical lipid-laden foam cells releasing cytokines
and metalloproteinases that contribute to plaque destabilization.30-31 The accumulation of
foam cells gives rise to lesion formation and eventual plaque rupture.
A plaque rupture in the coronary arteries leads to the formation of a thrombus
and potential occlusion of the vessel. The blockage of the coronary arteries is a
myocardial infarction also known as a heart attack. The role of monocytes in wound
healing after a myocardial infarct is critical to the long term clinical outcome. Monocytes
are necessary to clear necrotic tissue from the site as well as promote the repair of the
tissue. After an infarct monocytes are recruited from circulation to the injured area for
repair for up to two weeks.32 The recruitment of monocytes has been hypothesized to be
a biphasic response with separate monocyte subtypes dominating at each phase.
Nahrendorf et al proposed that in the first 1-4 days following the infarct, inflammatory Ly6c+ monocytes are the major recruitment subtype, promoting clearance through
phagocytosis and enzymatic digestion. Onward from day 4, reparative Ly-6c- monocytes
appear to be the actively recruited subtype for wound healing through anti-inflammatory
cytokines and growth factors.33 Similar to the recruitment to plaques, monocyte
recruitment to the infarcted area is mediated through the chemokine receptors CCR2,
CX3CR1, and CCR5. Moreover, it was proposed that the biphasic recruitment is due to a
shift in the expression of ligands specific to these receptors by the infarct tissue. The
production of MCP-1 (CCR2 ligand) promotes Ly-6c+ recruitment during “phase 1,” and
fractalkine (CX3CR1 ligand) expression promotes Ly-6c- recruitment during “phase 2.”33
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Studies have shown that increased recruitment of Ly6c+ can lead to improper healing
outcomes such as left ventricular dilation that can manifest into future clinical
cardiovascular events.34-36 Therefore, proper accumulation of monocyte population in
each phase after a myocardial infarct is critical to understanding infarct healing.

1.2.2 Imaging of coronary arteries
1.2.2a Introduction
Coronary artery disease is a chronic condition, typically developing for decades
before becoming symptomatic. While symptoms may differ in patients, a common early
indicator for CAD is chest pain i.e. angina pectoris. Risk factors such as age, sex,
weight, smoking, and hypertension are used to determine the risk of CAD for patients
with chest pain.37 Patients with high risk undergo electrocardiography for evidence of
ST-T wave changes or LV hypertrophy. If abnormalities are present, further evaluation is
necessary to determine extent of the CAD and risk of a cardiac event. 38-39 A coronary
angiogram is a commonly used method to assess the location and severity of the arterial
plaques. To perform a coronary angiogram, a catheter is fed to the coronary arteries and
an iodinated dye is released. X-ray is used to observed the location and extent of
stenosis in the coronary arteries. Coronary angiography also allows for stent and
angioplasty intervention in the cases that call for revascularization. There is interest in
developing imaging tools to non-invasively characterize plaque severity where magnetic
resonance imaging (MRI), positron emission tomography (PET), and x-ray computed
tomography (CT) are utilized.
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MRI provides excellent soft tissue contrast, but suffers from long image
acquisition times, preventing imaging of the coronary arteries from being performed in a
single breath hold (which is needed to limit the impact of respiratory motion). Moreover,
MRI of the coronary arteries lacks information on plaque calcification and cannot
quantify the extent of the disease.40 MRI is not routinely used for coronary artery imaging
in clinical practice. PET can provide functional cardiac information with the use of
radioisotope contrast agents.41 Radiolabeled contrast agents typically have short-halflives, which increases the complexity of their distribution from production centers. The
use of PET for coronary artery disease in the research field continues to expand, but still
remains extremely limited clinically.42 18F-fluorodeoxyglucose (18F-FDG) has been used
as a macrophage marker and subsequent marker of inflammation in atherosclerosis.43
However, the low spatial resolution of PET has caused concern about reliability when
quantifying 18F-FDG uptake in the coronary plaque.44 18F-sodium fluoride has also
been explored as a PET marker for arterial calcification.45 For both contrast agents, low
spatial resolution, motion and off-target uptake typically limits PET studies to evaluation
of plaque only in larger arteries such as the carotids or thoracic aorta. As we will explain
below, the modality of choice for clinical imaging of coronary artery disease is CT.

1.2.2b CT principles
CT has unique advantages for visualizing the coronary arteries that make it an
excellent modality for this application. CT relies on x-rays that are produced by
accelerating electrons from a cathode towards an anode, which is typically made of
tungsten. The impact of the electrons, depending on their energy, produces x-rays in the

10

form of bremsstrahlung and characteristic radiation. In bremsstrahlung radiation, the
incoming electron path is diverted by interaction with the nuclei, converting lost kinetic
energy into an x-ray. In the case of characteristic radiation, the incoming electron ejects
an inner-orbital electron of the atom. An electron from an outer orbital fills the vacancy
while releasing a characteristic x-ray. For imaging applications, x-rays from the
generating source interact with the object of interest in two primary mechanisms,
Compton scattering and the photoelectric effect (Figure 1.3a). For Compton scattering,
the incoming x-ray transfers a portion of its energy to an outer shell electron which
causes the x-ray to scatter in a different direction. For CT energy levels, the primary form
of interaction between x-rays and the subject is the photoelectric effect. The incoming xray ejects an inner shell electron of the atom, typically of the k or l shell. An outer shell
electron fills the inner-shell vacancy and produces a characteristic x-ray. The
photoelectric effect occurs when the energy of the incoming x-ray is higher than the
binding energy of the inner-shell electron, also known as the k-edge or l-edge energy.
The photoelectric effect produces a significant jump in mass attenuation, improving
contrast for imaging (Figure 1.3b). For CT contrast agents, imaging with peak voltages
higher than the k-edge energy of the x-ray attenuating agent improves contrast
enhancement between the agent and surrounding tissue. X-ray attenuation is quantified
by the Hounsfield scale which defines Hounsfield units (HU) = 1000 * (µ- µwater)/(µwater µair), where µ is the linear attenuation coefficient of the corresponding material. The
Hounsfield scale standardizes the attenuation of a material in reference to the
attenuation of water (HU= 0) and air (HU= -1000).
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Figure 1.3 X-ray interaction with materials.
(a) Incoming x-rays interact with matter via coherent scattering, Compton scattering, and
photoelectron effect depending on the energy of the incident x-ray. At CT energy levels,
the primary interaction is the photoelectron effect, where inner shell electrons are
ejected and characteristic x-rays are produced. (b) For high Z-elements, ejection of inner
shell (k or l shells) electron produces a spike in attenuation of x-ray, allowing for strong
discrepancy between materials. Reproduced from with permission from Lee et al.
(2013).46

1.2.2c Current CT technologies
Due to its non-invasive qualities and comparable effectiveness in predicting CAD
in patients, the use of CT angiography has begun to rival coronary angiography in the
12

emergency room.47-48 The coronary arteries in humans are approximately 4-5 mm in
diameter proximally, tapering rapidly to less than 1 mm, mandating high spatial
resolution for imaging. A variety of adjustable factors, including slice thickness,
reconstruction parameters, and field of view can affect spatial resolution in CT; most
modern scanners are capable of producing resolution of 0.5 mm or less in each
dimension.49 Moreover, cardiac and respiratory motion can be overcome by the fast
temporal resolution of CT and a volume coverage allowing imaging of the entire heart to
be acquired in a single breath hold. Increases in the number of detectors and
improvement in gantry rotation speed in CT scanners has considerably improved the
temporal resolution over the past two decades. Modern clinical 64-detector CT systems
are capable of sub-200 ms resolution,50 while the newest CT scanners are capable of
sub-100 ms temporal resolution.51 Synchronization of the acquisition to the
electrocardiogram (ECG) signal can be used to reduce artifacts from heart motion. 52
ECG synchronization can be performed using two methods, prospective triggering and
retrospective gating. Prospective triggering acquires images at a pre-defined portion of
the R-R interval, while retrospective gating acquires images throughout the cardiac
cycle, allowing for image reconstruction at any phase of the heartbeat, but at the cost of
a higher radiation dose.
CT can quickly image the coronary arteries and exclude coronary artery disease
from patients presenting with chest pain.53-55 CT allows for post-processing of crosssectional scans to create improved visual information, such as 3D renderings of
coronary arteries.56 The applications of cardiac CT for plaque characterization include
calcium scoring, determination of non-calcified plaque volume and extent of stenosis.57
These parameters can be assessed with CT angiography (CTA), a non-invasive CT
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scan using contrast agents to visualize arterial flow. The plaque characteristics that can
be derived from CTA can be used to identify patients at high risk of a significant cardiac
event. High risk plaque features that can be visualized with CTA include stenosis ≥ 50%,
positive remodeling, low HU, napkin ring sign, and spotty calcium. 58 A novel application
of cardiac CT angiography is noninvasive determination of the hemodynamic
significance of an observed stenosis. Fractional flow reserve (FFR) describes the
pressure difference across an arterial stenosis as compared to the pressure in the
absence of a stenosis and can be measured directly with catheter angiography.59
However, advancements in computer modeling has allowed calculations of fluid
dynamics from CTA scans for accurate determination of coronary flow and pressure
without the need for an invasive procedure. CTA-derived computational models of FFR
have been shown to have higher accuracy of determining the impact of stenoses than
CTA based measurements of stenosis dimensions alone.60 The myocardium can also be
visualized with high resolution allowing for detection of abnormal morphology in the
chambers of the heart and valves.61 Moreover, the degree of injured myocardium after
an infarct can be determined due to the changes in the thickness and/or scar formation
of the myocardium.62

1.2.2d Developing CT technologies
Advancements in x-ray CT technology are allowing for new potential clinical
indications. Most commonly, CT images have been reconstructed using back filtered
projection to create 3D datasets. With increases in computing power, iterative
reconstruction methods have become available, allowing for improved signal to noise
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ratios (SNR) as compared to current reconstruction methods i.e. back filtered
projection.63 With improved SNR, similar image quality compared to back filtered
projection reconstructions are achievable with less radiation dose.64 Various models of
iterative reconstruction have been compared to filtered back projection, and lower image
noise was consistently observed for identical CT imaging parameters. 65 Iterative
reconstruction could therefore be a boon for cardiothoracic imaging where image quality
can suffer from motion artifacts, obese patients, calcium artifacts, and blooming from
stents.66 Researchers have found that the improved image quality leads to more
accurate diagnoses with iterative reconstruction compared to filtered back projection for
coronary CT angiography.67-68 While various iterative reconstruction models are
available, further experimental validation is needed before wider adoption. There is also
current exploration for the use of iterative reconstruction methods to improve CT
sensitivity towards contrast agents.69 Improving CT sensitivity to contrast agents may
further enable CT applications such as cell tracking.
Multi-color or spectral computed tomography is an emerging CT technology
capable of distinguishing different elements based on their x-ray absorption at different
energies. This technology works by exploiting the x-ray absorption at the k-edge of high
Z-elements and creating discrete photon energy bins.70 By separating the incoming
photons by energy, multiple materials can distinguished in a single scan. 71 This
technology allows for material decomposition which results in material-specific images,
providing additional information compared with current CT scanners. Additionally,
spectral CT can offer new benefits for CT contrast agents due to material
discrimination.72-73 Specifically, this technology allows for quantification of localized
contrast agents and the possibility of discriminating multiple contrast agents in a single
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scan.74-75 The use of contrast agents for CT can benefit from both of these emerging
technologies, with the aim to improve CT sensitivity for contrast agents and expand
detection capabilities of current CT scanners.

1.2.3 CT cardiovascular contrast agents
1.2.3a Introduction
CT contrast agents play a key role in cardiovascular CT scans; the use of
contrast agents in CT can improve the delineation between different soft tissues and is
critical for highlighting blood vessels. The primary mechanism for x-ray attenuation in CT
is the photoelectric effect. At CT energy levels (25-140 keV), incoming x-rays have
enough energy to interact and eject inter-shell electrons (k or l shell) of the atom.
Ejection of a k-shell electron produces a significant increase in x-ray attenuation and
allows for increased separation between tissue and contrast media. For this reason, CT
contrast agents are typically high atomic number elements such as iodine, barium, gold,
bismuth, and lanthanides that have l and/or k edges that are at much higher energies
than tissue and are closer to diagnostic x-ray energies (Table 1.1). However, CT suffers
from low sensitivity to contrast agents, typically requiring millimolar local concentrations
to produce contrast that can be distinguished from the background.76
Table 1.1 Characteristics of elements commonly used to form CT contrast agents.
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Clinically, iodinated contrast agents (ICA) can be used to visualize the
vasculature as well as organs such as the brain, heart, liver, and kidneys.77-79 Clinical
ICA are small molecules that are based on a tri-iodinated benzene ring (Figure 1.4).
These types of structures have reduced osmolality and toxicity compared with iodide ion
based agents. These iodinated rings are typically functionalized with amides and alcohol
groups to provide water solubility, and can be monomers or dimers. These agents can
be further categorized into ionic and non-ionic formulations which yield different
properties in terms of toxicity and clearance from the blood stream. Regardless of the
molecular structure of these agents, clinically approved ICA suffer from rapid renal
clearance from the circulation after intravenous injection, on the order of minutes. 80
Given this rapid clearance, large amounts of contrast agent are often used for prolonged
or multiple CT scans, with doses of 150 ml being used routinely. 811 Injecting large
volumes of ICA increases the chance of severe renal impairment, known as contrast
induced nephropathy, in specific patient populations.82 Contrast-induced nephropathy is
more likely in patients with pre-existing renal dysfunction,83 who now compose 26% of
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the US population over 65.84 This proportion is expected to increase in the coming years,
since renal dysfunction is common in diabetics and the prevalence of diabetes is
predicted to rapidly rise.85-86 Iodinated contrast agents also can commonly cause
adverse reactions in patients ranging from mild symptoms including nausea and
vomiting to severe reactions such as anaphylaxis.87

Figure 1.4 Common used iodinated small molecules.
Tri-iodinated benzene ring based compounds that are clinically used as CT contrast
agents. Variations include (a) ionic monomers, (b) non-ionic monomers, (c) ionic dimers
and (d) non-ionic dimer. Reproduced from with permission from Lee et al (2013).46

As mentioned, iodinated small molecule contrast agents are the most widely
used class of agent in clinical CT scanning. While different formulations (ionic vs nonionic, dimer vs monomer) have slightly differing biocompatibility properties, they continue
to suffer from rapid clearance and the risk of adverse reactions.87 Researchers have
turned to nanotechnology to improve the properties of iodine-based agents.
Incorporation of iodinated agents into nanoparticles such as nano-emulsions, micelles,
liposomes, dendrimers have resulted in improvements in circulation time and
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biocompatibility. The structures of some of the nanoparticle agents used as CT contrast
agents are displayed in Figure 1.5. Long blood circulation times of contrast agents may
help to improve the assessment of cardiovascular health. A long circulating agent can
also decrease the total dose necessary for an imaging procedure, potentially reducing
the burden of the agent on the patient. The use of a blood pool contrast agent for CT
may provide information about coronary artery disease and progression, allowing
visualization of the extent of stenosis in an artery as well as calcified and non-calcified
plaques.88 Use of a contrast agent also allows for assessment of cardiac functions such
as ejection fraction and stroke volume.49 In addition, contrast agents are needed to
highlight blood vessels during stent placement procedures. Below, we further explore the
current state of CT contrast agents including iodinated nanotechnologies and inorganic
nanoparticles.

Figure 1.5 Nanotechnologies used for contrast agent development.
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Schematic representations of some of the nanoparticle platforms used to incorporate
iodinated agents and inorganic nanocrystals for improved biocompatibility and biological
function. Reproduced with permission from Mulder et al (2005).89

1.2.3b Iodinated nanoparticle contrast agents
To incorporate iodinated agents into nanoparticles, researchers have turned to a
number of different nanotechnology platforms, each with their own advantages.
Predominately, iodinated agents have been encapsulated or conjugated to oils and lipids
to form these nanoparticles. One such platform is nano-emulsions, where the core of the
particle contains iodinated oils. Nano-emulsions can be formed via simple methods that
produce stable iodinated particles and have been an attractive choice for iodinated
contrast agents. An emulsion is formed with a suitable amphiphilic surfactant
encapsulating an iodinated oil core. An iodinated oil called Lipiodol (also known as
Ethiodol) is FDA approved and consists of iodine combined with ethyl esters of poppy
seed oil.90 Because Lipiodol is hydrophobic, it has limited clinical uses (it is used as an
agent for lymphangiography and trans-arterial chemoembolization).91-92 To expand the
applications of Lipiodol as a blood pool agent, Pluronic F127 and a polyethylene glycol
(PEG) diamine was used to encapsulate Lipiodol into a nano-emulsion.93 These
particles, 150 nm in diameter, were shown to be thermodynamically stable and produce
vascular CT contrast in the ventricles and major arteries for up to 4 hours.
Nano-emulsions have also been reported where a mixture of phospholipids and
cholesterol was used to surround the hydrophobic core, which consisted of iodinated
triglycerides. A nano-emulsion formed with endogenous oils and lipids was
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demonstrated as an effective contrast agent for hepatic imaging and is available as a
commercial product known as Fenestra LC®.94-95 The iodinated triglycerides making up
the core of this nano-emulsion are rapidly metabolized by the liver.96 To provide longer
circulation as a blood pool contrast agent, the agent has been reformulated with PEG
included at the surface of the particle to reduce uptake by hepatocytes, which is known
as Fenestra VC®.97-98 As a blood pool agent, Fenestra VC® has been used to study
cardiac function in mice, quantifying ejection fraction, stroke volume, and cardiac
output.99 In this study, Fenestra VC® provided vascular contrast for 3 hours with a nearly
500 HU value difference between the blood and myocardium. Moreover, with the use of
Fenestra VC®, Detombe et al., studied cardiac function and ventricular remodeling in a
mouse model of myocardial infarction. The group was able to assess systolic and
diastolic volumes and ejection fraction non-invasively over the course of 4 weeks after
myocardial infarction.100 Both studies utilized cardiac gating with micro-CT to quantify
cardiac function accurately.
While Fenestra formulations have been used successfully for cardiac
applications, relatively poor inclusion of iodine by weight means that very large volume
administrations of the agent are required (up to 40% of total blood volume). To
overcome this issue, researchers have used denser iodinated oils to improve iodine
content in the formulations. Using, a dense, tri-iodinated oil, de Vries et al., formed nanoemulsions using the amphiphilic polymer, poly(butadiene)-b-poly(ethylene oxide) (PBDPEO).101 The agent was able to provide strong vascular contrast in the chambers of the
heart of up to 220 HU directly after administration. Attenuation of the liver and spleen
remained at high levels over the three hour observation period suggesting the
mononuclear phagocytic system as the main clearance pathway for the agent. Novel
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approaches to increasing the density of iodinated oils continue to be explored.102-103 For
instance, Attia et al. reported agents that contain up to 65% wt. of iodine via use of a
hexa-iodinated monoglyceride and a PEGylated nonionic surfactant.98 This formulation
showed clear delineation of the major arteries and heart chambers post-injection with a
long circulation half-life of 6.1 hours.
Micelles are similar to nano-emulsions, in that they are self-assemblies of
amphiphilic molecules where the hydrophilic head groups point outwards and the
hydrophobic tails point inwards (Figure 1.5). The main difference between emulsions
and micelles is that there is not an oil core for micelles. Therefore, to form micelle-based
CT contrast agents, iodinated molecules are typically linked to the hydrophobic tails of
the amphiphiles, concentrating the iodinated moieties into the center of the micelle. This
allows for high iodine payloads.104 There have been several reports of iodinated micelles
used as blood pool contrast agents.105 Torchilin et al. reported the synthesis of micelles
using

iodine

containing

poly-l-lysine

(MPEG-iodolysine).

The

micelles

were

approximately 80 nm in diameter with 33.8% iodine content. The agent was injected
intravenously and allowed for CT imaging of the aorta, heart, liver and spleen for up to 3
hours post-injection in rats.106
While nano-emulsions and micelles can carry hydrophobic contrast media,
liposomes are versatile platforms that can carry both aqueous and hydrophobic
payloads. Liposomes are synthesized through the use of amphiphilic lipids or polymers
that self-assemble into bilayers. This architecture allows for encapsulation of hydrophilic
agents in the core as well as hydrophobic agents in the bilayer. One of the first liposomal
iodinated contrast agents was synthesized using L-α-phosphatidylcholine and was
loaded with a number of different aqueous iodinated agents.107 The agent was injected
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intravenously as a blood pool contrast agent. Uptake of the liposome was seen in the
liver and spleen in a dose dependent manner with maximum attenuation of 240 HU seen
at 1 hour. Because these early liposomes provided strong contrast of the liver and
spleen, it was primarily used to visualize tumors in these organs.108-109
With improvements to liposome design, most notably the modification of
amphiphilic lipids/polymers with PEG, the diagnostic applications of liposomal contrast
agents expanded. The addition of PEG to liposomal formulations allows for significantly
increased blood circulation times improving their utility as blood pool agents. 110-111 One
of the earliest reports of PEGylated liposomes, PEG-phosphatidylethanolamine (PEGPE) liposomes, found that the addition of PEG increased the blood circulation time to up
to 5 hours as compared to 30 minutes for non-PEGylated formulations.112 Iodinated
PEGylated liposomes have been successful in providing strong vascular contrast of up
to 900 HU in the aorta, as reported in a study by Mukundan et al.113
With the use of liposomes, a significant issue is the leakage of internal payloads
through the lipid bilayer. Hydrophilic payloads have been found to diffuse through
bilayers due to chemical gradients. To overcome this issue, some groups have added
cholesterol to liposome formulations, which reduces the permeability of the liposome and
thereby decreases payload leakage.114-115 Additionally, direct iodination of the lipids used
to form the liposome can be used to prevent internal leakage, since covalently binding
iodine onto lipid constrains the contrast generating material in the bilayer.116
Moreover by incorporating iodinated molecules into the lipid bilayer, the aqueous
core can carry a separate payload including drugs for theranostics applications, another
imaging agent for multi-modal imaging, or more of the same agent for increased payload
delivery. A study by Kweon et al., reported liposomes that were simultaneously loaded
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with iodinated contrast into both the core and lipid bilayer.117 1,2-dimyristoyl-sn-glycero3phosphocholine (DMPC), cholesterol, and Lipiodol were mixed together, freeze-dried
and resuspended with a solution containing iopamidol to form the liposomes. As
mentioned above, cholesterol increases the rigidity of the lipid membrane decreasing
leakiness of the liposomes. This dual loading procedure produced particles about 280
nm in diameter, and a solution whose iodine concentration was 49.2 mg/ml. Inclusion of
both Lipiodol and iopamidol was found to improve iodine content in the nanoparticle
solution over either payload alone. Intravenous injection of the liposome produced strong
contrast in the aorta after injection and was observed for up to 2.5 hr. Because of the
lack of PEG in the formulation, high uptake was seen in the liver and spleen, resulting in
attenuation values of up to 684 HU for the spleen. This study demonstrates the
versatility of liposomes for contrast agent delivery.
Dendrimers are another platform that has been used to develop contrast agents
for computed tomography. Dendrimers are polymeric molecules formed through
sequential branched growth steps termed “generations”. Each generation exponentially
increases the number of branches, isolating the core from the external environment.
Additionally, the last generation of the branched sequence can be functionalized to
confer specific properties to the dendrimer. The branched structure provides excellent
molecular stability and can provide many sites for functionalization at the ends of the
branches.118 Dendrimers synthesized using poly(amido amine) (PAMAM) allow for
functionalization through amine groups at the available termini of the molecule. By
conjugating triiodobenzenepropanoic acid (DMAA-IPA) onto a PAMAM dendrimer,
Yordanov et al. were able to incorporate up to 33% iodine content by weight.119 Large
dendrimers are often quickly cleared through the mononuclear phagocytic system,
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however Fu et al. reported dendrimer-based CT contrast agents with improved
circulation times. These dendrimers were formed via the use of a large PEG core (600012000 MW) and poly-L-lysine for branch generation.120 The amine termini of these
dendrimers were functionalized with triiodophthalamide molecules to provide CT
contrast.
Nanotechnology offers several platforms upon which to develop contrast agents
for CT as outlined above. Blood pool agents are useful to help visualize several
pathologies in coronary artery disease and myocardial infarction, however specific
targeting of contrast agents can allow single mechanisms or processes in cardiovascular
disease to be probed. The progression of coronary artery disease occurs in many
stages, providing numerous targets to study. Targeting can be accomplished by
attaching ligands such as antibodies or peptides to the surface of the particle. Moreover,
the use of native biological material such as lipoproteins (e.g LDL or high density
lipoprotein) can provide targeting for cardiovascular disease.
Pan et al., used poly(styrene-b-acrylic acid) to produce nano-emulsions with high
payloads of Lipiodol (up to 37% wt of iodine) under 100 nm in diameter. 121 Furthermore,
the authors conjugated an anti-fibrin monoclonal antibody onto the particle using a
modified avidin-biotin linker. Fibrin is generated during the coagulation cascade and is a
key element in thrombus formation. It is a very high density target and therefore suitable
for molecular imaging via CT (high density targets are needed due to the low sensitivity
of CT). A fibrin targeted agent may reveal information on plaque rupture and subsequent
thrombus formation. Using a fibrin clot phantom, the agent found a CNR value of 98 ± 12
compared to the surrounding water. From rat experiments, the blood half-life of the
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agent was found to be 56 minutes, although in vivo thrombus targeting experiments
were not reported.
LDL is an attractive platform for targeted imaging due to its evasion of the
immune system, biocompatibility, biodegradability, defined size and innate targeting.
LDL infiltration in leaky endothelium is a key stage in early atherosclerosis development.
A number of studies have attempted to use LDL as nanoparticle platform to carry
imaging agents for detection of plaque for multi-modalities.122-124 For iodinated contrast
agents, a study by Hill et al. demonstrated the feasibility of using LDL containing
iodinated tri-glycerides to target liver cells (HepG2) that over express the LDLreceptor.125 This in vitro study resulted in contrast enhancement of the cells, but would
require further testing in vivo.

1.2.3c Inorganic nanoparticle contrast agents
While iodinated small molecules are the contrast agents used for x-ray computed
tomography clinically, there has been significant pre-clinical interest in the development
of inorganic nanoparticles as imaging agents. Inorganic nanoparticles can provide
improved x-ray attenuation at CT energy ranges due to higher k-edge energy levels as
compared to iodinated agents. Furthermore, the payloads of inorganic nanoparticles can
be much higher than for iodine based agents, since the density of inorganic materials is
often very high. For example, Brown et al., reported a solid bismuth core CT contrast
agent (core density 9.8 g/ml) whose 76 nm cores carried a payload of 6 million Bi atoms
each.126 Additionally, the use of inorganic nanocrystals may alleviate biocompatibility
complications associated with iodinated agents as outlined above.
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Of the various types of inorganic nanocrystals that have been proposed as CT
contrast agents, gold nanoparticles (AuNP) have been the focus of most work. Gold
nanoparticle syntheses allow for control of size, shape, and functionality of the particles.
This precise control allows for specific tailoring of these particles for a given application.
AuNP can be included in various nanotechnology platforms, i.e. micelles, liposomes,
dendrimers, and as ligand stabilized crystalline nanoparticles.127-128 Gold nanoparticles
are also well known for their biocompatible properties and have been used in a variety of
biomedical applications such as drug delivery, imaging, biosensors, and photothermal
ablation (Figure 1.6).129-133

Figure 1.6 Biomedical applications of gold nanoparticles.
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Gold nanoparticles can be synthesized in various shapes and sizes. Control over these
properties in addition to control over chemical functionalization allow for tailoring of
nanoparticles to specific biomedical applications. Reproduced with permission from
Dreaden et al (2012).134

As a CT contrast agent, the physical parameters of the particle as well as its
chemical properties can drastically influence the particle’s biological properties in terms
of clearance and biocompatibility. One of the first AuNP developed as an x-ray contrast
agent was a 1.9 nm spherical formulation, and was shown to provide strong
enhancement of the major vessels. However, due to the small size of the agent, the
particles were rapidly cleared through the renal system as evidenced by high attenuation
in the bladder in images acquired 10 mins after injection.135 Increasing the size and/or
modifying the surface functionality of AuNP has been shown to improve circulation time,
as found in studies of AuNP whose core size was around 10 nm. After coating with PEG,
the nanoparticles had an overall size of 38 nm. These nanoparticles were not renally
cleared and provided vascular contrast over a period of 12-24 hours.136
A study by Kim et al., examined the effectiveness of AuNP as blood pool contrast
agents after surface modification with PEG.137 AuNP 30 nm in diameter were
synthesized through the reduction of gold chloride by sodium citrate using a modified
Turkevich method.138-139 Ligand exchange was performed with 5000 molecular weight
methoxy-PEG-thiol for stabilization and to provide a long circulation half-life. Cytotoxicity
of the AuNP-PEG particles were evaluated in HepG2 (epithelial liver cell line). The
particles were well tolerated up to 1000 µg/ml of Au. After intravenous injection of AuNPPEG, the agent yielded strong contrast in the heart and major arterial vessels (>100
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HU). An increase in attenuation of roughly 100 HU in the heart and blood vessels was
sustained for 4 hours post-injection. The attenuation of the liver and spleen was found to
increase over the 24 hour period, indicating the major clearance pathways for the PEG
coated AuNP. Due to the uptake of the particles by Kupffer cells and hepatocytes, the
authors demonstrated visualization of a hepatoma in vivo in a rat model. In scans, 12
hours post-injection, strong attenuation in the aorta was seen with clear delineation of
the hepatoma. Other studies have focused on different AuNP structures (e.g.
nanorods140-141), coatings (such as gum-arabic142-143) or incorporated gold into other
platforms such as dendrimers.144-147 While AuNP have desirable properties for x-ray
imaging, the cost of gold may be an issue for widespread adoption and scale up. Other
high atomic number elements have been explored as CT contrast agents. For example,
studies have shown bismuth nanoparticles as a possible CT blood pool contrast
agent.148 Naha et al., reported the development of dextran coated bismuth-iron
nanoparticles for in vivo blood contrast imaging with both CT and MRI.149
Tantalum is another element that has been recently explored as a candidate for
CT contrast agents due to the low toxicity of its oxide and strong x-ray absorption.150-151
A group from General Electric have published on several tantalum oxide formulations
where the overall nanoparticle size is below 5 nm, thus allowing for swift renal excretion.
Due to the relative natural abundance of tantalum compared to gold, tantalum is an
order of magnitude cheaper, which may facilitate widespread use. In another study,
tantalum oxide nanocrystals were prepared using reverse emulsions and then surface
functionalized with PEG and a fluorophore tag.152 This synthesis can be done on a bulk
scale and allows the core size to be controlled in the 6-15 nm diameter range. As a
blood pool agent, strong contrast enhancement of the heart and major blood vessels
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could be seen for up to 3 hours post-injection, with eventual accumulation in the spleen
and liver.
Gadolinium chelates serve as MRI contrast agents for several biomedical
applications including cancer and vascular imaging.153-154 Despite the toxicity concerns
over non-chelated gadolinium and tissue retention, several studies have evaluated
gadolinium as a potential CT contrast agent.155-156 Due to its unique properties for MRI,
researchers have developed gadolinium nanoparticles for dual mode imaging with CT
and MRI. The addition of gadolinium chelates to gold nanoparticles has been shown to
provide significant contrast for both modalities.157-159
A number of other high atomic number elements have shown promise as
effective CT contrast agents. Gold and silver core-shell nanoparticles have been shown
to produce stronger CT contrast than iodinated agents.160-162 A report by Chou et al.,
demonstrated the use of iron/platinum nanoparticles for dual CT and MRI molecular
imaging after intravenous injection.163 Several studies have reported the use of tungsten
nanoparticles as CT contrast agents that provide better enhancement compared to
traditional iodinated agents.164-166 Moreover, ytterbium based nanoparticles have
received attention as potential CT agents due to favorable x-ray absorption spectra and
relative natural abundance compared to other potential elements mentioned.167-168
Ytterbium based nanoparticles also present multi-modal opportunities through
upconversion fluorescence imaging. Upconverting fluorescent probes allow for excitation
at NIR-wavelengths for deep tissue penetration with reduced background tissue
absorption. Liu et al., synthesized ytterbium based particles coated in PEG for use as a
CT contrast agent.169 Xing et al., synthesized tri-modal nanoparticles for upconversion
fluorescence, MR and CT imaging.170 The group synthesized gadolinium-based
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upconverting nanoparticles (doped with yttrium, ytterbium, erbium, and thulium) that
were also surface coated with gold nanoparticles. In vivo imaging of these trimodal
particles was demonstrated with subcutaneous injection of the particles at tumor bearing
locations in mice.

1.2.3c Cell tracking agents
The use of nanoparticles as contrast agents provides unique advantages that
can be exploited for specific biomedical applications. One such application is in vivo cell
tracking, where a population of specific cells can be monitored in real time via imaging.
Cell tracking offers the possibility of non-invasively observing cell behaviors such as
migration, localization, and viability over a period of time. 171 This technology has
emerged as a particular area of interest since the development of adoptive cell therapy
and stem cell transplantations.172 Both therapies involve the transplantation of
endogenous cells that have been modified ex vivo. The fate of these transplanted cells is
of high interest as it may provide information on the effectiveness of the therapies and
the conditions that predict a successful treatment. Cell tracking has been explored with
several imaging modalities including MRI, ultrasound, PET and optical imaging.173-174
Contrast agents have developed for in a variety of cell tracking applications including
neural stem cells,175 mesenchymal stem cells,176 hematopoietic progenitor cells,177 and
cardiac applications.178-179
In cell tracking, coronary artery disease is of high interest due to the cells
involved in the disease progression and regenerative opportunities after myocardial
infarction. With injection of stem cells after myocardial infarction, there have been clinical
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reports of improved left ventricle remodeling and function.180 However, concerns about
cell fate, localization and safety need to resolved before further adoption of the therapy.
Clinical imaging modalities are currently being explored as a method to address these
issues.181 The use of MRI and MRI contrast agents have been the main focus due to
high spatial resolution and reasonable contrast agent sensitivity. MRI contrast agents for
cell tracking typically contain superparamagnetic (SPION) or ultra small paramagnetic
(USPION) iron oxide particles.182 These agents primarily work by shortening T2
relaxation (iron oxide) to produce hypo-contrast in the images (i.e. image darkening).
There has a been a number of pre-clinical studies demonstrating success stem cell
tracking in infarct models.183-185 A study Bulte et al., labeled autologous mesenchymal
stem cells with Feridex (SPION) and directly injected the cells intra-myocardial into the
infarct border zone in a canine model.186 The cells could be detected for up to 8 weeks
post-injection with MRI and histology showed that the transplanted cells were indeed in
the infarct region. While tracking stem cells with MRI can provide information about
migration and localization, cell functionality can be difficult to assess. In a study by
Chapon et al., the study utilized both MRI and FDG-PET to evaluate the localization and
metabolic activity of the transplanted cells.187 FDG is a glucose analog with a fluorine-18
radionuclide substituted for a hydroxyl group. Its uptake in cells is closely correlated to
metabolic activity and viability. In a rat infarct model, bone marrow derived stem cells
were labeled with SPION and injected directly into infarct zone. The stem cells could be
detected for up to 6 weeks with MRI. With PET, an increase in FDG uptake was
noticeable in the first week in infarct animals with the labeled stem cells as compared to
infarct animals that did not receive stem cells. However, the increase in FDG did not
persist the duration of the 6 weeks, potentially indicating death of the injected stem cells
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providing valuable information about cell viability that could not be determined through
MRI alone.
While PET can be used to assess function of the injected cells, a number of
studies have sought to use radiolabeled tracers to track transplanted stem cells with
PET/SPECT. Because of short half-lives of radionuclides,
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In is the most commonly

explored agent (half-live 2.8 days) with most studies lasting one week.188-189 With
SPECT, Mitchel et al. were able to observe 57% retention of

111

In-tropolone labeled

endothelial progenitor cells in the infarct border zone in a canine infarct model. The
study observed that the cells could be detected after 15 days. Clinically, some studies
have used PET to determine the engraftment of stem cells after delivery in short term
cases of acute myocardial infarction.190-191 A study by Penicka et al. compared the
engraftment of

99m

Tc labeled bone marrow derived mononuclear cells in acute (AMI)

versus chronic myocardial infarction (CMI) patients. At 2 hours, myocardial activity from
the transplanted cells could be seen in all five patients with AMI and 4 out of 5 CMI
patients. However, after 20 hours, only 3 of the AMI patients had detection of the labeled
cells. These results demonstrate that engraftment of cells for myocardial infarction may
be limited to only acute cases. For cell tracking, PET/SPECT offers high sensitivity for
cell detection but is limited by poor spatial resolution and short half-lives of agents.
There has been in interest in developing cell tracking agents for ultrasound (US)
due to its low cost, non-invasiveness and real time imaging capabilities. Typical US
agents are based on inert gases trapped inside a microparticle for detection. For cell
labeling, long term stability of the agent within the cell remains a problem in addition to
poor spatial resolution. Most studies for cell tracking with US have been limited to in vitro
studies with polymer microbubbles as cell labels.192 A study by Toma et al. used lipid
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microbubbles to label mesenchymal stem cells and deliver these cells via an intra-aortic
injection to plaque rupture models in rabbits.193 After 24 hours, labeled cells could be
detected on the lumen surface at the delivery site but did not show migration towards
injury location.
Progress with CT cell tracking has been limited due to the low CT sensitivity
towards contrast agents requiring relatively large payloads of agent for detection.
Despite this limitation, researchers have developed cell tracking with CT, demonstrating
feasibility in a number of applications.96, 194 Barnett et al. have demonstrated the use of
perfluoroctylbromide (PFOB) nanoparticles (conjugated to rhodamine) to label and track
exogenous cells non-invasively over time. The PFOB acted as a multimodal label
allowing for CT and US imaging. Pancreatic islets were co-encapsulated with PFOB in
alginate-based capsules, which allowed their visualization in vivo.195
Several cell tracking applications with CT have found success in using AuNP to
label cells. For instance, Betzer et al. utilized 20 nm AuNP surface functionalized with
glucose to label mesenchymal stem cells.196 These gold labeled cells were injected
directly into the left ventricle in the brain and monitored over 21 days. The authors were
able to observe the migration of gold labeled cells over the 21 days to a specific region
of injury. The authors were able to non-invasively quantify the number of AuNP labeled
cells in particular regions, since x-ray attenuation is linearly proportional to the
concentration of contrast agent, allowing for quantification of cell number from CT scans.
This group has performed similar studies such as tracking the migration of AuNP labeled
T-cells to xenograft tumors.197
With AuNP and the use of synchrotron x-ray radiation sources, super high
resolution of in vivo cells have been demonstrated.198 Astolfo et al. demonstrated the
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feasibility of detecting engrafted rat F98 glioma cells in a mice model. The cells were
labeled with 50 nm citrate coated spherical AuNP and 200,000 cells were injected into
the striatum. The cells could be detected for the duration of the experiment, 7.5 days,
using CT synchrotron radiation.198 While synchrotron radiation imaging remains
experimental, researchers have been able to reach single cell resolution with AuNP
labeled cells, opening new possibilities of future CT applications.199

1.3 Conclusion
For medical imaging, contrast agents are able to provide additional anatomical
and functional information that can help assess the health of the patient. The
development of contrast agents continues to improve, further expanding their
applications and capabilities. As discussed previously for CT, contrast agents have
evolved from simple iodinated molecules to complex nanotechnologies with purposeful
design. However, expanding the breadth of these nanotechnologies into specialized
biomedical applications requires individual investigation to assess the effectiveness of
the nanoparticles in that application.
Interest in cell tracking continues to grow with the advancement in cell-based
therapies. While exploration of cell tracking contrast agents have been mostly limited to
MRI (clinical) and optical (pre-clinical), CT’s spatial and temporal resolution make it a
promising cell tracking modality for cardiovascular applications. Specifically, the
development of atherosclerosis in the coronary arteries, subsequent rupture, and
myocardial infarction present several stages where cell tracking technology is of high
need. Monocytes are a cell type that plays a role in each stage, infiltrating developing
plaques, promoting eventual plaque rupture, and participating in wound healing after an
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infarct. The labeling and tracking of these monocytes can lead to more in-depth
investigation of each stage, elucidating mechanisms in the disease. In the following
chapters we present the development and assessment of nanotechnologies designed for
labeling of monocytes for detection with CT. We investigate the parameters of the nanocomplexes that optimize the labeling and biocompatibility with monocytes. Lastly, we
explore the use of the nanotechnologies in tracking monocytes during the progression of
atherosclerosis in mice models.
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Chapter 2: Design of polymer nanoparticle constructs as CT
contrast agents
2.1 Abstract
Nanoparticles of complex architectures can have unique properties. Selfassembly of spherical nanocrystals is a high yielding route to such systems. In this
study, we report the self-assembly of a polymer and nanocrystals into aggregates, where
the location of the nanocrystals can be controlled to be either at the surface or in the
core. These nanospheres, when surface decorated with nanocrystals, resemble disco
balls thus the term nano-disco balls. We studied the mechanism of this surface loading
phenomenon and found it to be Ca2+ dependent. We also investigated whether excess
phospholipids could prevent nanocrystal adherence. We found surface loading to occur
with a variety of nanocrystal types including iron oxide nanoparticles, quantum dots, and
nanophosphors, as well as sizes (10-30 nm) and shapes. Additionally, surface loading
occurred over a range of polymer molecular weights (~30-3,000 kDa) and phospholipid
carbon tail length. We also show that nanocrystals remain diagnostically active after
loading onto the polymer nanospheres i.e. providing contrast in the case of magnetic
resonance imaging for iron oxide nanoparticles and fluorescence for quantum dots.
Hypothesizing that large, high payload nanoparticles would allow high cell loading, we
investigated the labeling of monocytes with core loaded nanospheres for CT cell tracking
applications.
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2.2 Introduction
Methods to create complex nanoparticle architectures such as stars, shells,
cubes and frames have led to structures with unique properties. 1-4 However, direct
syntheses of such structures are frequently low yielding and difficult to scale up. An
alternative approach is to form complex architectures from self-assembly of simpler,
high-yielding components. One such route is incorporation of inorganic nanocrystals into
polymeric nanoparticles. Such assemblies have a wide range of applications including
uses in catalysis,5 energy,6 drug delivery,7-8 and medical imaging.9 Often the structural
organization of these nanoparticles will dictate its function and behavior in a given
application. For example, previous research has shown that gold nanoparticles are
capable of quenching the emission of nearby fluorescent sources when closely
arranged. Jennings et al showed that fluorescence could be recovered by separating the
1.5 nm gold nanoparticles and fluorophore a distance as little as 15 nm. 10 Hence,
separate core and surface loading of gold cores and fluorophores could maintain
fluorophore fluorescence. Therefore, the ability to control localization of nanocrystals via
self-assembly would be a valuable tool in the synthesis of nanocrystal/polymer
composite particles. Control over nanocrystal distribution within the core of polymer
constructs has previously been demonstrated.11-17 For instance, Luo et al found that by
modifying the surface ligands of gold nanoparticles, their incorporation could be focused
to specific regions (i.e. the core center or at the edge of the core) within nanoparticles
formed from amphiphilic co-polymers of polystyrene and poly(acrylic acid).18
In this chapter, we report the serendipitous discovery of a system where
nanocrystals can be selectively loaded onto the surface of polymer nanospheres, as
opposed to the core. This forms a structure reminiscent of a disco ball, which we term a
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nano-disco ball. We have found that phospholipid coated inorganic nanoparticles can be
used

to

surface

decorate

a

polymer

nanosphere

formed

from

poly(bis(4-

carboxyphenoxy)phosphazene), or PCPP, whereas carboxylic acid coated nanocrystals
localize to the core. PCPP is a part of a larger class of phosphorous-nitrogen backbone
based polymers called polyphosphazenes.19 These polymers have drawn interest for
use in biomedical applications due to their tunable functionality and biocompatibility. 20-22
By

modifying

the

polyphosphazene

side

chains

and

molecular

weight,

the

biodegradation rate of polymers can be controlled, making this a promising platform for
drug and contrast agent delivery.23-24 Specifically, PCPP has been used to form ionically
cross-linked hydrogels,25-26 polymer films,27 and more recently microencapsulating
spheres.23, 28-29 This is the first report of a system that integrates polyphosphazenes and
nanocrystals. Furthermore, this is a rare instance of a system where nanocrystals can be
preferentially loaded onto the surface of a particle as opposed to internal loading. We
believe that this novel system has excellent potential as a contrast agent or theranostic
delivery platform.
Herein, we selectively incorporate nanocrystals into the core or surface of the
nanospheres synthesized with PCPP. We investigate the conditions for surface
localization of nanocrystals onto PCPP nanospheres (Figure 2.1). We report the
synthesis of these nano-disco balls and their characterization via transmission electron
microscopy, scanning electron microscopy and electron microscopy tomography. They
can be loaded with separate core and surface payloads, maximizing contrast for two
imaging methods. We have probed the synthetic process for the key steps in the
formation of the nano-disco balls. We evaluated the effects of varying the physical and
chemical properties of the nanocrystals used on surface loading. We also varied
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phospholipid tail length for micelle formation and PCPP molecular weights for synthesis.
In addition, we have investigated how competing micelles might affect the adherence of
nanocrystals. Lastly, we assessed the biocompatibility and effectiveness of core loaded
nanospheres and nano-disco balls as cell tracking contrast agents for monocyte
labeling. Since CT is limited by low sensitivity, we hypothesized that large, ultra-high
payload nanoparticles would be effective for creating high intra-cellular contrast agent
loading. We therefore evaluated CT contrast generation, viability, and cytokine release
for gold core loaded PCPP nanospheres. We also examined stability in serum and
applications as a dual cell tracking and drug delivery agent for nano-disco balls.

Figure 2.1 Schematic depictions of the PCPP nanosphere platform.
(a) Versatility of PCPP platform for nanocrystal type and loading location. (b) Schematic
of PCPP nanosphere synthesis.
Table 2.1: Definitions for abbreviations in PCPP study
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2.3 Materials and methods
2.3.1 Materials
Poly(bis(4-carboxyphenoxy)phosphazene) disodium salt (PCPP, 1 MDa) was
purchased from Sigma-Aldrich (St. Louis, MO). PCPP polymers of 3.8 MDa and 36.4
kDa molecular weight were synthesized at The Pennsylvania State University. All
phospholipids including 1-myristoyl-2-hydroxy-sn-glycero-3-phosphocholine (MHPC) and
chain length variants were purchased from Avanti Polar Lipids (Alabaster, AL). Oleic
acid capped cadmium sulfide quantum dots were purchased from NN-Labs, LLC
(Fayettville, AR). Oleic acid capped iron oxide nanoparticles (IONP) of various sizes (10,
15, 20, 25, 30 nm) were purchased from Ocean NanoTech (Springdale, AR) and some
IONP were synthesized at University of Pennsylvania (vide infra). All other chemicals of
analytical grade were purchased through Sigma Aldrich (St. Louis, MO) with the
exceptions of sodium fluoride (Acros Organics, NJ), trifluoroacetic acid (Alfa Aesar, MA),
Tetrahydrofuran (EMD, PA), dichloromethane (EMD, PA), and ethyl ether (EMD, PA).
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Gadolinium or lanthanum trifluoroacetate precursors were prepared using a literature
method by refluxing gadolinium or lanthanum oxide in trifluoroacetic acid/water mixture
(50 vol%).30 A monocyte cell line, RAW 264.7, was purchased from ATCC. Cells were
cultured in Dubecco’s Modified Eagle Medium supplemented with 10% fetal bovine
serum and 1% penicillin/streptomycin (10,000 units/mL, 10,000 µg/mL) from Life
Technologies Invitrogen (Grand Island, NY).

2.3.2 Polyphosphazene synthesis
For 35.6 kDa PCPP preparation, PCl5 (0.11 g) was dissolved in 50 mL anhydrous
dicholormethane (DCM) for 10 min. Chlorophosphoranimine (6.00 g) prepared by a
previous report,30 was added to the solution rapidly, and the mixture was stirred at room
temperature for 4 hr. DCM was then removed under reduced pressure to give colorless
viscous living oligo(dichlorophosphazene). The polymer was re-dissolved in anhydrous
tetrahydrofuran (THF), and propyl 4-hydroxybenzoate (14.43 g) and CsCO3 (26.00 g)
was added to the solution. The mixture was stirred at room temperature for 2 days.
Afterwards, the reaction medium was concentrated and precipitated into water (300
mL×3). The precipitate was isolated by centrifugation. Then, the crude product was redissolved in DCM, and dialyzed versus methanol/DCM (1:4) for 3 days (Spectra/Por
dialysis membrane, MWCO: 1,000). The solvent was removed under vacuum to give a
white adhesive polymer. (Molecular weight: 35.6 g/mol; PDI: 1.07; repeat units: 82) For
the deprotection reaction, the above 1.00 g of polymer was dissolved in 100 mL
anhydrous THF. Potassium tert-butoxide (2.50 g) and water (0.45 g) were added to the
polymer solution. The mixture was stirred at room temperature for 3 days. Then, the
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reaction medium was dialyzed versus water for 1 day, water/methanol (1:1) for 2 days,
and then methanol for 2 days (Spectra/Por dialysis membrane, MWCO: 1,000).
Poly(bis(4-carboxylatophenoxy)phosphazene) dipotassium was obtained by the removal
of all solvent under vacuum at 35 °C (overall yield: 46%).

P NMR (D2O): δ -18.75 (s).

31

H NMR (D2O): δ 7.31 (d, 2H), 6.50 (d, 2H).

1

A high molecular weight (MW) PCPP (3.8 MDa) was synthesized by first
dissolving

poly(dichlorophophazene)

(2.00

g)

in

200

mL

of

THF.

Poly(dichlorophosphazene) was prepared by the thermal ring-opening polymerization of
recrystallized and sublimed hexachlorocyclotriphosphazene (Fushimi Chemical Co.,
Japan) in evacuated Pyrex tubes at 250 °C. Propyl-4-hydroxy-benzoate (9.33 g) was
dissolved in THF (100 mL) then added to the polymer solution. Solid cesium carbonate
(16.9 g) was then immediately added to the reaction mixture. The reaction proceeded at
room temperature for 3 days. Afterward, the solution was concentrated, and precipitated
into water 3 times and hexane once. The solvent was removed under reduced pressure
to yield a white solid that was obtained in an 80% yield (molecular weight: 3,882,000
g/mol; PDI: 1.62; repeat units: 9,600). For the de-protection reaction, the polymer (3.00
g) was re-dissolved in anhydrous THF (300 mL). Potassium tert-butoxide (7.51 g) and
water (1.34 g) were added to the polymer solution. The reaction was stirred at room
temperature for 3 days and was then concentrated. This was dialyzed versus water for 2
days, (1:1) methanol/water for 2 days, and then (4:1) methanol/water for 1 day. The
solvent was then removed under reduced pressure to yield the product with an 81%
yield. 31P NMR (D2O): δ -18.53 (s). 1H NMR (D2O): 7.16 (s, 2H), 6.36 (s, 2H).
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2.3.3 Iron oxide synthesis
Iron oxide nanoparticles (IONP) were synthesized using oleic acid as the capping
ligand following a modified literature method.31 Typically, 1.5 g of iron chloride and 5.2 g
of sodium oleate were first added in a 100 mL flask. Subsequently, 20 mL of hexane,
11.5 mL of ethanol, and 8.8 mL of distilled water were added to the flask and the mixture
was sonicated. The two-phase mixture was heated to reflux (~70 °C) for four hours,
which produced iron-oleate in the organic layer. The upper organic layer was washed
three times with 30 mL of water and separated by centrifugation (5,000 rpm, 10 min).
After washing, the hexane was evaporated from the dark brown organic layer and stored
under vacuum. The synthesis of 15.6 nm iron oxide nanoparticles was carried out by
reacting 5.5 g of iron-oleate and 1.5 g of oleic acid in 31 g of 1-octadecene in a 250 mL
round-bottom flask. The reaction mixture was heated to 320 °C at a rate of 200 °C/hour,
and kept at that temperature for 30 minutes. The color of the solution turned from dark
brown to black upon the formation of nanoparticles. The resulting solution was cooled to
room temperature and nanoparticles were precipitated by adding ethanol (35 mL). The
precipitated nanoparticles were collected by centrifugation (5,000 rpm, 10 mins) and
then redispersed in hexane (10 mL). The nanoparticles were further purified by
precipitation with acetone (35 mL), centrifuging at 5,000 rpm for 10 min, and
redispersing the collected nanoparticles in hexane (10 mL). This washing step was
repeated two more times. After the final washing step, the IONP were redissolved in
chloroform (10 mL) and centrifuged at low speed (3,000 rpm, 5 min) to remove
aggregates. A sample of these IONP was rendered water soluble through encapsulation
with dimercaptosuccinic acid (Figure 2.2) following previous literature methods (IODMSA).32
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Figure 2.2 Chemical structures.
Chemical structures of iron oxide coatings (DMSA), and phospholipids used for micelle
formation (MHPC, DMPC).

2.3.4 Gold nanoparticle synthesis
Carboxylic-acid coated gold nanoparticles (AuNP) were synthesized using the
Turkevich method with slight modifications.33 Briefly, 85 mg of chloroauric acid (HAuCl3)
was dissolved in 250ml of Milli-Q water for a final concentration of 1 mM. After heating to
a boil, a 38.8 mM solution of sodium citrate (285 mg in 25 ml Milli-Q water) was added,
causing the color of the solution to become dark red. The solution was heated for
another 15 minutes and then allowed to cool to room temperature. For carboxylic-acid
ligand exchange, an 11.9 mM solution of 11-mercaptoundecanoic acid (11-MUA, 2.6 mg
in 1 ml of EtOH) was added to the citrate AuNP as prepared above. The solution was
stirred for 24 hours. Afterwards, the AuNP were purified and collected by centrifuging at
12.5 krcf for 45 minutes. The pellet was resuspended with Milli-Q water and repeated
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two times. The AuNP solution was finally resuspended in 1 ml of Milli-Q water and
filtered through a 0.45 µm syringe filter.

2.3.5 Nanophosphor synthesis
Hexagonal phase sodium gadolinium tetrafluoride nanospheres (β-NaGdF4) were
synthesized according to a previously reported procedure with slight modification.34
Briefly, gadolinium trifluoroacetate (2 mmol) and sodium fluoride (5 mmol) were added
into a 125 mL three-neck flask containing 60 mL of 1-octadecene/oleic acid solvent
mixture (50% by volume). The solution was then degassed under vacuum at 125 oC for
an hour to remove water. For nanocrystal growth, the solution was heated to 290 oC
under N2 environment at a rate of 10 oC/min and maintained at this temperature for 5
hours. Purification was performed twice by washing with ethanol and then centrifuging at
6000 rpm for 2 min The nanocrystals were redissolved in hexane (10 mL) and residual
sodium fluoride were removed by centrifugation at 3000 rpm for 2 min. β-NaGdF4
nanorods were synthesized by using 2.5 mmol of sodium fluoride in the same method to
synthesize nanospheres. Lanthanum trifluoride (LaF3) discs were synthesized using
similar methods as β-NaGdF4 nanospheres while substituting lanthanum trifluoroacetate
for gadolinium trifluoracetate The reaction were conducted at 290 oC for 5 hours under
N2 environment. LaF3 nanoplates were redissolved in hexane and centrifuged at 3000
rpm for 2 min to remove lithium fluoride salts.
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2.3.6 Nanocrystal micelle synthesis
IONP, quantum dots, and nanophosphors were rendered water soluble through
encapsulation in phospholipid micelles. In a typical preparation, 50 mg of MHPC (Figure
2.2) was dissolved in a 1 mL chloroform/methanol mixture (4:1). Oleic acid coated IONP
(5.00 mg in 0.5 mL chloroform) were added to the MHPC solution. This mixture was then
added to heated Milli-Q water (10 mL) in a slow, drop-wise fashion. The resulting
solution was heated for an additional 10 min to ensure organic solvent evaporation and
then cooled to room temperature. Afterwards, the aqueous solution was centrifuged at
800 g for 10 min to remove precipitates and multi-cored micelles. The supernatant was
collected and centrifuged at 20,000 g for 90 min. The pellet was redispersed in Milli-Q
water (~15 mL). These washes were performed three times to ensure purification.
Finally, the sample was resuspended in approximately 1 mL of Mill-Q water yielding
IONP encapsulated in MHPC micelles (IO-MHPC). Quantum dots and nanophosphors
were encapsulated using similar methods as the IONP. Iron oxide encapsulation was
also performed using the following additional lipids: 1-lauroyl-2-hydroxy-sn-glycero-3phosphocholine (IO-LHPC), 1-palmitoyl-2-hydroxy-sn-glycero-3-phosphocholine (IOPHPC), and 1-stearoyl-2-hydroxy-sn-glycero-3-phosphocholine (IO-SHPC). Additionally,
MHPC micelles were formed in the absence of any nanocrystals to obtain samples of
empty MHPC micelles. Mixed phospholipid micelles encapsulating IONP (10, 15, 20, 25,
and 30 nm diameter) were formed with a 1:1 mixture of MHPC and dimyristoyl-2hydroxy-sn-glycero-3-phosphocholine (DMPC, Figure 2.2).
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2.3.7 PCPP sphere synthesis
Formation of polyphosphazene polymer nanospheres was performed using
modified literature methods.28, 35 A typical synthesis was performed as follows, 40.0 mg
of PCPP (1.0 MDa MW) was dissolved in 20 mL of Dulbecco’s phosphate buffered
saline (DPBS, pH 7.4). IO-MHPC (0.15 mg, 200 µL) were added into 1 mL of this PCPP
solution. Then 16.8 µL of a 70.0 mg/mL spermine solution (DPBS, pH 7.4) was added to
the PCPP/IO-MHPC solution (0.98% spermine). The mixture was immediately added
into a beaker of 88.0 mg/mL CaCl2 buffer (~100 mL) and incubated at room temperature
for 30 minutes while stirring. This suspension was purified through centrifugation (800 g,
10 min) and washed three times with Milli-Q water. The resulting IO-MHPC surface
loaded nanospheres (IO-NB) were resuspended in 1 mL of Milli-Q water. This process is
depicted schematically in Figure 1b. Synthesis of non-loaded PCPP nanospheres were
formed similarly, except without the addition of IO-MHPC. PCPP nanospheres (AuIONB) were formed, for example, by mixing IO-MHPC (0.15mg, 42 ul) and AuNP (1 mg, 32
ul) together. Afterwards this solution was added to 1 mL of previously described PCPP
solution. The synthesis followed as described above. Nanocrystal variants such as CdS
quantum dots, nanophosphors (β-NaGdF4 spheres, rods, LaF3 discs), or iron oxides of
varying cores sizes and coatings were substituted for IO-MHPC for inclusion in the
PCPP nanosphere synthesis. PCPP of additional molecular weights (35.6 kDa and 3.88
MDa) were also used to form surface loaded nanospheres. Additionally, FITC-BSA (0.1,
0.25 mg) was core loaded into PCPP nanospheres using the standard synthesis method
with and without the simultaneous surface loading of IO-MHPC (0.15 mg) to form FITCPCPP and FITC-IO, respectively.
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2.3.8 Polymer and particle characterization
1

H and 31P NMR spectra were recorded on a Bruker WM–360 NMR spectrometer

operated at 360 and 145 MHz, respectively. 1H NMR spectra were referenced to solvent
signals while

31

P NMR chemical shifts were relative to 85% phosphoric acid as an

external reference, with positive shift values downfield from the reference. Molecular
weights were estimated using a Hewlett–Packard HP 1090 gel permeation
chromatograph (GPC) equipped with an HP-1047A refractive index detector, American
Polymer Standards AM gel 10 mm and AM gel 10 mm 104 Å columns, and calibrated
versus polystyrene standards.
Transmission electron microscopy images were acquired on a FEI Tecnai T12
microscope at 120 kV. Scanning electron microscopy was performed with a Philips XL20
at 10 kV. Fluorescent imaging for both the quantum dots and the FITC-BSA was
performed with an IVIS Spectrum system using 465 nm excitation and 520 nm emission
filters. Relaxivities were measured using a Bruker Minispec mq relaxometer at 1.41 T
(60 MHz) and 40°C.

Freely suspended IO-MHPC were prepared in DPBS for

measurements. PCPP samples were prepared in a 1% agar gel in DPBS to prevent
sedimentation of nanospheres. Iron oxide concentrations were determined through
inductively coupled plasma-optical emission spectroscopy (ICP-OES) on a Spectro
Genesis system.
Magnetic

hysteresis

measurements

were

performed

on

a

MicroMag

Magnetometer (Westerville, OH) at in field range of 10 kOe. Samples (5 µl) were
prepared on a coverglass for measurements. Magnetic resonance imaging (MRI) was
used to evaluate IO-NB contrast generating properties. IO-NB were prepared in a 1%
agar gel at concentrations of 0.05 mM and 0.16 mM of Fe. Additionally, control samples
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of DPBS, non loaded PCPP, and 0.16 mM of Fe IO-MHPC in 1% agar gel were
scanned. For MRI phantom preparation, samples were placed in a 2% agar gel doped
with 0.35 mM manganese chloride. The samples were scanned using a head coil on a
Siemens Magnetom Trio with a 3 T magnet. A 2D spin echo sequence was used.
Relevant imaging parameters were: echo time (TE), 15 ms; repetition time (TR), 10 s; 1
slice with thickness 3mm, 1 average, flip angle (FA), 90 degrees; acquisition matrix,
184x256; in-plane spatial resolution 0.546 mm2, field of view (FOV) 140 mm2. The
resulting images were processed using Osirix v.3.0.1 32-bit (Geneva, Switzerland;
www.osirix-viewer.com). CT images were acquired with a Siemens Definition DS 64slice clinical CT scanner at 140 kV (245 mA) with a matrix size of 512x512, field of view
37x37 cm, reconstruction kernel B30f and slice thickness of 0.6 cm. Images were
analyzed using Osirix 64 bit (v3.7.1).

2.3.9 In vitro incubations
RAW 264.7 cells were cultured on 6-well plates at a concentration of 2 million
cells/mL at 37° C. After 24 hours, the cells were treated with IO-NB at a concentration of
50 µg Fe/mL (0.89 mM) for 4 hours. The cells were washed 3 times with DPBS and then
collected by gentle scraping. The cells were fixed in a solution of 2% glutaraldehyde and
5% paraformaldehyde in DPBS. Fixed cells were embedded in resin and prepared for
TEM using standard methods.36 Cell sections were imaged using a FEI Tecnai T12
electron microscope.
For cytotoxicity, Au-PCPP5 (AuNP core loaded in PCPP nanospheres at 5:1
mass ratio, 10 mg gold to 2 mg PCPP) was incubated with monocytes for 24 hours at
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37˚C on 20 mm glass bottom dishes at 7.5 x 104 cells per dish. Afterwards, the media
was washed with DPBS and LIVE/DEAD cocktail was added (2 mL DPBS, 2 µL stock
Ethidium-1 homodimer, 0.5 µL stock Calcein AM, and 0.5 µL 3.2 mM Hoechst 33342).
The cocktail was left on for 20 mins before imaging with Nikon Eclipse Ti-U fluorescent
microscope. Filters for DAPI (Ex. 359, Em. 461 nm), FITC (Ex. 495, Em. 519 nm), and
Texas Red (Ex. 595, Em. 613 nm) were used to visualize cell nuclei, living cells and
dead cells respectively. Four fields were taken per dish and analyzed with a custom
written MATLAB (MathWorks, Natick MA) program for cell counting. The values for each
field were averaged for cytotoxicity results. Viability % is expressed as living cells/total
cells *100.
To evaluate cytokine expression, ELISA was used to measure TNF-α from media
collected following treatment of monocytes with Au-PCPP5. Monocytes were cultured in
96 well plates at 1.0 x105 cells per well for 24 hours. Afterwards, cells were treated with
increasing concentrations of Au-PCPP5 for 24 hours. Cells were washed twice with
DPBS and the media was replaced with or without lipopolysaccharide (LPS) for 3 hours.
The media was collected and ELISA was performed according to kit instructions (Life
Technologies Invitrogen, Grand Island, NY).
For fluorescent microscopy, RAW 264.7 cells were cultured on glass-bottomed
well dishes (20 mm diameter) at a concentration of 800k cells per well. After 24 hours,
the cells were treated with 50 ug Fe/ml (0.89 mM) of FITC-NB or FITC-PCPP for 4
hours. The cells were then washed with DPBS 3 times and stained with DAPI. Imaging
was performed on a Nikon Eclipse fluorescence microscope (Nikon Eclipse Ti-U,
Melville, NY). The DAPI stain was imaged using a 358 nm excitation filter and a 461 nm
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emission filter. FITC was imaged using a 494 nm excitation filter and a 516 nm emission
filter.

2.4 Results
2.4.1 Core loading of PCPP nanopsheres
Gold nanoparticles of 15 nm in diameter were synthesized and coated in small
chain carboxylic acid (11-mercaptoundecanoic acid). Inclusion of these particles into the
one pot synthesis with PCPP, formed AuNP core-loaded PCPP nanospheres (AuPCPP).
The core loading of AuNP into the PCPP nanospheres increased with higher starting
concentrations of gold (Figure 2.3). The internal loading of the AuNP was confirmed with
3D tomographic reconstruction, showing aggregation of AuNP into clusters within the
core of the nanosphere (Figure 2.3d). At the highest ratio examined (10 mg Au to 2 mg
PCPP), the incorporation of AuNP into the core distorted the morphological sphere
shape of the nanosphere.
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Figure 2.3 AuNP loaded PCPP nanospheres.
TEM of PCPP nanoparticles loaded with varying amounts of carboxylic acid coated gold
nanoparticles. A) 1:5, B) 1:1 and C) 5:1 mass ratios. D) 3D reconstruction of sample in
B).

2.4.2 Surface decoration of PCPP nanospheres
PCPP is a biocompatible polymer, which we have used to create a novel platform
to exploit for nanocrystal delivery in biomedical applications. PCPP nanospheres were
synthesized using a modified method that was previously developed to make
microspheres.28 The polycarboxylate PCPP is cross-linked with the polycation spermine
to form polymer spheres. The self-assembled nanospheres were dispersed in CaCl2,
which we found necessary to halt nanoparticle growth.35 This process resulted in
polymer nanoparticles of 508 ± 185 nm (Figure 2.4a). With loading of these polymer
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nanoparticles, we added dimercaptosuccinic acid coated iron oxides (IO-DMSA) to the
synthesis prior to adding the spermine cross-linker. We found that IO-DMSA were
included in the core of the polymer spheres (Figure 2.4b) similar to our findings with
AuNP. We then decided to explore the incorporation of iron oxide nanoparticles with
alternative coatings.

Figure 2.4 Surface loaded PCPP nanospheres.
Electron microscopy images of PCPP nanospheres. TEM images of (a) non loaded
PCPP nanospheres, (b) IO-DMSA core loaded into PCPP nanospheres, (c) IO-MHPC
surface loaded PCPP nanospheres (IO-NB). (d) Image of disco ball. SEM images of (e)
non loaded PCPP and (f) IO-NB. (g) z-slice of tomographic reconstruction of IO-NB. (h)
Localization control of IO-MHPC and AuNP with PCPP nanospheres.

Lipid

coatings

are

a

common

method

used

to

make

nanocrystals

biocompatible.37 Oleic acid coated nanocrystals were rendered water soluble through
encapsulation in micelles formed by MHPC.38-39 We mixed these phospholipids coated
nanocrystals with PCPP before the addition of spermine. In the final product, we found
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that surprisingly, the nanocrystals were exclusively localized to the surface of the
nanospheres, in a structure we found reminiscent of a disco ball (Figure 2.4c, d).
Electron microscopy images of these IO-MHPC surface loaded PCPP nanoparticles, or
iron oxide loaded nano-disco balls (IO-NB), can be seen in Figure 2.4c. The average
diameter of IO-NB was found to be 384 ± 127 nm (from analysis of 100+ nanoparticles in
TEM images). SEM images revealed IO-NB to be an average diameter of 473.7 ± 125.9
nm and non loaded PCPP nanospheres to be 548.7 ± 200.8 nm. (Figure 2.4e,f). Three
dimensional tomographic reconstructions were performed to confirm the localization of
IO-MHPC within PCPP nanoparticles. The reconstructions proved exclusive loading of
IO-MHPC on the surface of PCPP nanospheres (Figure 2.4g). The total surface area
available for IO-MHPC binding was calculated using the average size of PCPP
nanospheres and found to be 123.2 cm2/mg polymer. The total occupied binding space
of IO-MHPC was found to be 96.96 cm2, i.e. 78.7%. This coverage corresponds to 609
IO-MHPC particles per PCPP nanosphere. However, we found that the coating density
could be tuned, depending on the amount of IO-MHPC added in the synthesis
procedure. These calculations can be found in the Appendix.
Next, we studied whether two types of nanocrystal could be loaded into the
PCPP nanoparticles. We added both carboxylic acid coated gold nanoparticles and IOMHPC to the synthesis at the same time. As can be seen in Fig. 2.4h, the gold
nanoparticles could be selectively localized to the core, while the IO-MHPC were
localized to the particle surface. Gold nanoparticles produce computed tomography (CT)
contrast in high concentrations, with no access to water needed,40-41 therefore core
loading is best for gold nanoparticles. On the other hand, less iron oxide is needed to
produce MRI contrast and access to water is needed, which surface loading provides.
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This formulation demonstrates the benefits of selective nanocrystal localization via
optimization of the contrast properties for each technique.
Having made the surprising observation of surface loading of PCPP nanospheres
with IO-MHPC, we probed the role of different steps in the synthesis, the flexibility of the
process, examined the contrast generating potential of the nano-disco balls, evaluated
whether the surface attachment of the IO-MHPC was robust to biological conditions in
vitro and demonstrated the theranostic potential of the nanoparticles.

2.4.3 Surface adhesion occurs during stabilization with CaCl2
The surface loading of PCPP nanospheres occurs via self-assembly during
synthesis. To investigate the crucial step in the formation of surface loaded
nanospheres, we added IO-MHPC at different points in the process. Initially, we formed
IO-NB by mixing IO-MHPC with a PCPP solution and then immediately adding spermine
as schematically outlined in Figure 1b. The mixture was quickly transferred to a CaCl 2
solution and incubated at room temperature for 30 minutes. Afterwards the solution was
washed through centrifugation and resuspended in water. To determine if longer
incubations of IO-MHPC and PCPP solution together would result in internal loading of
IO-MHPC, the reagents were incubated together at room temperature for 30 minutes
and 24 hours before the addition of spermine. Results in Figure 2.5a-c, show no visible
differences between our standard synthesis, 30 minute pre-incubation, or 24 hour preincubation, indicating that longer incubation times did not affect spatial distribution of IOMHPC in PCPP nanospheres (Fig. 2.5c).
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Figure 2.5 Probing synthesis steps of IO-PCPP.
TEM images of synthesis variations: (a) standard synthesis, (b) 30 minute and (c) 24 hr
pre-incubation of PCPP and IO-MHPC before spermine addition. TEM of (d) PCPP
spheres formed with spermine and then incubated with IO-MHPC, (e) PCPP spheres
formed with spermine, stabilized in CaCl2 and then incubated with IO-MHPC, (f) purified
non loaded nanospheres re-synthesized with surface loading

Next we examined the effect of mixing PCPP with spermine before the addition
of IO-MHPC. As shown in Figure 2.5d, IO-MHPC surface adherence was unaffected
when added after spermine addition, demonstrating that surface loading does not occur
during the PCPP and spermine cross-linking process. To further explore the mechanism
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of surface loading, non loaded spheres were completely formed before the addition of
IO-MHPC. The PCPP solution and spermine were first mixed and then transferred to
CaCl2 for 30 minutes at room temperature. Afterwards, IO-MHPC were added into the
solution and stirred for an additional 30 minutes. The results seen in Figure 2.5e showed
no surface loading of IO-MHPC in the sample. These data demonstrate that surface
loading of MHPC lipid coated IONP (IO-MHPC) is achievable at any stage before CaCl2
stabilization. We also found fully synthesized non loaded nanospheres (nanospheres
formed in the absence IO-MHPC) could be surface loaded by incubating the non loaded
spheres with IO-MHPC and then transferring to 0.88% CaCl2 solution for 30 minutes
Figure 2.5f). This data suggests a calcium dependent mechanism for surface loading.
Presumably there is some form of calcium-mediated binding between the PCPP and
phospholipid head group (Ca2+ binding to phospholipids is well known).42 Other divalent
cations could likely produce similar phenomenon as Ca2+.
With our standard synthesis method, we studied the IO-NB stability over time
when stored in Milli-q water at room temperature. After 24 hours, the IO-NB were found
to loosely settle, but could easily be re-dispersed with gently mixing. The surface loading
and structure of these nanospheres was unaffected over the observed time frame of 7
months as determined by TEM (Figure 2.6). These data indicate that the particles are
robustly stable when stored at room temperature for extended periods of time.
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Figure 2.6 Shelf life of IO-PCPP.
TEM of IO-NB stored at room temperature for (a) 1 day, (b) 3 days, (c) 1 week, (d) 2
weeks, (e) 3 weeks, and (f) 7 months.

2.4.4 Surface loading is independent of polymer size, lipid length, core size, and
core type
Exclusive surface loading was found with the use of MHPC lipids encapsulating
15.6 nm diameter iron nanoparticles. We examined the flexibility of the reaction by
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varying parameters such as PCPP molecular weight, phospholipid length, and
nanocrystal core size and type. Surface loaded nanospheres were synthesized using our
standard method with PCPP in a range of molecular weights (35.6 kDa, 1.0 MDa, 3.8
MDa MW). Surface loading of IO-MHPC was found with each PCPP MW, demonstrating
that the process is independent of polymer size (Figure 2.7). The effect of phospholipid
tail length was studied by encapsulating 15.6 nm diameter IONP with 12 (LHPC), 14
(MHPC), 16 (PHPC), and 18 (SHPC) carbon tail chain length phospholipids. PCPP
nanospheres were successfully synthesized and surface loaded with each micelle
formation (Figure 2.8). Note that LHPC is a relatively poor amphiphile and therefore
formed aggregates as opposed to individually dispersed nanocrystals). Additionally,
oleate-coated IONP of increasing sizes (10, 15, 20, 25, 30 nm diameters) were
encapsulated in micelles using MHPC/DMPC mixtures (IO-MHPC-DMPC). Micelles
synthesized using only MHPC to encapsulate the larger 25 and 30 nm IONP were not
stable, however, we found that they could be stably coated with a 1:1 mixture of
MHPC/DMPC and that nanoparticles with such coatings adhered to PCPP nanospheres
also. The PCPP nanospheres were synthesized using our standard method with the
various IONP core sizes. TEM revealed surface loading occurred for each core size
(Figure 2.9).
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Figure 2.7 IO-PCPP molecular weight.
Surface loading using increasing PCPP MW polymer: (a) 35.6 kDa PCPP, (b) 1.0 MDa
PCPP, (c) 3.8 MDa PCPP

Figure 2.8 Loading with varying micelle phospholipid length.
Surface loading of IONPs with increasing carbon tail lengths. (a) IO-LHPCs (12 carbon
tail length) (b) IO-MHPCs (14 carbon tail length), (c) IO-PHPC (16 carbon tail length),
and (d) IO-SHPC (18 carbon tail length) loaded onto PCPP nanospheres.
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Figure 2.9 Size variants of IONPs formed in phospholipid micelles.
TEM images of PCPP nanosphere phospholipid mixture micelles: (a) 10 nm IO-MHPCDMPC, (b) 15 nm IO-MHPC-DMPC, (c) 20 nm IO-MHPC-DMPC, (d) 25 nm IO-MHPCDMPC, (e) 30 nm IO-MHPC-DMPC particles.

To further explore the breadth of applicability of this surface loading process, a
variety of diagnostically active nanocrystals were investigated for adherence to PCPP
nanospheres. Oleic acid coated quantum dots (CdS spheres) and nanophosphors (βNaGdF4 spheres, rods, LaF3 discs) were all found to incorporate into MHPC micelles
using the same procedure as for IONP. Surface loading of each core variant was
achieved through our standard method of PCPP nanosphere synthesis. TEM verified
surface adsorption to be present in each sample (Figure 2.10). From these data,
nanocrystals encapsulated into phosphocholine head group lipid micelles can be
90

successfully surface adsorbed onto PCPP nanospheres regardless of the core type,
size, or shape.

Figure 2.10 Surface loaded nanocrystals variants.
TEM images of PCPP nanosphere surface loaded with various nanocrystals. (a) βNaGdF4 spheres, (b) β-NaGdF4 rods, (c) LaF3 discs, and (d) CdS quantum dots surface
loaded onto PCPP nanospheres (QD-NB).

2.4.5 Excess empty micelles disrupt nanosphere formation but not surface
adherence
We examined whether an excess of empty micelles would reduce surface
adsorption of IO-MHPC on PCPP nanospheres. Empty MHPC micelles were mixed
together with IO-MHPC at increasing ratios (1:1, 5:1, 10:1, 25:1, based on phospholipid
content). PCPP nanosphere synthesis was performed using our standard method with
these empty micelles:IO-MHPC ratios. From TEM, lower ratio mixtures did not appear to
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affect surface adsorption of IO-MHPC onto the PCPP nanospheres (Figure 2.11).
However, at larger ratios of 10:1 and 25:1, disruption of nanosphere formation was
observed. These particles appeared amorphous but the surface adsorption of the IOMHPC was still present. The increased concentration of empty micelles appeared to
interfere with the spermine-PCPP cross-linking. We hypothesized that performing the
cross linking before the addition of IO-MHPC and empty micelles would allow for the
observation of competition without disrupting the PCPP nanosphere formation. We found
that by adding the spermine before the IO-MHPC, we were able to surface load IOMHPC in the presence of high concentrations of empty micelles. Ratios of 10:1, 15:1,
20:1, 25:1 were used in the synthesis, and surface loading of IO-MHPC appeared similar
in all samples (Figure 2.12). This phenomenon could be due to the larger area of
interaction for the IO-MHPC with the PCPP nanospheres creating stronger attachments,
therefore preferentially binding IO-MHPC as compared to empty MHPC micelles.
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Figure 2.11 Empty micelle inhibition of PCPP formation.
TEM images of PCPP nanosphere standard synthesis with increasing ratios of empty
MHPC-micelles to IO-MHPC: (a) 1:1 (b) 5:1 (c) 10:1 (d) 25:1
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Figure 2.12 Competitive inhibition with cross-linking before surface loading.
TEM images of PCPP nanospheres formed with increasing ratios of empty MHPCmicelles to IO-MHPCs: (a) 10:1 (b) 15:1 (c) 20:1 (d) 25:1. Samples synthesized with
spermine addition preceding addition of IO-MHPCs and empty MHPC-micelles mixture.

2.4.6 Particles remain diagnostically active after surface loading
With the ability to load a variety of diagnostically active nanoparticles, we
evaluated the contrast generating properties of nanocrystal loaded polymer particles.
Magnetic moment curves measured for IO-MHPC and IO-NB did not indicate magnetic
hysteresis (Figure 2.13). IO-MHPC and IO-NB had almost identical magnetization
saturation values of 67.81 and 65.01 emu/g, respectively. The longitudinal and
transverse relaxivity (measures of MRI contrast) of surface loaded IO-NB were
examined (Table 2.2) at 1.41 T and 37 °C. Surface loaded particles, IO-NB were found
to have a lower transverse (r2) relaxivity than free IO-MHPC, although still at a
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substantial value of 68.2 mM-1s-1. The decreased relaxivity could be caused by some
loss of interaction between the surrounding water due to the absorption of IO-MHPC to
the PCPP nanospheres.43

Figure 2.13 Magnetic hysteresis curves for IO-NB and IO-MHPC.
Measured magnetic saturation values were IO-MHPC, 67.81 and IO-NB, 65.01 emu/g.

However, the ratio of transverse to longitudinal relaxivity (r 2/r1) was higher for IONB indicating good properties for T2-weighted imaging. Additionally for further
evaluation, contrast generation for IO-NB was evaluated with a MRI scan. Iron oxide
increases the rate of transverse relaxation therefore leading to a decrease in signal
intensity, or darkening in T2/T2*-weighted MR images. An MR image of a phantom
containing IO-NB (0.05 and 0.16 mM Fe), DPBS, free IO-MHPC (0.16 mM Fe) and non
loaded PCPP spheres are displayed in Figure 2.14a. The DPBS and non loaded PCPP
nanospheres were of relatively similar signal intensity. As expected, the IO-NB were
much darker, with a concentration dependent intensity. Although, the IO-NB and IOMHPC samples were at the same concentration, the IO-NB produced less signal. This
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effect could be due to the increased relaxivity (r2/r1) ratio seen in the relaxation
measurements, or perhaps is due to the different field strengths used for imaging and to
determine relaxivities. Overall, IO-NB retained relaxation properties that allow for
contrast generation in MRI. Moreover, PCPP nanospheres loaded with quantum dots
(QD-NB) exhibit similar fluorescent properties as free quantum dots (QD-MHPC). The
fluorescence of the quantum dots persisted after encapsulation in micelles and PCPP
surface loading (Figure 2.14). The phantom image in Figure 2.14 indicates the strong CT
contrast produced by gold loaded PCPP particles.
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Figure 2.14 Applications of surface loaded PCPP nanospheres.
(a) MRI phantom image. (b) fluorescence image of non loaded PCPP particles, QDMHPC micelles and QD-NB. Scale bar in units of radiant efficiency (*107
(p/s/cm2/sr)/µW/cm2) (c) CT phantom image of gold loaded PCPP particles (17 mg/ml).

Table 2.2: Relaxation measurements for free IO-MHPC and IO-NB at 1.41 T.

2.4.7 In vitro evaluation of core loaded nanospheres for monocyte labeling
With confirmation of diagnostic activity of core and surface loaded PCPP
nanospheres, their effectiveness in biomedical applications were assessed. PCPP
nanospheres core-loaded with AuNP were investigated for cell viability and function.
97

Monocytes were incubated with Au-PCPP for 24 hours for all studies. Uptake of these
particles (5:1 ratio of gold to PCPP by mass, Au-PCPP5) were assessed with CT scans
demonstrating an increase in x-ray attenuation with increased incubation concentrations
(Figure 2.15a). Cytotoxicity across different gold concentrations were assessed with both
Au-PCPP1 (1:1 mass ratio) and Au-PCPP5 (5:1 mass ratio). Cytotoxicity was observed
with increasing concentration for both formulations, but was more pronounced for the
Au-PCPP1 formulation (Figure 2.15b). We also sought to investigate the release of TNFα, an inflammatory cytokine released during activation of the monocytes. Monocytes
were incubated with Au-PCPP5 at increasing concentrations with and without
lipopolysaccharides (LPS). LPS causes the activation of the monocytes and subsequent
release of TNF-α. At the highest concentrations examined (0.25 and 0.5 mg/ml), the
difference between LPS and non LPS groups were non-significant indicating that the AuPCPP5 at those concentrations were activating the monocytes (Figure 2.15c).
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Figure 2.15 In vitro assessment of AuNP core loaded in PCPP nanospheres.
PCPP nanospheres loaded with AuNP (5:1 ratio gold to PCPP) incubated with a
monocyte cell line for 24 hours. (a) X-ray attenuation measured at different treatment
concentrations of Au-PCPP5. (b) (1:1, Au-PCPP1 and 5:1, Au-PCPP5) viability
assessed at increasing concentrations after 24 hour treatment. (c) TNF-α release of
monocytes treated with Au-PCPP5 for 24 hours with and without LPS activation. Student
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t-test used to compare significance between groups with and without LPS at identical
concentrations (p<0.05 for significance). Non-significance represented by n/s.

2.4.8 In vitro evaluation of surface loaded nanospheres
The robustness of surface attachment of IO-MHPC to PCPP nanospheres was
briefly evaluated for potential biological applications. We incubated nano-disco balls (IONB) for 1, 4, 24 hr in cell culture media at 37 °C. IO-NB were then collected through
centrifugation and iron oxide content was measured through ICP-OES (Figure 2.16a).
The loss of iron content in the samples appeared similar at each time point suggesting
that after some initial IO-MHPC release, the remainder was retained over the timeframe
tested. TEM performed on these nanoparticles revealed that many IO-MHPC were still
attached to the surface of PCPP nanospheres after 4 hr incubation (Figure 2.16b). Next
we incubated IO-NB with RAW 264.7 monocytes for 4 hr. Remarkably, TEM performed
on these cells revealed IO-MHPC organized in ring shapes located within endosomes
(Figure 2.16c). We believe this demonstrates that the IO-MHPC still remain surface
bound to PCPP nanospheres after undergoing cellular uptake.
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Figure 2.16 IO-NB stability and uptake for cell studies.
(a) Remaining iron oxide concentration after incubation in serum for 1, 4, and 24 hrs. (b)
TEM image of IO-NB incubated for 4 hours in cell culture media. (c) TEM images of
macrophages that have been incubated with IO-NB. Arrows indicate areas of IO-NB
uptake.

2.4.9 Delivery of protein loaded IO-NB
With exclusive surface loading of polymer nanospheres, the internal core of the
nanospheres can be used for drug loading. We used bovine serum albumin conjugated
with fluorescein isothiocyanate (FITC-BSA, 0.25 mg) as a model drug. This was loaded
into PCPP nanospheres (FITC-PCPP). Additionally, FITC-BSA was loaded into the core
of nanospheres with simultaneous surface loading of IO-MHPC (FITC-NB, 0.1, 0.25 mg).
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TEM and fluorescence imaging were used to characterize FITC-PCPP and FITC-NB.
Both particles demonstrated successful loading of FITC-BSA into the PCPP nanosphere
as evident from the fluorescence of the purified material. TEM of FITC-NB revealed that
IO-MHPC were surface loaded in the presence of the additional FITC-BSA payload,
without alteration of the NB structure (Figure 2.17).

Figure 2.17 FITC-BSA loaded PCPP.
Characterization of PCPP nanospheres with core loaded FITC-BSA. TEM images of (a)
FITC-PCPP particles and (b) FITC-NB particles. Image of fluorescent intensity of FITCPCPP, FITC-NB, IO-NB, and DPBS. Scale bar in units of radiant efficiency (*108
(p/s/cm2/sr)/µW/cm2).

To evaluate the ability of these particles to deliver FITC-BSA to cells, they were
incubated with monocytes for 4 hours. Afterwards the cells were stained with DAPI and
imaged with fluorescence microscopy. Phase images of treated cells reveal areas of
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particle uptake within the cells (Figure 2.18). Additionally, FITC can be seen within the
cells as defined by DAPI (nuclei stain). The added surface loaded IO-MHPC did not
prevent the delivery of FITC-BSA to the cells. These data demonstrate that “drug” (FITCBSA) loading can be achieved with additional exclusive surface loading. Furthermore,
the loaded nanospheres remained stable for in vitro tracking of delivery into cells.

Figure 2.18 Delivery of FITC-BSA in PCPP nanospheres.
Fluorescence of monocytes treated with FITC-BSA encapsulated PCPP nanospheres.
Images of phase, DAPI (blue), FITC (green), and the combination of DAPI and FITC for
the conditions indicated after 4 hours.
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2.5 Discussion
In this study, we have examined the PCPP nanosphere platform, investigating
the ability to load nanocrystals both internally and externally. With polymer nano-carriers,
drugs and/or nanocrystals are incorporated into the core of the complex and have been
explored with several biomedical applications.44-45 Similarly in our study, inclusion of 11MUA AuNP aggregated into the core of the PCPP-nanospheres. These Au-PCPP
particles were able to incorporate up to a 5:1 mass ratio between gold and PCPP, albeit
with a morphological distortion (Figure 2.3). However, with the use of MHPC coated
nanocrystals, we found selective loading onto the surface of the PCPP nanospheres.
The controlled localization of nanocrystals to the surface opens opportunities in
various delivery and imaging applications. In the study, the robustness of the synthesis
and its steps were probed, demonstrating that many parameters (lipid coating, PCPP
MW, nanocrystals) can be varied and still achieve selective surface loading of those
particles. As shown in Figure 2.6, the IO-NB remain stable for prolonged periods at room
temperature, demonstrating an overall stability. Additionally, the ability to load many
different types of nanocrystals regardless of size, shape, or elemental composition
(Figure 2.10) opens a number of interesting avenues for the platform. In the single pot
synthesis, particles can be controlled to localize on the surface or core allowing for
multimodal applications carrying different agents. In Figure 2.18, FITC-BSA was core
loaded into PCPP with IO-MHPC localized to the surface of the platform. We
demonstrated that the FITC-NB could be internalized by monocytes with the structure
remaining intact. Both agents could be delivered simultaneously while remaining
separated.
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Gold nanoparticles loaded into the PCPP nanospheres can be used as CT
contrast agents due to gold’s x-ray attenuation. We investigated this potential application
by evaluating 5:1 mass ratio (Gold to PCPP) Au-PCPP5. The Au-PCPP were able to
generate CT contrast, as demonstrated by the phantom images shown in Figure 2.14.
Additionally, when incubated with monocytes, high uptake was observed in the cells by
measuring the x-ray attenuation in cell pellets (Figure 2.15). For biocompatibility, AuPCPP5 incubated with monocytes showed some cytotoxicity at the highest concentration
of 0.5 mg/ml. At the same concentration, Au-PCPP1 showed nearly 100% cytotoxicity.
These results demonstrated, that at high concentrations, Au-PCPP may be affecting cell
behavior. To further investigate, the release of TNF-α from monocytes after incubation
with Au-PCPP5 was measured. In Figure 2.15, high treatment concentrations of AuPCPP5 resulted in comparable releases of TNF-α to LPS activated monocytes. LPS is
an activator of monocytes, causing monocytes to release TNF-α and other inflammatory
cytokines.46 Ideally, the uptake of Au-PCPP5 should not affect the normal function of
monocytes for cell tracking applications. For CT applications, high concentrations of gold
are required for imaging, however at high concentrations of Au-PCPP5, some cytotoxic
and activation effects were seen. For these reasons, Au-PCPP is not ideal for monocyte
labeling and we therefore examined alternative nanoparticles for this application, as
described in subsequent chapters.

2.6 Conclusion
As we have described above, PCPP nanospheres can be loaded with
nanocrystals in a controlled fashion to result in exclusive localization of the nanocrystals
to the surface of the sphere rather than the typically observed core loading of polymer
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nanoparticles. We found that simultaneous surface and core loading is possible. A range
of diagnostically active nanocrystals could be surface loaded onto the PCPP
nanospheres regardless of their individual core size, shape, or chemical composition.
The nanocrystals loaded on the spheres retained their contrast generating properties,
i.e. MR contrast in respect to relaxation for iron oxide particles and fluorescence for
quantum dots. The point of nanocrystal attachment was also probed through the
investigation of each synthesis step. We observed that surface loading was successful
prior to CaCl2 addition. In addition, we found that surface loading was achievable using a
variation of polymer sizes and phospholipid tail lengths, demonstrating multiple feasible
approaches to surface loading. We showed the stability of the nano-disco balls in cell
culture media and the potential for drug delivery and cell tracking. However, labeling of
monocytes with AuNP core-loaded PCPP nanospheres showed adverse effects on
viability and cytokine expression, despite the excellent x-ray attenuation results. For
monocyte tracking, the contrast generation of gold nanoparticles is promising, but further
refinement of nanoparticle parameters to improve biocompatibility is necessary. We
explore the physical and chemical properties for gold nanoparticles as optimized
monocyte labeling in the following chapters.
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2.7 Appendix
Determination of IO-MHPC coverage on PCPP particles

PCPP Available Surface Area
Average diameter of sphere (from TEM): 487 nm
Surface area of one sphere: 4πr2
4π*((4.87e-5)/2)2) = 7.45e-9 cm2
Volume of one sphere: 4/3πr3
(4/3) π*(4.87e-5)/2)3) = 6.04e-14 cm3
Assume density of PCPP = 1000 mg/ml,
PCPP mass in one sphere: Vol of one sphere*density
(6.04e-14)*(1000) = 6.04e-11 mg
Assume 50% PCPP use in batch, total mass = 1mg
Total number of PCPP spheres in batch: Total mass/mass of one sphere
1/(6.04e-11) = 1.65e10 spheres
Total available surface area for binding in one batch: SA for one sphere *total spheres
(7.45e-9)*(1.65e10) = 123.2 cm2

Binding Space of Iron Oxide Nanoparticle
Average diameter of IONP (from TEM): 15.6 nm
Volume of one particle: 4/3πr3
(4/3) π*(1.56e-5)/2)3) = 1.98e-18 cm3
Density of IO = 5175 mg/ml
IO mass of nanoparticle: Vol of IONP*density
107

(1.98e-18)*(5175) = 1.03e-14 mg
Average iron content in one batch (from ICP) = 0.075mg
% iron in IO particle (Fe3O4):
(3*55.6)/((3*55.6)+(4*15.9))*100 = 72.34%
Total IO mass in one batch: (ICP mass)/(% iron in IO)
0.075/(72.34/100) = 0.104 mg
Total number of IONP particles in batch: (total IO mass)/(mass IO sphere)
0.104/(1.03e-14) = 1.00e13 particles
Hydrodynamic diameter of IONP =35 nm
Binding area of IONP (area of circle) = 2πr2
2π((3.5e-6)/2)2 = 9.63e-12 cm2
Total binding area occupied by IONP in one batch: Binding Area*total IONP particles
(9.63e-12)*(1.00e13) = 96.96 cm2

Coverage of PCPP nanosphere
Total binding area of IONP/Total available surface area of PCPP:
(96.96/123.2) = 78.7%

# of IONPs per PCPP sphere
SA of one PCPP sphere *Coverage / Binding area of one IONP
(7.45e-9)*(78.7/100) / (9.63e-12) = 609.49 IONPs per PCPP sphere
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Chapter 3: Effect of size and surface functionality of AuNP for
monocyte labeling

3.1 Abstract
With advances in cell therapies, interest in cell tracking techniques to monitor the
migration, localization and viability of these cells continues to grow. X-ray computed
tomography (CT) is a cornerstone of medical imaging but has been limited in cell
tracking applications due to its low sensitivity towards contrast media. In this study, we
investigate the role of size and surface functionality of gold nanoparticles for monocyte
uptake to optimize the labeling of these cells for tracking in CT. We synthesized gold
nanoparticles (AuNP) that range from 15 to 150 nm in diameter and examined several
capping ligands, generating 44 distinct AuNP formulations. In vitro cytotoxicity and
uptake experiments were performed with the RAW 264.7 monocyte cell line. The
majority of formulations at each size were found to be biocompatible, with only certain
150 nm PEG functionalized particles reducing viability at high concentrations. High
uptake of AuNP was found using small capping ligands with distal carboxylic acids (11MUA and 16-MHA). Similar uptake values were found with intermediate sizes (50 and 75
nm) of AuNP when coated with 2000 MW poly(ethylene-glycol) carboxylic acid ligands
(PCOOH). Low uptake values were observed with 15, 25, 100, and 150 nm PCOOH
AuNP, revealing interplay between size and surface functionality. TEM and CT
performed on cells revealed similar patterns of high gold uptake for 50 nm PCOOH and
75 nm PCOOH AuNP. These results demonstrate that highly negatively charged
carboxylic acid coatings for AuNP provide the greatest internalization of AuNP in
monocytes, with a complex dependency on size.
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3.2 Introduction
The ability to track specific cells non-invasively in biological systems is of growing
importance.1 With surging interest in adoptive cell therapies for cancer treatment and the
promise of stem cell therapy, techniques to monitor the behavior of transferred cells are
becoming increasingly valuable tools.2-4 Labeling and tracking of transferred cells can be
uniquely informative, revealing insights about cell migration, differentiation and viability
without invasive procedures.3, 5 A number of studies have explored the potential benefits
of cell tracking for cellular therapies including applications for stem cell implantations, Tcell immunotherapy, and myeloid cells for treatment of myocardial infarction.6-10
Only a few groups have attempted to use the advantages of x-ray computed
tomography (CT) for the purpose of cell tracking.11-13 CT is a whole body imaging
technique that has high spatial and temporal resolution, which has led it to become one
of the foremost clinical imaging methodologies, with more than 70 million scans
performed annually in the USA alone.14-15 CT is therefore the first-in-line imaging
modality for a number of conditions, such as cardiovascular disease, lung cancer and
trauma.15-16 The development of cell tracking for CT is therefore of considerable interest.
For CT, attenuation from contrast agents is linearly proportional to the concentration of
the agent allowing for quantification opportunities in cell tracking. For instance, Betzer et
al., were able to estimate the number of gold labeled cells in vivo in a region of the brain
non-invasively using CT scans.17 Quantifying cell numbers can reveal vital information
for cell tracking studies including cell migration and viability. Advances in emerging CT
technology continue to open new possibilities for cell tracking; e.g., with the use of x-ray
synchrotron beams, some groups were able to achieve single cell resolution for cell
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tracking.18-19 Additionally, with the emergence of spectral CT for specific differentiation of
contrast agents from tissue, opportunities for cell tracking with CT continue to grow. 14, 20
Cell tracking requires the labeling of specific cells of interest with a reporter for
imaging. The challenge for CT is its low sensitivity towards contrast agents, which
demands efficient methods for labeling cells with high payloads. Gold nanoparticles
(AuNP) are an attractive platform upon which to base CT contrast agents due to being
biologically inert, providing strong attenuation for CT and their high density, which allows
efficient payload delivery.21-22 Moreover, developments in AuNP chemistry have allowed
for control over their size, shape and chemical functionality allowing the nanoparticle
properties to be tailored for specific biomedical applications.23-24 Previous investigations
have shown that these nanoparticle properties can affect cytotoxicity, cell uptake and
serum protein interactions in biological systems.25-27 However, the interaction of the
nanoparticles appears to be dependent on the surrounding biological environment and
system of interest, so the optimal nanoparticle properties for desired interactions (i.e. cell
avoidance or uptake) must be determined for each specific case.28
Monocytes play a critical role in the progression of plaques and other diseases,
with monocyte recruitment being prominent in early stages of disease development.29-32
Imaging recruitment of these monocytes can reveal information about the disease state
and allow further investigation of factors that may affect this behavior. In this study, we
sought to optimize the uptake of AuNP by monocytes via examining in depth, the effects
of size and chemical functionality on AuNP uptake. We synthesized and characterized a
library of particles ranging from 15 nm to 150 nm in diameter, each coated with several
functionally distinct ligands, totaling 44 unique formulations. We sought to explore short
carbon chain carboxylic acid and poly(ethylene) glycol ligands with carboxyl acid end
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groups. Additionally, we explored poly(ethylene) glycol ligands with alternate end groups
to explore how differences in surface properties affect interactions with monocytes. The
interactions of these nanoparticles with monocytes were assessed via viability and
uptake studies. Moreover, parameters of incubation time were explored to optimize cell
uptake. CT contrast generation of AuNP labeled monocytes was examined with CT
scans and intracellular localization studied with TEM.

3.3 Materials and methods
3.3.1 Materials
Chemicals of analytical grade were purchased from Sigma-Aldrich (St. Louis, MI)
unless specified elsewhere. The monocyte cell line used for cell studies, RAW 264.7,
was purchased from ATCC (Manassas, VA). Cells were cultured with Dubecco’s
Modified Eagle Medium (DMEM) supplemented with 10% fetal bovine serum (FBS) and
1% penicillin/streptomycin (10000 units/MI, 10000 µg/mL), purchased from Cellgro,
Corning (Manassas, VA).

3.3.2 AuNP synthesis
Spherical AuNP of 15 nm and 25 nm in diameter were synthesized using a
modified Frens/Turkevich method.33-34 For 15 nm AuNP, 600 µl of 1% gold(III) chloride
(HAuCl3) was dissolved in 60 mL of ultrapure water (Milli-Q, EMD Millipore, Billerica MA).
The solution was brought to a boil before 1.8 mL of 1% sodium citrate dihydrate was
added to the mixture. The solution was left to reflux for 15 min before cooling to room
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temperature. Similarly, 25 nm AuNP were synthesized by adding 1 mL of 1% sodium
citrate dihydrate to the boiling gold solution.
AuNP ranging from 50 nm to 150 nm in diameter were synthesized using the
seeded growth method described by Perrault et al.35 Briefly, 15 nm spherical AuNP were
used as seeds in this method and were produced as outlined above. For the synthesis, 1
mL of 1% HAuCl3 was added to 100 mL of ultrapure water at room temperature. A
number of gold “seeds” were added to the solution to create nanoparticles 50, 75, 100 or
150 nm in diameter. The number of seeds needed for each size was empirically
determined (Figure 3.1). A typical solution of seeds contained 1.54 x1012 seeds/mL. For
example, 50 nm AuNP were synthesized by adding 3 mL of seed solution (as made in
the above method) to HAuCl3 solution. To initiate the AuNP growth reaction, 220 µL
sodium citrate dihydrate (1% weight/volume) and 1 mL of 0.03 M hydroquinone solution
were added quickly in succession to the seed/HAuCl3 solution. The solution was allowed
to stir for an hour before performing ligand exchange.
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Figure 3.1 Seed number vs gold size diameter.
Effect of seed number (15 nm seeds) on gold nanoparticle diameter in the seeded
growth method used in this study.

After AuNP core synthesis, ligand exchange was performed with a library of
ligands to stabilize the AuNP for biomedical applications and provide differing chemical
functionalities to explore their effect on cell uptake. AuNP that did not undergo ligand
exchange remained coated with citrate and were also used in the study. Short carbon
chain carboxylic acid ligands 11-mercaptoundecanoic acid (11-MUA) and 16mercaptohexadecanoic acid (16-MHA) were examined. Additionally, 2000 MW
poly(ethylene-gycol) with methoxy (MPEG), carboxylic acid (PCOOH), and amine
functional groups were examined. AuNP synthesized with PEG-amine were found to
aggregate during ligand exchange, however, amine containing coatings were achieved
by using 1:4 ratio of PEG-amine to MPEG (2N8M) or PCOOH (2N8C). Each
nanoparticle size was capped with a ligand amount that we estimated based on the total
nanoparticle surface area for that size. A ratio of 1.35 x 106 mmol/cm2 was used to
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determine the amount of ligand to use (Table 3.1). Each ligand was dissolved at 5
mg/mL concentration before addition to the gold solutions. 11-MUA and 16-MHA ligands
were dissolved in ethanol and all PEG functionalized ligands were dissolved in water.
For example, for 100 nm PCOOH, 85 µL (0.421 mg) of 5 mg/mL PCOOH solution was
added to a typical 100 nm seeded growth solution (100 mL) for exchange. Gold solutions
were allowed to stir overnight for complete ligand exchange. Afterwards, the
nanoparticles were washed twice by centrifugation and then purified through a 0.45 µm
syringe filter (EMD Millipore, Billerica MA). The parameters for centrifugation were
specific to each size and can be found in Table 3.2.
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Table 3.1 Ligand determination for each size of AuNP.

123

Table 3.2 Centrifuge parameters for gold nanoparticles.
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3.3.3 Particle characterization
The AuNP concentration after purification was determined through inductively
coupled plasma – optical emission spectroscopy (ICP-OES). Samples (typically around
10 µL) were dissolved in 1 mL aqua regia (3 parts HCl:1 part HNO 3) for 30 mins before
making the final volume of the sample to 3 mL with ultrapure water. The resulting
solutions were analyzed with a Spectro-Genesis ICP (Spectro Analytical Instruments
GmbH, Kleve, Germany) for gold content. Transmission electron microscopy (TEM) was
used to visualize the AuNP and evaluate core size and was performed on a JEOL 1010
(JEOL USA Inc., Peabody MA) at 80 kV. Over 200 AuNP in the TEM images were
measured with ImageJ (National Institutes of Health) to determine the average diameter
for each core size. UV/Vis spectra were recorded using an Evolution 201 UV-Visible
Spectrophotometer (Thermo Scientific, Waltham, MA) scanning from wavelengths of 700
to 300 nm. Typically, 10 µL of sample was added to a cuvette and diluted to 1 mL with
ultrapure water. The hydrodynamic diameters (dynamic light scattering) and zeta
potentials of the AuNP were evaluated using a Nano ZS-90 Zetasizer (Malvern
Instruments, Worcestershire, UK). AuNP samples were diluted to 1 mL with ultrapure
water for analysis with these techniques.

3.3.4 In vitro studies
The effects of AuNP size and coating were studied using a monocyte cell line,
RAW 264.7. The LIVE/DEAD assay (Life Technologies, Frederick, MD) was used to
study cytotoxicity. Monocytes were cultured in 20 mm glass bottom dishes at 7.5 x 104
cells per dish for 24 hours at 37˚C, 5% CO2 with DMEM (10% FBS, 1%
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streptomycin/penicillin). After this time, the media was removed and fresh media
containing AuNP at 0.1, 0.5, 1.0 mg/ml or without AuNP was added. The cells were
incubated with the AuNP for 24 hours before performing analyses, unless specified
otherwise. After incubation, cells were washed twice with DPBS before 400 µL of
LIVE/DEAD cocktail (2 mL DPBS, 2 µL stock Ethidium-1 homodimer, 0.5 µL stock
Calcein AM, 0.5 µL 3.2 mM Hoechst 33342) was gently added to the cells. The cells
were incubated for 20 mins with the LIVE/DEAD cocktail. Afterwards, the cells were
imaged with Nikon Eclipse Ti-U fluorescence microscope. Filters for DAPI (Ex. 359, Em.
461 nm), FITC (Ex. 495, Em. 519 nm), and Texas Red (Ex. 595, Em. 613 nm) were used
to visualize cell nuclei, living cells and dead cells respectively. Four separate fields were
taken for each dish for each filter channel. The images were analyzed by a custom
MATLAB (MathWorks, Natick MA) program to count the number of stained cells in each
field. The viability percent is expressed as number of living cells divided by total number
of cells present in each field of view. Viability experiments were repeated 3 times (n=3).

3.3.5 Cell uptake studies
For uptake studies, monocytes were cultured in 12 well plates, 8.0 x 105 cells per
well for 24 hours at 37˚C, 5% CO2 with DMEM (10% FBS, 1% streptomycin/penicillin). At
this point, the media was removed and replaced with fresh media containing AuNP.
Various concentrations, formulations and timeframes were used, see results for details.
After incubation with AuNP, the media was removed and the cells were washed twice
with DPBS and then scraped for collection in 1 mL of DPBS. The cells were counted with
a hemocytometer and centrifuged at 200 g for 5 mins to form a pellet. The supernatant
was discarded and the cells were re-suspended in 200 µL of 4% paraformaldehyde
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(PFA) until preparation for ICP-OES. Cells were dissolved in 1 mL of aqua regia (3 parts
HCl:1 parts HNO3) for 30 mins and then centrifuged at 200 g for 5 mins to pellet and
discard cell debris. The supernatant was collected and diluted to 3 mL with ultrapure
water and analyzed with ICP-OES.
Cells treated with AuNP for 24 hours were also collected and fixed in 2%
PFA/2.5% glutaraldehyde, cut into 60 nm sections and prepared using standard
techniques for examination with TEM.36 Sections were viewed with a JEOL 1010
Electron Microscope at 80 kV. For CT scans, after treating cells with AuNP, monocytes
were collected and fixed with 200 µL 4% PFA. The cells were allowed to loosely settle
into pellets in 250 µl tubes before scanning with a small animal MicroCAT II scanner
(Imtek Inc., Knoxville, TN). The parameters used for the scan were 100 µm slice
thickness (100 x 100 µm in-plane spatial resolution), 51.2 mm x 76.8 mm field of view,
80 kVp tube voltage, and tube current of 500 µA. The microCT contains a 1.0 mm
aluminum beam filter. Image reconstruction was done using a Feldkamp cone beam
correction and a Shepp-Logan filter, which produced images scaled in Hounsfield units
(HU). Images were analyzed with OsiriX v3.7.1 64-bit software. Identical regions of
interest (1.5 mm2) were drawn on 3 sequential slices in the cell pellets and the recorded
attenuation values averaged. The ΔHU was defined as the difference in attenuation
between non treated cell pellets and samples treated with AuNP.

3.3.6 Statistical methods
All error bars shown on figures are standard errors of means. Statistical analysis
was performed using Stata-14 (64-bit, College Station, Texas). For viability of 150 nm
PCOOH, 2N8M, and 2N8C, a one-way ANOVA was used to determine significance
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among concentrations. Post-hoc, Tukey pairwise mean comparison was used to
compare the interactions between each concentration. For our time course experiment,
a one-way ANOVA was used to analyze significance for cell numbers and AuNP uptake.
Tukey pairwise mean comparison was used to compare interactions between each time
point for both cell number and uptake. For uptake experiments, a two-way ANOVA was
used to analyze significance differences caused by both size and coating on uptake.
Afterwards, a post-hoc Tukey pairwise mean comparison was used to analyze
differences between coatings at each size. For CT attenuation experiments, a one-way
ANOVA was performed to determine significant differences at each concentration
examined. A post-hoc Tukey pairwise comparison was used for the coatings at each
concentration examined.

3.4 Results
3.4.1 AuNP synthesis
Spherical AuNP of approximately 15, 25, 50, 75, 100, and 150 nm in diameter
were synthesized to examine the effect of size on cellular uptake. AuNP of 15 and 25 nm
were synthesized using the Turkevich method.33-34 Diameters of 50 nm and above were
synthesized using a modified seeded growth method described by Perrault et al.35 This
method utilized 15 nm AuNP synthesized via the Turkevich method as nucleation points
to further “grow” gold around these “seeds.” We used the seeded growth method for
these larger diameter nanoparticles, since we found that the Turkevich method resulted
in highly heterogeneous sizes and shapes when forming nanoparticles 50 nm or above.
The number of seeds added to the synthesis dictated the final size of the AuNP. We
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empirically determined the number of seeds needed to form nanoparticles of a range of
sizes with this synthesis (Figure 3.1). TEM images in Figure 3.2 were analyzed to
determine core sizes of the AuNP. The distributions for each nanoparticle size can be
seen in Figure 3.3. A Shapiro-Wilk test was used to test for normality. Each nanoparticle
formulation was found to be normally distributed except the 15 nm particles (p<0.05).

Figure 3.2 TEM of AuNP from 15 to 150 nm.
TEM images of spherical gold nanoparticle of increasing size from 15 to 150 nm. 15 and
25 nm AuNP were synthesized through the Turkevich method. 50, 75, 100, and 150 nm
AuNP were synthesized through a seeded growth method.
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Figure 3.3 AuNP synthesis size distributions.
Histogram plots of size distributions for each AuNP size. Sizes are measured
nanoparticle core diameters from TEM images (>200 particles surveyed). Shapiro-Wilk
test was used to test for normality. Normality was rejected for only 15 nm size particles
(p<0.5).

In addition to forming nanoparticles of a range of sizes, several different coatings
were used for each nanoparticle size. With the use of thiol ligands, the surface coating of
AuNP was exchanged to produce particles with various chemical functionalities. We
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examined seven different coatings for each size of AuNP (including citrate) and each
formulation was characterized for UV/Vis absorption, hydrodynamic diameter (dynamic
light scattering) and overall surface charge (zeta potential) (Table 3.3). The chemical
structure for each ligand is shown in Figure 3.4. Straight-chain hydrocarbon ligands with
distal carboxylic acid functional groups (11-MUA and 16-MHA) were used as they
demonstrate high uptake in monocytes without affecting viability as shown in our
previous work with 15 nm AuNP.13 In addition, a variety of thiol-poly(ethylene-glycol)
(PEG) based coatings were examined. PEG with a distal methoxy group (MPEG) is
widely used to coat nanoparticles, typically providing high stability and resulting in low
cell uptake.37-38 We used this coating as a control.
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Table 3.3 Surface characterization of AuNP formulations

132

Figure 3.4 Schematic of gold ligand exchange.
Schematic depiction of the range of AuNP sizes used in this study and the chemical
structures of the ligands used as coatings. PEG-amine coatings were mixed in 1:4 ratios
with MPEG and PCOOH to provide particle stability. Ligands examined represent
different functionalities and charges.

For this study, we sought to improve AuNP uptake by monocytes, therefore we
investigated PEG coatings with charged distal end groups such as carboxylic acid
(PCOOH) and PEG-amine. The bulky PEG coating should help to provide AuNP
stability, while we hypothesized that the charged surfaces may increase cell uptake. 39
We found that 100% PEG-amine coated AuNP aggregated after 24 hours (data not
shown). However, we found that AuNP coated with PEG-amine mixed in a 1:4 ratio with
MPEG (2N8M) or with PCOOH (2N8C) were stable, and therefore were used in this
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study. Characterization data for each AuNP core size coated are shown in Table 3.3. As
the core diameter of the AuNP increases, the UV/Vis absorbance maxima increase in
wavelength, in agreement with previously published results.40 The surface potential of
PCOOH coated particles for each size is highly negative as expected due to the
carboxylic acid functional end group. Measurements of hydrodynamic diameters were
larger than core diameters measured by TEM as expected due to the ligands attached to
the nanoparticle surfaces. Large PDI values were seen for 25 nm formulations indicating
some heterogeneity for these particles (Table 3.3). With the 11-MUA ligand, 50, 75, 100,
and 150 nm particles were not stable and aggregated during ligand exchange (Figure
3.5) and therefore were not used in the study.

Figure 3.5 Stability of 50 nm AuNP after 24-hour incubation with various ligands.
Aggregation seen for short carboxylic acid coated 50 nm AuNP as compared to other
coatings

3.4.2 Cytotoxicity
As an initial screen for suitability for cell labeling purposes, the effect on cell
viability of each AuNP formulation was examined. The cells were treated with AuNP for
24 hours at concentrations of 0.1, 0.5, and 1.0 mg Au/ml to examine the effect of each
size and surface functionality over a large concentration range (Figure 3.6). The majority
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of formulations studied in the 15-100 nm diameter range were found to be biocompatible
for the concentrations tested. However, significant reductions in cell viability were
observed for several 150 nm AuNP that had PEG-based coatings. For 150 nm PCOOH
AuNP, significant (p<0.05) cytotoxicity was only observed at the highest concentration
tested (1.0 mg Au/ml). In the case of 150 nm 2N8M AuNP, 0.5 and 1.0 mg Au/ml
concentrations resulted in cell viability of approximately 60% but only 0.5 Au/ml was
found to be statistically significant. Lastly, 150 nm 2N8C AuNP caused significant
reductions in cell viability at all concentrations examined.
Formulations that did not cause adverse effects on cell viability were studied for
their uptake by monocytes, as detailed in the next section. However, we found that some
formulations aggregated under the conditions used for cell culture (i.e. 50 nm 2N8C, 75
nm 16-MHA, 75 nm 2N8C, 100 nm 16-MHA, 100 nm 2N8M, 100 nm 2N8C, 150 nm 16MHA, 150 nm 2N8M and 150 nm 2N8C) likely due to a combination of particle instability
and sedimentation. Since co-injection of free nanoparticles with labeled cells would
result in erroneous conclusions in cell tracking experiments, these formulations were
excluded from cell uptake experiments. Notably, this effect was seen in all citrate
formulations regardless of size. This effect was also more common for larger size AuNP
formulations such as 100 nm and 150 nm, for which only MPEG and PCOOH were
found to be stable. This is likely due to the higher van der Waals interactions for these
larger AuNP overcoming the steric/charge-based repulsion of the ligands. Additionally,
formulations that resulted in toxicity at 0.5 mg/ml were excluded from uptake studies.
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Figure 3.6 Cell viability with AuNP formulations.
Cell viability of monocytes incubated with AuNP of a range of diameters and coatings.
Cells were incubated with AuNP for 24 hours at 0.1, 0.5, 1.0 mg Au/ml. Viability was
assessed with the LIVE/DEAD assay. Values are normalized to those for untreated
monocytes. Values represent the mean of 3 replicates (n=3) and error bars represent
standard error of mean. Significance for 150 nm AuNP was examined with one-way
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ANOVA and post hoc Tukey pairwise comparisons. * indicates significance of treated
groups compared to non-treated group (p<0.05).

3.4.3 AuNP uptake by monocytes
We first investigated the optimal incubation time to yield high AuNP uptake.
Figure 3.7 shows the results of experiments where monocytes were incubated with 15
nm 11-MUA AuNP (0.5 mg Au/ml) for several different durations, ranging from 2 to 48
hours. From 2 to 24 hours, AuNP uptake in the cells increased with increasing time in
addition to the number of cells rising. However, there was no significant difference
(p>0.05) in gold uptake between 24 and 48-hour incubations suggesting that the
maximum limit of AuNP uptake had been reached at 24 hours. Additionally, when the
cells were incubated with these AuNP for 48 hours, fewer cells were present after culture
than at 24 hours (p<0.05). From these data, we concluded that 24 hours was the best
duration over which to incubate monocytes with AuNP for both maximum uptake and
number of cells. We therefore used 24 hours incubation time in all subsequent
experiments.
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Figure 3.7 Optimization of AuNP incubation time.
Evaluation of gold content in monocytes incubated with 15 nm 11-MUA AuNP (0.5 mg
Au/ml) for up to 48 hours. In addition, the total number cells at each time point is
displayed. Values represent mean of 3 replicates (n=3) and error bars are standard error
of mean. A one-way ANOVA was used to determine significance for both uptake and
number of cells. Post-hoc Tukey pairwise comparison was used to compare significance
between time points (p<0.05). Results for statistical comparisons between 24 and 48
hours shown only.

For the investigation of cell uptake, all sizes and formulations were incubated
with monocytes at a concentration of 0.5 mg/ml for 24 hours. In Figure 3.8, a number of
distinct relationships between size of nanoparticle and coating ligand on uptake can be
observed. Particles coated with small molecule functionalized carboxylic acids (11-MUA
and 16-MHA) show high uptake with smaller size particles between 15 nm and 50 nm.
However, these ligands were increasingly unstable at larger sizes, preventing
experimental measurements being acquired. MPEG AuNP exhibited low gold uptake in
cells with slightly increasing values at larger sizes. We suspect this result was due to
these larger AuNP settling in the cell culture media, resulting in increased cell contact
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and uptake. Most notably, PCOOH AuNP exhibited a complex relationship between
uptake and particle size. Minimal uptake was found at 15 and 25 nm while the highest
uptake values were observed at 50 and 75 nm. Interestingly, cell uptake for 100 and 150
nm PCOOH AuNP was significantly less than for 50 and 75 nm AuNP. The uptake for
50, 75, and 100 nm PCOOH AuNP was found to be significantly different than all other
coatings at that size (p<0.05). Similar uptake values for 150 nm PCOOH and MPEG
AuNP suggests that for both these nanoparticles uptake may be largely due to particle
settling (non-significant, p >0.05). Low uptake was observed for 15 and 25 nm 2N8C and
were found to aggregate at 50 nm and above.

Figure 3.8 Uptake of gold nanoparticles in monocytes.
Gold uptake in monocytes incubated with AuNP of a variety of sizes and coatings.
Formulations exhibiting particle instability (significant aggregation and sedimentation) or
cytotoxicity were excluded from the study. The cells were treated for 24 hours at 0.5 mg
Au/ml and evaluated for gold content with ICP-OES. Values represent mean of typically
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six replicates (n=6) and error bars are standard error of mean. A two-way ANOVA was
used to determine significance of AuNP uptake for size and coating. A Tukey pairwise
mean comparison was used to determine significance between coatings at each size. *
indicates significance of PCOOH compared to all other coatings at that size.

Monocytes incubated with selected AuNP formulations were additionally
examined with TEM to observe the intra-cellular localization of AuNP. Cells were treated
for 24 hours with 0.5 mg/ml of 15, 75, 100, and 150 nm PCOOH AuNP. The results in
Figure 3.8 show AuNP aggregated into intercellular vesicles located in the cytoplasm of
the monocytes. With monocytes, the uptake of AuNP is likely through phagocytosis with
particles concentrated into lysosomes. Further investigation would be required to confirm
the route of uptake, but other researchers have shown that the major route of uptake of
nanoparticles in monocytes and macrophages is phagocytosis.41-42 More AuNP were
seen more frequently in 75 nm PCOOH AuNP treated monocytes as compared to other
sizes, in agreement with the results observed from ICP-OES measurements (Figure
3.9).
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Figure 3.9 TEM of cells after treatment with AuNP.
TEM of monocytes treated with 15, 75, 100, and 150 nm PCOOH AuNP. Cells were
treated at 0.5 mg/ml for 24 hours before being harvested and fixed for TEM.

3.4.4 CT imaging
To demonstrate the contrast generating properties of the AuNP taken up in
monocytes, cells were scanned with a microCT scanner at 80 kVp. Monocytes were
treated with 50, 75, 100 and 150 nm PCOOH AuNP for 24 hours at 0, 0.1, 0.25, and 0.5
mg/ml. Afterwards, cells were collected in 4% PFA and allowed to settle into loose
pellets before scanning (Figure 3.10). Figure 3.10A shows CT scans of cells treated at
increasing concentrations for 75 and 150 nm AuNP. The contrast generated from the
AuNP increases as treatment concentration increases for these formulations.
Quantitative analysis of the attenuation of these cell pellets is shown in Figure 3.10B,
and revealed that the highest contrast enhancement arose for 50 and 75 nm AuNP. This
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size dependent attenuation for the PCOOH AuNP closely matches the AuNP uptake
results in Figure 3.8, signifying that the observed attenuation is due to the internalized
AuNP. The change in attenuation was measured by normalizing to values obtained from
untreated monocytes. A one-way ANOVA and post-hoc tukey pairwise mean
comparison was used to determine significance between sizes at each concentration
group. At each treatment concentration, the quantified attenuation was found to be
significant between all sizes for PCOOH (p<0.05). To explore the relationship between
gold uptake and CT attenuation, the attenuation of cell pellets (HU) was plotted against
gold uptake (pg/cell). Figure 3.11 shows that there is a linear relationship (R2 = 0.89)
between attenuation and gold uptake.

Figure 3.10 CT attenuation of monocytes labeled with AuNP of each size.
A) CT scans of monocytes settled into pellets after treatment with 75 and 150 nm
PCOOH AuNP for 24 hours at 0, 0.1, 0.25 and 0.5 mg/ml. Cells were collected in 4%
PFA solution after treatment. Scans performed on small animal microCT scanner with
100 µm spatial resolution at 80 kVP and 500 µA. (B) Quantification of attenuation in
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Figure 3.10A of monocytes incubated with PCOOH AuNP of various sizes. Values
normalized to untreated cells. Error bars are standard error of the mean with (n=3 for
each data point). A one-way ANOVA and post-hoc Tukey pairwise mean comparison
used to compare different sizes at each concentration group. * indicates significance
between all sizes at that concentration (p<0.05).

Figure 3.11 Correlation of uptake and attenuation for PCOOH AuNP.
Attenuation of cell pellets plotted against cell uptake for PCOOH coatings. Attenuation of
untreated cell pellets used for zero uptake. The dotted line is the line of best fit for this
data, assuming linearity.

3.5 Discussion
We studied a total of 44 AuNP formulations with a range of diameters and
diverse capping ligands as potential labels for monocyte cell tracking. While the majority
of the formulations studied did not affect cell viability, we observed that 150 nm AuNP
with PEG-amine as part of the coating (2N8M, 2N8C) resulted in significant reductions in
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cell viability (Figure 3.6). This toxicity is likely due to the presence of the positively
charged amine groups in combination with increased AuNP-cell interactions due to these
large nanoparticles settling in the cell culture media. Researchers have hypothesized
that cytotoxicity from cationic surface coatings could be due to increased diffusion of
nanoparticles through the cell membrane, disrupting the lipid bilayer.43 Formation of
protein coronas adsorbed onto the AuNP from the serum in the cell culture media during
the incubation is also likely to play a role in their monocyte interactions.44 The protein
corona formed would be unique to each AuNP formulation and some speculate these
adsorbed proteins are highly influential in the interactions between cells and
nanoparticles.45
The small animal microCT scanner used in the study was limited to 80 kVp as
the maximum x-ray tube voltage. At 80 kVp the photons produced are below the k-edge
(80.7 keV) of Au. However, at 80 kVp, the attenuation difference between Au and tissue
remains substantial, allowing for strong contrast in our study. With the higher voltages
typically available on clinical scanners (100-140 kVp), we would likely see greater
contrast between Au and controls than seen in this study.
In the uptake experiments, high uptake of AuNP was found with short carbon
chain carboxylic acid ligands, consistent with those of others.7, 46 It may be the case that
upon incubation in serum, formation of protein coronas or aggregation of these AuNP
with proteins cause changes in size. The resulting nanoparticles may be highly taken up
by monocytes due to their size or due to settling. Future experiments will probe the
structure of these nanoparticles in serum to answer these questions. For AuNP coated
with these short carboxylic acid ligands, uptake was greater for 15 nm particles than 25
nm particles, however a size trend could not be discerned due to a lack of stability of
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larger diameter AuNP with these coatings. 11-MUA particles were unstable during ligand
exchange for particles larger than 25 nm, while 16-MHA coated were stable during
synthesis but produced significant aggregation artifacts in uptake studies with particles
larger than 50 nm (Figure 3.8). These results indicate that larger AuNP may require
larger ligands for robust stability. For increased stability at larger AuNP diameters, we
explored a variety of PEG-2000 ligands. PEG-2000 is well known to provide nanoparticle
stability in serum as well as ‘stealth’ properties.47 As expected, MPEG coated AuNP
were taken up at low levels for all particle sizes, although slightly increased uptake was
seen at the largest sizes, i.e. 100 and 150 nm (Figure 3.8). This uptake is likely a
function of the increased settling rates for larger nanoparticles rather than due to the
particle’s surface properties. Due to the lack of uptake with methoxy-PEG coating, we
explored PEG coating ligands that possessed carboxyl and amine functional groups at
their distal ends.
PEG functionalized carboxylic acids coated particles (PCOOH) were stable for
each diameter of AuNP studied. The monocyte uptake of AuNP coated with this ligand
demonstrated a complex relationship with size (Figure 3.8). The highest gold uptake
values were seen with 50 and 75 nm PCOOH AuNP. Other researchers have suggested
50 nm as optimal uptake size for AuNP in other cell lines. 48 For instance, Chithrani et al.,
observed the highest accumulation for 50 nm citrate coated AuNP in HeLa cells after 24
hours.49 While the data for PCOOH AuNP from our experiments are in agreement with
these prior studies, maximal uptake for 50 nm AuNP was not common to all coatings,
demonstrating that uptake is dependent on both size and surface functionality. The
PCOOH ligand and citrate both expose carboxylic acid groups to the surrounding milieu

145

and may therefore form similar protein coronas around them, which may explain the
similarity between our results and those of Chithrani et al.
Several studies have reported favorable nanoparticle uptake with amine based
coatings.50-51 Therefore for this study, we incorporated PEG-amine ligands into MPEG
(2N8M) and PCOOH (2N8C) at a 1:4 ratio (AuNP coated with 100% PEG-amine were
not stable). Low uptake values with both coatings at 15 and 25 nm suggest similar
properties to MPEG and PCOOH coated AuNP. However, for larger core sizes only 50
and 75 nm 2N8M AuNP were found to be without stability issues, limiting the extent to
which these coatings could be explored. The gold uptake values of 50 and 75 nm 2N8M
AuNP are similar to those of MPEG of the same sizes, suggesting the observed
behavior is dominated by the presence of MPEG and that the availability of the amine
groups was limited. A higher ratio of PEG-amine to MPEG may be necessary to fully
explore the effect of size with PEG-amine coated AuNP.
In CT imaging of cell pellets, the uptake of PCOOH coated AuNP resulted in
large attenuation values, <2000 HU for the formulations with the highest uptake. These
values are dependent on the amount of gold present in the volume of the cell pellet. For
75 nm PCOOH, we calculated the total mass of gold in the cell pellet from the cell
uptake value (174.68 pg/cell) and the number of cells in the pellet (2.5 million) to be 0.44
mg. Since the volume of the pellet was 10 µL, we calculated the concentration of gold in
the pellet to be 221.7 mM. The attenuation change relative to the concentration of gold
was therefore approximately 9.65 HU/mM of Au. This attenuation per concentration of
gold value is close to those reported previously in the literature when using similar CT
scanners.52
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For the purpose of labeling monocytes, similar values of gold uptake were seen
with 15 nm 11-MUA, 50 nm PCOOH, and 75 nm PCOOH AuNP. Both types of coatings
have functional carboxylic acid end groups with strong negative surface charge.
Previous research has shown that anionic surface charges may lead to favorable protein
corona formation for uptake by preferential binding of Apolipoprotein H (ApoH)
compared to positively charged particles.53 The increased presence of ApoH on
nanoparticles showed increased uptake in human mesenchymal stem cells compared to
other highly abundant proteins composing the corona. Considering synthetic efficiency,
15 nm AuNP are easier to produce on a large scale (performing seeded growth to form
50-75 nm AuNP adds another synthetic step which we have found challenging to scale
up). The scalability of a synthesis is important feature for future translation, an issue that
few studies have sought to address.54 Additionally, the low cost of the 11-MUA ligand
($13.14/g, Sigma-Aldrich, St. Louis, MO) compared to the ligand PCOOH ($1400/g,
Creative PEGworks, Chapel Hill, NC) reinforces the justification for use of 15 nm 11MUA coated AuNP for future monocyte labeling studies.

3.6 Conclusion
In this study, we explored the effect of size and surface coating on AuNP
biocompatibility and uptake in monocytes. We synthesized AuNP ranging in diameter
from 15 to 150 nm and examined both short carbon chain ligands and PEG-2000
functionalized ligands. The majority of these formulations had no adverse effect on cell
viability except 150 nm AuNP coated with charged PEG ligands. We found that small
AuNP coated with short carboxylic acid ligands were taken up extensively. We also
observed a complex effect of diameter for PCOOH coated AuNP, with high uptake
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values at the intermediate sizes of 50 and 75 nm but lower uptake for smaller and larger
diameters. Additionally, TEM and CT scans of monocytes incubated with these
formulations showed similar patterns of high uptake for 50 and 75 nm PCOOH AuNP.
Gold uptake values at 50 and 75 nm for PCOOH AuNP were similar to values seen for
15 nm 11-MUA particles. Therefore in the following chapter, we evaluate 15 nm gold
nanoparticles as an effective monocyte label and track these labeled cells in a mouse
model of atherosclerosis.
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Chapter 4: Labeling of monocytes for CT cell tracking to
atherosclerotic plaques
4.1 Abstract
Monocytes

are

actively

recruited from

the

circulation

into

developing

atherosclerotic plaques. In the plaque, monocytes differentiate into macrophages and
eventually form foam cells. Continued accumulation of foam cells can lead to plaque
rupture and subsequent myocardial infarction. X-ray computed tomography (CT) is the
best modality to image the coronary arteries non-invasively, therefore we have sought to
track the accumulation of monocytes into atherosclerotic plaques using CT. Gold
nanoparticles were synthesized and stabilized with a variety of ligands. Selected
formulations were incubated with an immortalized monocyte cell line in vitro and
evaluated for cytotoxicity, effects on cytokine release, and cell uptake. These data
identified a lead formulation, 11-MUA capped gold nanoparticles, to test for labeling
primary monocytes. The formulation did not the affect the viability or cytokine release of
primary monocytes and was highly taken up by these cells. Gold labeled primary
monocytes were injected into apolipoprotein E deficient mice kept on Western diet for 10
weeks. Imaging was done with a microCT scanner. A significant increase in attenuation
was measured in the aorta of mice receiving the gold labeled cells as compared to
control animals. Following the experiment, the biodistribution of gold was evaluated in
major organs. Additionally, plaques were sectioned and examined with electron
microscopy. The results showed that gold nanoparticles were present inside monocytes
located within plaques. This study demonstrates the feasibility of using gold
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nanoparticles as effective cell labeling contrast agents for non-invasive imaging of
monocyte accumulation within plaques with CT.
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4.2 Introduction
Cardiovascular disease is the leading cause of death in the United States,
accounting for 1 in every 3 deaths.1 The majority of these deaths arise from the
development of atherosclerosis in the coronary arteries, where rupture of vulnerable
plaques can potentially lead to thrombus formation and myocardial infarction. Over the
last decade, the role of inflammation in atherosclerosis has become a prominent point of
study in progression of the disease.2
After the initial development of inflammation in the arterial wall, monocytes are
actively recruited from the circulation into the arterial wall. In the intima, monocytes
differentiate into macrophages and eventually foam cells after engulfing low density
lipoproteins (LDL).3 These foam cells release cytokines and enzymes that lead to growth
and destabilization of the plaque over time.4 Continued recruitment of monocytes and
subsequent accumulation of foam cells increase the likelihood of plaque rupture and
clinical manifestations of atherosclerosis. Monocyte recruitment is a possible drug target
for atherosclerosis regulation.5 Studies have found that targeting the chemokine
receptors on monocytes reduces overall plaque progression.6-8 The accumulation of
monocytes has been found to correlate to the progression and severity of
atherosclerosis.9 These studies typically involve destructive processes to analyze
monocyte population in plaques preventing the study of multiple time points in the same
animal. With non-invasive detection, monocyte accumulation can be rapidly assessed,
informing the direction of the study before its end. This information can be revealing in
clinical trials, where imaging may demonstrate the effectiveness or lack of effectiveness
of drug therapies without invasive measures or waiting for patient mortality outcomes. 10
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CT is one of the best and most frequently used modalities to image the coronary
arteries non-invasively in patients.11 Modern CT scanners allow for fast, high resolution
image acquisition, reducing common cardiac and respiratory motion artifacts when
imaging the coronary arteries.12 With increasing interest in cell imaging, the use of x-ray
CT is an emerging modality in cell tracking applications. Astolfo et al. and Menk et al.
performed detailed analysis of gold nanoparticle uptake in cells, as well in vivo detection
and proliferation of gold labeled tumor cells in rat brain tumor models.13-14 Moreover,
recent studies utilizing synchrotron radiation sources for x-rays, have been able image
gold nanoparticle labeled cells with single cell resolution in ex vivo and in vitro
samples.15-16 Of the few studies regarding monocyte tracking, SPECT and MRI
modalities were used.17-18 SPECT and MRI face challenges due to chest and heart
motion when imaging the coronary arteries.19 Therefore, we sought to develop a
technique to monitor the monocyte accumulation in atherosclerotic plaques noninvasively through computed tomography.
Gold nanoparticles (AuNP) have been explored for biomedical applications due
to the synthetic control over size, shape and coating, their high biocompatibility and their
unique physical properties.20 This allows the development of AuNP that have specific
properties tailored for given biomedical applications. For instance, the addition of
poly(ethylene glycol) (PEG) coatings to particles can be used to increase in vivo
circulation time by avoiding uptake by cells of the reticuloendothelial system. 21 AuNP are
popular as experimental CT contrast agents, as they attenuate x-rays strongly, as well
as the afore-mentioned characteristics of biocompatibility and control over size and
surface functionality.22-24 AuNP have been shown to be effective as both blood pool and
targeted contrast agents for CT.25-28
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In this study, we demonstrate the use of AuNP to label monocytes and track their
migration into atherosclerotic plaques non-invasively using CT. We synthesized AuNP
15 nm in diameter and performed ligand exchange with a variety of ligands to create a
library of AuNP. These particles were characterized with dynamic light scattering (DLS),
zeta potential, and transmission electron microscopy (TEM). After characterization,
AuNP were evaluated in vitro for the effects on cytotoxicity, cytokine production, and cell
uptake with monocytes. A lead formulation was then evaluated in vitro with primary
monocytes isolated from spleens. Lastly, atherosclerotic mice were injected with AuNP
labeled monocytes and scanned with CT before injection and days 3, 4, and 5 post
injection. The CT scans were analyzed for intensity. Aortic plaques were excised and
examined with TEM for the presence of gold labeled monocytes.

4.3 Materials and methods
4.3.1 Materials
All chemicals were of analytical grade and were purchased from Sigma Aldrich
(St. Louis, MO). A monocyte cell line, RAW 264.7, was purchased from ATCC
(Manassas, VA). Dubecco’s Modified Eagle Medium (DMEM) and RPMI-1640
supplemented with 10% fetal bovine serum and 1% penicillin/streptomycin (10000
units/Ml, 10000 µg/mL) were purchased from Cellgro, Corning (Manassas, VA).
LIVE/DEAD assay and ELISA kits were purchased from Life Technologies Invitrogen
(Grand Island, NY). All mice were acquired from Jackson Laboratory, Bar Harbor, ME.
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4.3.2 Gold synthesis
Citrate capped gold nanoparticles were synthesized using the Turkevich
method.29 Briefly, 85 mg of gold(III) chloride hydrate was dissolved in 250 mL of
ultrapure water (Milli-Q, EMD Millipore, Billerica MA). The gold solution was heated to a
boil. 25 mL of a 38.8 mM sodium citrate solution was then added, producing citrate
coated gold nanoparticles. The solution was refluxed for 15 minutes and allowed to cool
to room temperature. For ligand exchange, capping ligands were added to the solution
for a final concentration of 0.047 mM in the gold solution. For instance, 2.6 mg of 11mercaptoundecanoic acid (MW 218.36) was dissolved in 1 ml of ethanol and added into
the gold solution to stir overnight. The full library of ligands examined can be found in
Figure 4.1. After exchange, the particles were spun at 8.5 krcf for 3 hours to pellet the
particles. The pellets were collected into 1.5 ml micro-centrifuge tubes and washed twice
with ultrapure water by centrifuging at 8.5 krcf for 45 minutes. The AuNP were then
filtered through a 0.45 µm syringe filter (EMD Millipore, Billerica MA) in a biosafety
cabinet for sterilization.
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Figure 4.1 Library of capping ligands.
Ligand library explored for AuNP stability. Chemical structures and stability
determination shown for each ligand.

4.3.3 Particle characterization
For electron microscopy, AuNP samples were drop casted onto Formvar carbon
copper grids with 200 mesh (Electron Microscopy Sciences, Hatfield, PA). Samples were
exposed to air for 30 mins and excess solution was blotted away with filter paper. The
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grids were viewed with an FEI Tecnai T12 electron microscope at 120 kV. Dynamic light
scattering and zeta potential analysis was performed with a Nano ZS-90 Zetasizer.
Stability was tested by diluting 10 µL sample of AuNP into 1 mL of DPBS and 1 mL of
cell media.

4.3.4 In vitro viability assessment
The interaction of stable AuNP formulations with monocytes was evaluated using
RAW 264.7 and isolated primary monocytes. The LIVE/DEAD assay was used to assess
cytotoxicity. Briefly, RAW 264.7 cells were cultured in 20 mm diameter glass bottom
dishes at 7.0 x 105 cells per well with DMEM supplemented with 10% FBS and 1%
penicillin/streptomycin (PS). After 24 hours of incubation, monocytes were treated with
AuNP formulations for an additional 24 hours. After treatment, cells were washed 2x with
DPBS and incubated with 400 µL of LIVE/DEAD cocktail (2 ml DPBS, 2 µL stock
Ethidium-1 homodimer, 0.5 µL stock Calcein AM and 0.5 µL 3.2 mM Hoechst 33342).
Primary isolated monocytes were prepared similarly but cultured using RPMI-1640
supplemented with 10% FBS and 1% PS. Cells were imaged with Nikon Eclipse Ti-U
fluorescence microscope using DAPI (Ex: 359, Em: 461 nm), FITC (Ex: 495, Em: 519
nm), and Texas Red (Ex: 595, Em: 613 nm) filters. Four images were taken per well for
each channel. A custom MATLAB (MathWorks, Natick, MA) program was used to count
the number of cells for the Hoechst, Ethidium-1 homodimer, and Calcein AM stain for
each sample. The ratio of living cells to total number of cells was used to determine the
viability percentage.

164

4.3.5 In vitro cytokine expression
Monocyte cytokine expression of TNF-α and IL-6 was evaluated using an ELISA
kit from Life Technologies, (Frederick, MD). First, monocytes were cultured in 96 well
plates at 1.0 x 105 cells per well for 24 hours. Immortalized monocytes were then treated
with 0.5 mg/ml of various AuNP formulations for 24 hours (note: all nanoparticle
concentrations are given as mg/ml of gold). Primary monocytes were treated with
concentrations of 0.1, 0.25, and 0.5 mg/ml of 11-MUA AuNP. The cells were then
washed twice with DPBS to remove remaining free AuNP. Afterwards cell media in each
well was replaced with 100 µL of cell media containing 100 ng/mL of lipopolysaccharides
(LPS) for 3 hours or replaced with new media for non-activated samples. The media was
then collected for use in the ELISA, which was performed according to kit instructions.

4.3.6 Cell uptake evaluation
The uptake of AuNP was measured using both a direct method (analytical
determination of gold content) and an indirect method (CT imaging of cell pellets). For
both methods, cells were cultured onto 6-well plates at 2.0 x 106 cells per well for 24
hours. The cells were treated with varying concentrations of AuNP formulations for 24
hours. The cells were then washed twice with DPBS and collected. For direct
measurements, the cells were dissolved in aqua regia (3 parts hydrochloric acid, 1 part
nitric acid) for 15 mins. The gold content of these samples were measured using
inductively coupled plasma-optical emission spectroscopy (ICP-OES) on a Spectro
Genesis ICP (SPECTRO Analytical Instruments GmbH, Boschstr, Germany). Gold
content was normalized by the number of cells in each sample to express the value as
gold per cell.
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For CT measurements, after AuNP treatment, the cells were collected and fixed
in 4% paraformaldehyde. The cells were allowed to loosely settle and then scanned
using a clinical CT scanner (Siemens Definition DS 64-slice) at 100 kVp, 440 mA,
512x512 matrix, 37x37 cm FoV, a slice thickness of 0.6 cm and reconstructed using
kernel B30f. Intensities in the scan were measured in 3 sequential sections using ROI
measurements and averaged for an intensity measurement using OsiriX v.3.7.1 64-bit
software.

4.3.7 Primary monocyte cell dispersion scans
Primary monocytes were cultured for 24 hours after isolation and then
subsequently treated with 0.5 mg/ml of 11-MUA AuNP. After 24 hours, the cells were
washed x2 with DPBS and resuspended into increasing concentrations of 0, 100 k, 250
k, 500 k, 1.0 M, 2.5 M, and 5.0 M cells/ml in 100 µl of DPBS and then 100 µl of 1%
agarose. The agarose was heated prior to addition and then cooled on ice for 15
minutes. The suspensions were then scanned with microCT scanner (Imtek Inc, 80 kVP,
500 µA). The scans were quantified using OsiriX v3.7.1 with 64-bit software.

4.3.8 Transmission electron microscopy of tissue
RAW 264.7 cells and aorta samples from treated ApoE-/- mice were prepared for
TEM imaging using standard preparation techniques.30 Cells and tissue were fixed in 2%
PFA and 2.5% glutaraldehyde before staining and embedding. Samples were cut into 60
nm thick sections and mounted onto grids before viewing with a JEOL 1010 Electron
Microscope at 80 kV.
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4.3.9 Primary monocyte isolation
Spleens from C57BL/6 donor mice were used as the source for primary
monocytes. Mice were anesthetized with isoflurane and then euthanized. The chest
cavity was opened and mice were perfused through the left ventricle with 10 mL of
DPBS before removal of the spleen. After excision, the spleen was mechanically
homogenized using the plunger of a 1 mL syringe in 1 mL of Hank’s balanced salt
solution (HBSS). The resulting cell slurry was filtered through a 70 µm filter and spun at
250 rcf for 5 mins to pellet the cells. The pellet was then re-suspended in 250 µL of RBC
lysis buffer for 1 min on ice. Afterwards, HBSS supplemented with 0.6% bovine serum
albumin (BSA) and 0.3 mM EDTA was added to the cells for a total volume of 10 mL.
The cell solution was centrifuged at 250 rcf for 5 mins and re-suspended with HBSS+
BSA. This step was repeated twice. The cell suspension was then incubated with antiCD11b magnetic microbeads (Mitlenyi Biotech, 140-049-601) for 30 mins at 4°C. After
incubation, the suspension was washed with eluting buffer (DPBS, 0.5% BSA, 2mM
EDTA). The cell suspension was then passed through a LS separation column (Miltenyi
Biotech, 130-042-401) in the presence of a strong magnet to retain only CD11b+ cells in
the column. Afterwards, the column is removed from the magnet and 5 mL of eluting
buffer is used to remove the cells from the column. The cells were eluted through two
sequential LS columns for increased purity. The resulting solution was spun at 250 rcf
for 5 mins and re-suspended with RPMI medium 1640 supplemented with 10% FBS and
1% penicillin/streptomycin for cell culture.
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4.3.10 Flow cytometry
The purity of the resulting cell suspension was analyzed using flow cytometry. Cells
were incubated with Fc blocking agent for 15 minutes. After blocking, cells were
incubated with markers for CD11b-PE Cy7, Ter119-PE, CD3-APCeF780, CD19-PerCP
Cy5.5 for 30 mins on ice. Flow cytometry were performed on a BD FACSCanto System
(BD Sciences, San Jose, CA). Fluorescence minus one solutions and compensation
beads for each fluorophore were used for controls.

4.3.11 Animals
Six week old male apolipoprotein E (ApoE) deficient mice (B6.129P2-ApoEtm1UnC/J) were
fed western chow diet (Research Diets Inc, New Brunswick, NJ) for 10 weeks to
establish early atherosclerosis before use. Age-matched male C57BL/6 were kept on
regular chow diet for the duration of the experiment as controls. All experimental
protocols were approved by University Laboratory Animal Resources in conjunction with
the Institutional Animal Care and Use Committee at University of Pennsylvania.

4.3.12 In vivo monocyte imaging
The treated group (AtT, n=8) received AuNP labeled monocytes following the
procedure below. Briefly, primary monocytes isolated through magnetic sorting as
described above were cultured for 24 hours before gold labeling. The cells were then
treated with 0.5 mg/ml of 11-MUA AuNP for an additional 24 hours. The cells were
washed twice with DPBS and collected. After resuspension in 250 µl of DPBS, 1.0 x 106
cells were injected intravenously into the ApoE deficient mouse model. The animals
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were scanned with a microCT II scanner (Imtek Inc, 80 kVp, 500 µA, 512x512 matrix,
100 µm slice thickness) pre-injection and on day 3, 4, and 5 post-injection. Wild type
mice receiving gold labeled monocytes following a similar procedure were used as
controls (WdT, n=9). Additionally, atherosclerotic mice receiving non labeled monocytes
were also used as a control group (AtN, n=8). CT scans were analyzed using OsiriX
software. For aorta measurements, 3 sequential ROI were measured in the ascending
aorta and averaged for a final attenuation value. The location of the aorta was identified
by comparing the CT images with scans from a separate mouse experiment using a CT
blood pool contrast agent. Identical ROI were used for each day for each mouse. The
image sets from different days were matched for each animal using the spine and
ribcage as markers.

4.3.13 Ex-vivo and biodistribution
After the final scan, mice were euthanized and dissected for biodistribution.
Tissue including the heart, lungs, spleen, kidney, and liver were fixed in 4% PFA after
excision. For biodistribution, tissue was dissolved in 500 µL of HNO3 for 18 hours at
60°C. Afterwards, 300 µL of HCl was added and incubated at 60°C for an additional
hour. The resulting solution was spun at 300 rcf for 10 mins for remove cell debris. The
samples were analyzed using ICP-OES for measurement of gold content.
4.3.14 Statistics
Statistical analysis was performed with guidance from the Center for Clinical
Epidemiology and Biostatistics at the University of Pennsylvania. A linear mixed effect
model was used to analyze intensities from in vivo scans. Each mouse was assumed to
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have a unique intercept and inputted into the model as a random effect to control for
baseline differences between mice. Attenuation measurements were used as the
dependent variable and each day as the independent variable in the model. Analysis
was performed using Stata 13.1 (64-bit, College Station TX).

4.4 Results
4.4.1 Gold nanoparticle synthesis and characterization
The Turkevich method of synthesizing gold nanoparticles was used to produce
citrate coated gold nanospheres (Figure 4.2a).29 For additional stability in biological
media, a library of thiol-ligands was used to displace the citrate ligands of the AuNP
(Figure 4.1). Stability for each AuNP formulation was evaluated with Dulbecco’s
Phosphate Buffered Saline (DPBS). When suspended in a salt based solution, stable
gold nanoparticles of this size appear as a deep red solution while non-stable gold
particles aggregate causing the solution to change to a blue-black color. We identified
the following 5 stable coatings which we tested further: 11-mercaptoundecanoic acid
(11-MUA), 16-mecaptohexadecanoic acid (16-MHA), poly(ethyleneimine) (PEI), 4mercapto-1-butanol (4-MB), and 11-mercaptoundecyl-tetra(ethylene gycol) (MTEG).
These ligands give the nanoparticles several different surface functionalities, which
could influence cellular interactions including cell uptake and cytotoxicity.
TEM was used to observe the particle size and shape (Figure 4.2b). TEM
revealed monodispersed spheres of 14.6 ± 1.5 nm in average diameter. DLS and zeta
potential were performed to characterize hydrodynamic diameters and surface charges
(Table 4.1). The hydrodynamic diameter of the particles seemed to relate to the size of
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the ligand used to stabilize the particle, i.e the shortest ligand 4-MB displayed the
smallest hydrodynamic diameter, although it seems likely that for the PEI and MTEG
coated AuNP that there is some degree of aggregation of cores. The zeta potential
results showed that carboxylic acid ligands (11-MUA, 16-MHA) and alcohol ligands (4MB) had negative surface potentials, as expected. Additionally, AuNP coated with PEI,
which has many amine groups, had a positive surface potential. AuNP that were coated
with MTEG, which has a methoxy group at the distal end, had a nearly neutral charge.

Figure 4.2 AuNP synthesis, coating and characterization.
(a) Schematic of ligand exchange for citrate capped gold nanoparticles. (b) Chemical
structures of 5 formulations further used in experiments. (c) TEM image of 11-MUA
capped AuNP.
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Table 4.1 Characterization of selected AuNP formulations.

4.4.2 In vitro evaluation of selected AuNP formulations
Following selection of AuNP formulations, we examined the interaction of these
particles with a monocyte cell line, RAW 264.7. The viability of the cells after the
treatment with AuNP formulations was examined using the LIVE/DEAD assay. Each
formulation was assessed at several concentrations (0.025, 0.05, 0.1, 0.5, and 1.0
mg/ml of Au) for 24 hours. The ratio of living cells to total cells was determined via
automatic counting by a custom MATLAB program. The results shown in Figure 4.3a
demonstrate high biocompatibility for each formulation at the concentrations examined
except for PEI. Due to being a polycation, PEI has been widely used as a transfection
agent in gene therapy applications, but it is known that PEI can cause toxicity.31
We next assessed if the uptake of AuNP would affect monocyte function in an
inflammatory role. Circulating monocytes produce pro-inflammatory cytokines such as
TNF-α, and IL-6 after activation.32 We therefore evaluated the cytokine release of TNF-α
and IL-6 from monocytes after 0.5 mg/ml treatment of each AuNP formulation and
activation with lipopolysaccharides (LPS). The AuNP formulations did not appear to
disrupt cytokine release for 11-MUA, 16-MHA, and MTEG. However, the 4-MB
formulation was found to decrease the cytokine release of TNF-α, but not IL-6. PEI
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coated AuNP, on the other hand, were found to decrease the release of IL-6, but not
TNF-α. Expression of TNF-α and IL-6 for AuNP treated monocytes was relatively similar
to non-treated cells.

Figure 4.3 Effects of AuNP on the viability and cytokine release of monocytes.
(a) Viability of monocytes after treatment with different AuNP formulations at increasing
concentrations. Viability % expressed as the ratio of living cells to total cells in the well.
(b) Results from ELISA for TNF-α and IL-6 release after treatment (0.5 mg/ml) with
different AuNP formulations. LPS groups were treated with LPS for 3 hours after gold
treatment. * P<0.05 compared to samples not treated with AuNP. (Student’s t-test)

Previous studies have demonstrated that size, shape, and surface functionality of
the AuNP can significantly affect the amount of uptake into the cells.33-34 While each of
our formulations are spherical in shape, the different surface ligands resulted in altered
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hydrodynamic sizes and surface properties of the particle. After treating with AuNP,
monocytes were found to take up the AuNP into vesicles, likely to be lysosomes. Figure
4.4a shows TEM images of sections of monocytes that had been incubated with 11MUA. The uptake of these gold particles may be via phagocytosis as found in other gold
cell labeling studies.35
We studied the amount of AuNP uptake by monocytes for each formulation by
examining CT contrast generation. Each formulation was incubated at three
concentrations (0.1, 0.25, 0.5 mg/ml) for 24 hours. After treatment, cells were collected
and scanned using a clinical CT scanner. The scans show an observable increase in CT
attenuation dependent on the treatment concentration for our formulations (Figure 4.4b).
The attenuation was quantified by measuring the intensity of the pellets. The attenuation
of 11-MUA, 16-MHA, and 4-MB increased proportionally with treatment concentration of
AuNP. It is important to note that the images seen in Figure 4.4b are not saturated, but
some pixels are very bright due to the CT windowing scale used. All attenuation values
in these experiments were well below the maximum CT attenuation values handled by
this clinical system (3000 HU).22 The attenuation for the PEI formulation was not
dependent on the concentration of gold, likely due to the toxicity seen in Figure 4.3a.
Interestingly, 11-MUA displayed significantly higher attenuation than 16-MHA despite
both ligands having carboxylic acid functional groups. The size difference in
hydrodynamic diameter (Table 4.1) may account for the difference in gold uptake
between the formulations. The MTEG formulation was found to have the lowest uptake,
which was not surprising since ethylene glycol based ligands are known to reduce
nanoparticle uptake by the mononuclear phagocytosis system.36 The results show that
formulations of 11-MUA and 4-MB displayed the highest CT attenuation and therefore
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AuNP uptake (Figure 4.4c). From the DLS and zeta potential results, both formulations
4-MB and 11-MUA have relatively low hydrodynamic diameters and strong negative
surface charge suggesting that these particle properties may encourage high AuNP
uptake.37 Taking together all the results from these in vitro experiments, we chose to
move forward with 11-MUA as our lead formulation as it displayed low cytotoxicity, no
disruption of cytokine release, and high uptake in monocytes.
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Figure 4.4 Uptake of AuNP in monocytes.
(a) TEM image of a RAW 264.7 monocyte cell after 24 hr incubation with 11-MUA AuNP.
(b) CT images of pellets of 11-MUA and 4-MB AuNP treated monocytes at increasing
concentrations. (c) Quantification of intensities from CT scans for each formulation.
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4.4.3 In vitro evaluation of 11-MUA coated AuNP with primary monocytes
We first isolated primary monocytes from donor C57BL/6 mice. Others have
shown the spleen to be a large reservoir of monocytes that are nearly identical in
subtype and behavior to circulating blood monocytes.38 Purified monocytes isolated from
the spleen of donor mice were examined with flow cytometry. Cells were incubated with
cocktail of antibodies consisting of CD11b-PE Cy7, Ter119-PE, CD3-APCeF780, and
CD19-PerCP Cy5.5. The enriched monocyte population contained 99.3% of CD11b+
(monocyte marker), CD19- (B-cell marker), CD3- (T-cell marker) cells in the suspension
(Figure 4.5).

Figure 4.5 Flow cytometry for primary monocytes.
Flow cytometry of cell suspension from spleen. Purity determined by population of
CD11b+, CD3-, and CD19- cells. (a) Original population of cell suspension. (b) Depleted
cell population from magnetic cell sorting. (c) Enriched population from magnetic cell
sorting.

We examined these primary monocytes in a method similar to the immortalized
monocyte cell line. The primary monocytes were treated with 11-MUA AuNP and
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evaluated for cytotoxicity and cytokine release of TNF-α. Additionally, the uptake of
AuNP was directly quantified using ICP-OES and compared to the uptake of the
immortalized cell line. The results show that 11-MUA AuNP treatments up to 1.0 mg/ml
did not decrease cell viability of cultured primary monocytes (Figure 4.6a). Similarly, the
uptake of 11-MUA AuNP did not significantly alter the release of TNF-α after activation
with LPS as seen in Figure 4.6b. In much the same way, the uptake of 11-MUA AuNP
did not significantly alter the release of TNF-α after activation with LPS as seen in Figure
4.6b. The TNF-α release for monocytes without LPS activation was found to be at similar
low levels for non-treated and 11-MUA treated cells. These results confirm that the
primary monocytes were not activated during the isolation, culturing, and gold labeling
procedures. Comparable results were found with the monocyte cell line, RAW 264.7.
The quantified cell uptake of AuNP was comparable between the primary monocytes
and the cell line. The uptake of AuNP in primary monocytes after 24 hours of 0.5 mg/ml
11-MUA AuNP incubation was found to be 127 pg/cell (Figure 4.6c). These data
demonstrated that the uptake of 11-MUA AuNP did not impact the behavior of the
primary monocytes during the ex-vivo labeling process.

178

Figure 4.6 Effects of 11-MUA coated AuNP on primary monocytes.
Mouse monocytes from the spleen were cultured and evaluated in vitro for (a) viability
using LIVE/DEAD assay, (b) TNF-α release using ELISA, and (c) AuNP cell uptake
using ICP-OES for primary monocytes compared to the cell line.
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4.4.4 In vivo detection of gold labeled monocytes
Having established a method for labeling monocytes with AuNP without affecting
cell viability or cytokine production, we proceeded to track the recruitment of these
labeled monocytes in a mouse model of atherosclerosis via CT imaging. ApoE deficient
mice were kept on a Western diet for 10 weeks to promote the development of aortic
plaques. To track the recruitment of monocytes, primary monocytes were cultured and
labeled ex-vivo with 11-MUA AuNP a day before intravenous injection of these cells. The
timeline of the experiment is shown in Figure 4.7. The mice were scanned with CT
(Imtek, Inc, 80kVp, 500 µA) before I.V. injection and on days 3, 4, and 5 post-injection.
The groups consisted of atherosclerotic mice receiving gold labeled monocytes (AtT),
atherosclerotic mice receiving non-labeled monocytes (AtN) and wild-type mice receiving
gold labeled monocytes (WdT).

Figure 4.7 In vivo experiment timeline.
Experimental timeline for CT scanning of ex-vivo labeled monocytes injected I.V. into
atherosclerotic mice.
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Figure 4.8 shows images of an atherosclerotic mouse that received AuNP labeled
monocytes for day 0 and day 5 scans; attenuation was seen to increase in the aorta over
time as compared to the day 0 scan. The AtT group (atherosclerotic mice receiving
AuNP labeled monocytes) showed a continual increase in attenuation over time resulting
in a final 15.3 HU difference on day 5 as compared to the pre-injection scan (Figure
4.8c). The increase for the AtN group (atherosclerotic mice receiving non-labeled
monocytes) animals was much less. The WdT group (wild type mice receiving gold
AuNP monocytes) attenuation values varied across acquisitions with no significant
increase. Due to the heterogeneity of developing atherosclerosis, a linear mixed effects
statistical model was used to account for disease variation among animals over time.
Accounting for the attenuation values obtained each day (day 1 through 5) and random
effects, we found a statistically significant increase in attenuation for the AtT group
(p=0.002) of 15.3 HU. In comparison, the WdT (p=0.305) and the AtN (p=0.251) models
showed no significant change in attenuation over time. This increase in attenuation in
our AtT animals suggests that the recruitment of AuNP labeled monocytes can be
detected by CT imaging. While the change in attenuation in the AtN group was not
statistically significant, there may be small increases in the attenuation of the plaque
during the 5 days of the experiment due to disease progression.
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Figure 4.8 In vivo attenuation of gold labeled monocytes.
CT scans of an atherosclerotic mouse injected with gold labeled monocytes (AtT) for (a)
day 0 and (b) day 5. White boxes indicated aortic region of interest. Attenuation
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increases in the aorta over 5 days as compared to the pre-injection scan. (c) Graph
plotting the average intensities in the aorta of mice in CT scans over time.

For an estimation of the number of gold labeled cells in the plaque, a standard
curve of attenuation versus gold labeled cells per unit volume was generated. Primary
monocytes were treated with 0.5 mg/ml of 11-MUA AuNP for 24 hours and resuspended
in an agarose gel at increasing concentrations. The cell concentrations were scanned
with microCT scanner (Imtek Inc., 80 kVp, 500 µA) and quantified (Figure 4.9). Using
this standard curve, the change in attenuation of 15.3 HU in the AtT treated group
correlated to be approximately 15 gold labeled cells/voxel in the plaque. The true
number of gold labeled cells in the plaque would vary depending on plaque size but we
believe this to be a reasonable estimation.
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Figure 4.9 Quantification of gold labeled cells.
Standard curve of attenuation versus cells per voxel (isotropic voxel size 0.1 mm).
Quantification of attenuation for gold labeled primary monocyte, values normalized to
attenuation at 0 cells/voxel.

4.4.5 Biodistribution of AuNP
At the end of the experiment, animals were sacrificed and organs excised for
biodistribution. The gold content in the tissue was analyzed using ICP-OES to measure
the distribution after 5 days post injection. Figure 4.10 shows high gold uptake in the
spleen and liver, which are organs that typically host large numbers of monocytes and
monocyte derived cells. Swirski et al., showed similarly high uptake of labeled
monocytes in the spleen 5 days after intravenous injection.9
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Figure 4.10 Biodistribution of gold from in vivo experiments.
Gold content of tissue analyzed by ICP-OES at 5 days post injection of the
atherosclerotic and wild type mice receiving AuNP labeled monocytes.

4.4.6 Ex-vivo analysis of atherosclerotic plaques
The aortas of AtT mice (received AuNP labeled monocytes) were sectioned
through the atherosclerotic plaque and examined with TEM. AuNP were found in
monocytes that were located in the atherosclerotic plaque (Figure 4.11). This indicates
that the attenuation increase seen in the in vivo CT scans is due to recruitment of the
AuNP labeled monocytes into the plaques.
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Figure 4.11 AuNP labeled cells in aortic sections.
Excised aortas from atherosclerotic mice receiving AuNP labeled monocytes were
sectioned through the plaque and examined with TEM for localization of gold
nanoparticles.

4.5 Discussion
In this study, we demonstrate the successful labeling of monocytes with AuNP of
varying formulations. Each ligand conferred a distinct combination of particle parameters
including hydrodynamic diameter, surface potential and chemical functionality (Table
4.1). Formulations of 4-MB and 11-MUA, which have similar diameters and negative
surface potential, were found to have low cytotoxicity and the highest monocyte
uptake.37 Previous reports have shown that anionic AuNP exhibit less toxicity as
compared to cationic nanoparticles.39 The authors suggest that positively charged
particles may directly diffuse through the plasma membrane, disrupting the lipid bilayer
causing cytotoxicity. Additionally, our incubation of monocytes with AuNP occurs in
media with serum. Studies have shown that the makeup of the protein corona
surrounding the particle could be responsible for differences in cellular uptake. 40-41 It is
likely that 4-MB and 11-MUA AuNP formulations form a protein corona preferential for
cell uptake as compared to other our examined ligands. We found uptake of 127 pg
Au/cell in our in vitro incubations performed with 0.5 mg Au/ml in the cell culture media.
This is comparable to previous work since Menk et al. reported uptake of 33-36 pg
Au/cell for incubations performed with 0.052 mg Au/ml, a ten-fold lower concentration
than in our experiments, over a similar timeframe.14 Furthermore, others have loaded
cells with iron oxide nanoparticles up to a weight of 39 pg Fe/cell. Adjusting for the
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differing densities of gold and iron oxide, this would be equivalent to 209.9 pg Au/cell. 4243

We found that the migration of these labeled monocytes to atherosclerotic
plaques could be observed and measured with CT. We believe this is the first study to
non-invasively track monocyte recruitment into atherosclerotic plaques using computed
tomography. For plaque imaging, a number of targets have been previously studied with
MRI, PET, SPECT, and NIRF. Researchers have successfully imaged cell-adhesion
molecules, lipoproteins, ECM, proteases, and angiogenesis in plaques.44 Studies looking
to image inflammatory cells primarily focus on macrophage presence in the plaque. 45-47
Due to the insensitivity of contrast agents in CT, few imaging studies of plaque use x-ray
computed tomography as the sole means of imaging. Researchers have previously
demonstrated the in vivo detection of macrophages in atherosclerotic plaques with CT
by using an iodinated agent,48 PEGylated nanoparticles49 and gold core lipoproteins.27-28
High macrophage content atherosclerotic plaque is a potential indicator of imminent risk
of plaque rupture.50 In the present study, we sought to track the process of monocyte
recruitment, which has been found to be informative of disease progression. A study by
Robbins et al. found that monocyte recruitment is a significant source of the macrophage
population in early plaques while the macrophage populations in established are due to
in-situ proliferation.51 Therefore, the detection of monocyte recruitment into the plaque
could be an early marker for patients at risk of development of cardiovascular disease.
Our study presented here looks at the important process of monocyte recruitment
in early stage atherosclerosis utilizing CT. This technique can improve the study of
monocyte recruitment and help elucidate monocyte role in atherosclerosis progression
and/or regression. Additionally, this technique may help assess new atherosclerotic
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interventions that target monocytes and plaque inflammation. However, CT sensitivity to
contrast agents has been a significant obstacle in the further development of this
method. The present study demonstrated increased intensity in the aorta (Δ 15.3 HU)
as compared to pre-scan values. This attenuation change is on par with similar studies
in the field. For instance, Hyafil et al. reported a change of 13.3 HU in the atherosclerotic
plaques of rabbits intravenously injected with iodinated nanoparticles designed to target
macrophages.48 Similarly, Eck et al., injected anti-CD4 gold nanoparticles intravenously
to target lymph in-vivo and found an attenuation change of 20 HU at 1 hr and 25 HU at
48 hrs for 28 nm gold nanoparticles.52 However, for our study, an increase in sensitivity
and overall attenuation change would be required to discern small reductions of
monocyte uptake (e.g. <30%). A recent study by Betzer et al., presented the use of a
“CT ruler” to approximate the number of gold labeled cells in a tissue non-invasively.53
However, the high attenuation required for this method was achieved by directly injecting
the gold labeled cells at the site of interest. In our study, increasing the signal from our
cells may be achieved by further optimizing the method. By increasing the number of
injected gold label monocytes, we hypothesize a higher intensity in our scans is
possible; however in this approach, injecting more monocytes than are physiologically
present in the circulation may significantly alter the response of the animal to these cells.
Instead, increasing the amount of gold per cell may be the ideal strategy to increase CT
contrast in the images without increasing the number of injected cells. Translation of
nanoparticle-facilitated cell tracking to clinical scanners would be beneficial, due to the
lower image noise in clinical scanners as compared with preclinical scanners. 54 Lower
image noise improves signal-to-noise ratios and hence improves sensitivity.
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An alternative solution to achieve higher intensities may be to purify the
monocyte subtype further. In the current study, monocytes are isolated by the
expression of CD11b marker, a conserved monocytes marker across many subtypes.55
In mice, the “inflammatory” Ly6CHi monocyte subtype has been described as the
dominant subtype for migration in early atherosclerotic plaques as compared to the
“resident” monocyte, Ly6CLo.56-57 Hence, we may improve the overall recruitment of our
gold labeled monocytes by further purifying our isolated monocytes for CD11b+, Ly6CHi
subtype in future studies.
In this cell tracking study, isolated monocytes are labeled ex-vivo before injection
as opposed to labeling in-situ. The emergence of adoptive cell therapies as successful
clinical therapies reinforces the need for methods of cell tracking ex-vivo cultured cells.58
Cell tracking using ex-vivo labeled cells with CT has been demonstrated with a number
of applications including T-cell labeling for cancer, C6 glioma cells for brain tumor
models, olfactory ensheathing cells for spinal compression injury models and pancreatic
islets labeling for diabetes.14, 59-63 In-situ labeling, where nanoparticles are injected into
animals and cells take up the nanoparticles in vivo, is more straightforward and simpler
to implement clinically.64-65 However, in-situ labeling may result in labeling a variety of
cells, such as macrophages and monocytes resident within the plaque, as well as
circulating monocytes, confounding results from imaging. In the future, we will explore
ways to adapt our current approach for in-situ labeling and compare the results.

4.6 Conclusion
In this study, we screened AuNP formulations for effective uptake in monocytes
without disruption of viability or inflammatory function. We identified a lead formulation
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with these characteristics, which was confirmed with primary monocytes. These labeled
monocytes were intravenously injected and monitored for recruitment into atherosclerotic
plaques using x-ray computed tomography. We found an increase in the attenuation in
the aorta, post injection of these labeled cells. We confirmed the presence of these
labeled monocytes in the plaque through the use of TEM. This study demonstrates the
feasibility of tracking labeled monocytes with CT. Further studies are required to
optimize the detection of these cells for quantification of monocyte accumulation in the
plaque. Increased sensitivity will allow for examination of monocyte recruitment in the
presence of emerging atherosclerosis therapies.
While we demonstrated that detection of gold labeled monocytes recruited to
atherosclerosis is achievable, further experimental refinement is needed to be utilized as
research tool. However, we believe this study continues to expand the use of CT as a
cell tracking modality. The use of gold nanoparticles to track monocytes and other cells
in other disease applications is possible. In the following chapter, we indicate future
directions for the work and discuss expanded biomedical applications for gold labeling of
cells for cell tracking.
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Chapter 5: Discussion and future directions
5.1 Overall discussion
5.1.1 Overview
In the work presented herein, we hypothesized that we could track monocyte
migration with x-ray computed tomography (CT) through the use of gold nanoparticle
constructs as labels. Cell tracking tools have become increasingly desired due to the
ability to track cells that have been delivered from an external source. These tools are
able to provide near real time information about cell location, migration, and viability. We
sought to develop gold nanoparticles (AuNP) agents that could label monocytes and
monitor their recruitment into atherosclerotic plaques.
We first explored using polyphosphazene polymers to create nanospheres with
AuNP loaded into the core as discussed in Chapter 2. We also assessed the controlled
localization of nanoparticles onto the surface of the nanospheres. We found substantial
uptake of these nanospheres both for core-loaded and surface-loaded variants allowing
for CT imaging of gold labeled monocytes in addition to drug delivery with surfaceloaded particles. However, we found that high levels of uptake of core-loaded
nanospheres negatively affected monocyte viability and cytokine release. Because CT
requires high payloads of gold for contrast production, we explored alternative AuNP
formulations for improved biocompatibility with high monocyte uptake.
In chapter 3, we examined a range of AuNP sizes (15 to 150 nm) and various
surface ligands, totaling 44 distinct AuNP formulations. We sought to explore the
relationship between size and surface ligand in the application of monocyte labeling.
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AuNP formulations were examined for cytotoxicity and uptake by monocytes. Only the
largest size, 150 nm AuNP, with polyethylene glycol (PEG) surface ligands were
cytotoxic. We found the relationship between size and uptake to be specific for each
surface ligand. High uptake in monocytes was seen with small (15, 25 nm) particles
coated in short chain carboxylic acids. We also found a complex relationship between
size and uptake for PEG-carboxylic acid coated (PEG-COOH) AuNP. High uptake in
monocytes was found for intermediate sizes (50, 75 nm), but relatively low uptake at
smaller and larger sizes. With synthetic efficiency and cost advantages for 15 nm
particles, we choose to further proceed with this size to evaluate monocyte labeling for
CT cell tracking in atherosclerosis.
With a focus on 15 nm diameter AuNP, we examined their potential as cell
tracking agents for labeling monocytes. We examined an expanded library of surface
ligands for stability and selected five ligands to evaluate with monocytes. Of these
ligands, AuNP coated with 11-mercaptoundecanoic acid (11-MUA) did not affect
monocyte viability or cytokine release, and were highly taken up by these cells (in both a
monocyte cell line and primary monocytes). Therefore, we used this formulation to label
primary monocytes and deliver the cells to mice with early atherosclerotic lesions. Using
CT, we were able to detect a significant increase in x-ray attenuation in aortic plaques
after 5 days. Sections through the aortic plaque showed the presence of gold labeled
cells, reaffirming the migration to gold labeled monocytes to the plaque.
While this work demonstrated the feasibility of using AuNP constructs to track
monocyte recruitment in atherosclerosis, further development is needed to improve this
tool for expanded applications in monocyte tracking. Here, we discuss factors involved in
the uptake and cytotoxicity seen with some AuNP formulations. We also discuss
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strategies for improving monocyte detection in the atherosclerosis model and expanded
uses for monocyte cell tracking. Last, we explain the barriers that need to be overcome
to translate such a technology into the clinic.

5.1.2 Uptake and toxicity
One of the key features of the work presented here is the interaction between
nanoparticles and cells. Specifically, the interaction between monocytes and each gold
nanostructure investigated led to differing uptake and/or effects on monocyte
viability/function. The work explored different structures (i.e. free and polymer
nanosphere encapsulated AuNP), AuNP of differing sizes (15 to 150 nm) and a variety
of gold nanoparticle surface chemistries.
In the work presented in Chapter 3, the highest uptake values in the monocyte
cell line were seen with short chain carboxylic coated (11-mercaptoundecanoic acid, 11MUA; 16-mercaptohexadecanoic acid, 16-MHA) 15 nm AuNP and intermediate sized
AuNP (50, 75 nm) coated with a PEG carboxylic acid. Both the coating and size play a
role in the gold uptake of the monocytes. Chithrani et al. also reported a size
dependency of cellular AuNP uptake, with 50 nm particles being taken up to the greatest
extent. In that study, the AuNP were citrate coated and uptake was examined in HeLa
cells.1-2 Other studies have also shown intermediate sized (~50 nm) AuNP to have
highest cellular uptake.3 A number of studies have sought to explain this observation.
Jiang et al. and Chithrani et al. hypothesized that there is an optimal size for receptor
mediated uptake of nanoparticles.3-4 Receptor mediated uptake relies on binding of
surface receptors on the cell and then “wrapping” around the bound material through
invagination.5-6 These works hypothesized that, with receptor mediated endocytosis as
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the uptake route, particles (with surface adsorbed proteins) interact with surface
receptors of the cell. With activation of those surface receptors, the cells “wrap” around
the nanoparticle through invagination and internalize the particle. In this mechanism,
smaller nanoparticles (less than 40 nm), due to low surface ligand density, do not bind to
the cell surface for a long enough duration for this process to occur frequently.
Conversely, larger nanoparticles (less than 70 nm) bind efficiently, but their large size
presents challenges for the cell to wrap around the nanoparticle and therefore are not
taken up extensively. However, intermediate sized nanoparticles (i.e. around 50 nm)
have strong enough binding kinetics and their size allows for successful internalization.
This mechanism may explain the uptake profile seen with our differently sized
nanoparticles. Phagocytosis, the likely uptake route of AuNP in our study, operates in a
similar manner to receptor-mediated endocytosis, with binding of surface receptors and
invagination for internalization of the nanoparticle. Monocytes have a family of toll-like
receptors (TLR4, TLR2, TLR8) used to recognize foreign materials for phagocytosis.7 In
Chapter 3, AuNP above 25 nm in size and coated with 11-MUA aggregated severely in
serum-containing media. It is likely that 15 nm 11-MUA AuNP also aggregate in serumcontaining media to a certain extent, forming aggregates of an intermediate size that
allow for very high uptake. This may explain why coatings that minimize aggregation
such as the PEG-COOH coating result in high uptake at intermediate AuNP sizes, but
low uptake at small sizes.
In addition to the size of the nanoparticles, surface ligands also play a large role
in defining the biological interaction between nanoparticles and cells. Surface ligands
provide stability and a surface charge (neutral, positive, negative) to the particle
depending on the chemical groups of the ligand. Mammalian cells, due to the

203

phospholipid bi-layer, are typically negative in charge. Hence for cellular uptake,
research has focused on the use of positively charged coating for preferential
electrostatic interaction.8 However, some researchers have shown cellular uptake with
anionic nanoparticles to be greater than cationic nanoparticles in the same system. 9-11
This effect has been noted in greater frequency with phagocytic cells than nonphagocytic mammalian cells.12-13 While intuitively, negatively charged nanoparticles
should be repulsed by negatively charged cell membranes, researchers have shown that
the adsorption of serum proteins onto the surface of the membrane drastically affects the
interaction between the cell and nanoparticle.14 In the 2006 study by Chithrani et al.,
after incubation in serum, negatively charged AuNP were found to contain amine groups
through Fourier transform infrared spectroscopy.2 The authors attribute this finding to the
amine groups contained in amino acids. Ritz el al. took a further step by identifying the
serum proteins that adhered to polystyrene (PS) nanoparticles functionalized with
different chemical groups.15 The study evaluated a variety of surface coatings including
carboxylic acids (PS-COOH), amine (PS-NH2), or sulfates (PS-SO3), with each
nanoparticle approximately 100 nm in diameter. Apolipoproteins were found to adsorb
onto all of these nanoparticles, however some proteins were found to significantly
adsorb to specific formulations. For PS-COOH nanoparticles (carboxylic functional
group), a significant increase in the presence of apolipoprotein-H was shown to increase
the uptake of these particles with human mesenchymal stem cells. Our work presented
here found highest uptake with carboxylic acid coated AuNP. Adsorption of serum
proteins that aid in uptake in combination with the optimal size for uptake may explain
why the highest uptake in monocytes were seen with those specific formulations.
Examination of the composition of the protein corona of these nanoparticles and
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consequent determination of their mechanism of uptake could be the topic of future
work.
In the work presented here, some AuNP formulations exhibited cytotoxic effects
at high concentrations. A number of studies have sought to elucidate the mechanisms
behind the toxicities of various AuNP formulations since gold is typically described as
bio-inert. The generation of reactive oxygen species (ROS) has previously been shown
to be responsible for the observed cytotoxicity with nanoparticles.16-17 A study by Chuang
et al., investigated the cytotoxicity of citrate capped gold nanorods (10 x 39 nm, 10 x 41
nm, 10 x 45 nm) at different concentrations in multiple mammalian cell lines. 18 The group
found different mechanisms of cytotoxicity based on the cell type. For instance, these
gold nanorods delayed the cell cycle for lung epithelial (A549) cells but induced
apoptosis in gastric adenocarcinoma cells (AGS). These gold nanorods also increased
the generation of ROS in AGS cells. However, the authors suggested that the observed
increase in ROS did not induce apoptosis due to low response of anti-oxidative proteins.
Another study utilizing 20 nm carboxyl-polysytrene particles demonstrated that negative
nanoparticles were able to induce apoptosis and necrosis in the absence of reactive
oxygen species.19 A study by Chueh et al. also demonstrated that cytotoxicity of AuNP
(citrate capped nanorods, 10 x 40 nm) may be dependent on the cell type. 20 After
incubation with AuNP, kidney epithelial cells were found to undergo apoptosis mediated
through inhibition of enzyme activity. In lung fibroblasts, arrestment of cell cycle and
damage to DNA mechanisms were likely causes of cytotoxicity. Embryonic fibroblasts
were found to undergo autophagy, a form of programmed cell death. Other studies have
reported different mechanisms of cytotoxicity in the presence of AuNP in other cell
systems.21-23

205

In this thesis, monocyte toxicity was observed with AuNP into loaded PCPP
nanospheres (Chapter 2), large AuNP (Chapter 3), and PEI coated AuNP (Chapter 4).
Taking into account the studies mentioned above, toxicity in instances of high uptake of
AuNP may be due to arrest of cell cycle leading to apoptosis. Therefore, the toxicity we
observed with AuNP loaded PCPP nanospheres and large AuNP may be due to this
reason. More studies evaluating apoptosis with those formulations would be necessary
to confirm this hypothesis. However, toxicity with PEI coated AuNP are likely due to the
positively charged amine groups on the PEI coating. Previous reports have indicated
that the high positive charge of PEI can cause toxicity at even low concentrations.24-25

5.1.3 Increasing sensitivity of monocyte detection
In this thesis, we systemically delivered gold labeled monocytes and after 5 days
were able to detect a significant increase in CT attenuation in the region of the aorta.
This increase was attributed to the migration of gold labeled monocytes from circulation
to the plaque. Ex-vivo sectioning and transmission electron microscopy of the plaque
revealed the presence of gold labeled cells. The change in attenuation over 5 days was
15.3 HU on average. This value is comparable to in vivo detection with CT contrast
agents seen in other studies.26-27 However, to be able to detect the effects of genes or
drugs on modulating monocyte recruitment would likely necessitate higher changes in
attenuation.
In Chapter 4, in vivo experiments were carried out using 1 x 106 labeled primary
monocytes that were injected intravenously. Increasing the number of gold labeled cells
for delivery may be an avenue to increase the amount of monocytes recruited to the
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plaques. In preliminary studies, we trialed a 5-fold (5 x 106) delivery of gold labeled
monocytes to apolipoprotein deficient (ApoE -/-) mice on a western diet for 10 weeks
(AtT). The control groups were wild type mice injected with gold labeled monocytes
(WdT) and atherosclerotic mice injected with non-labeled monocytes (AtN). Similar to
the experiment in Chapter 4, the mice were CT scanned at 3, 4, and 5 days post
injection. The results in Figure 5.1a show an attenuation change of 33.6 HU for the AtT
group which was found to be significant (p <.002). Therefore, a significant increase in CT
attenuation was achievable with an increase in the number of delivered gold labeled
monocytes. The CT attenuation for atherosclerotic mice receiving 5 x 106 compared to
receiving 1 x106 gold labeled monoyctes were also found to be significant. The
biodistribution of this dose of gold labeled monocytes was similar 1 x 106 monocytes,
with high accumulation of gold per tissue weight in the spleen (Figure 5.1b). However,
mice have approximately 1 x 106 monocytes in blood circulation and the delivery of 5 x
106 monocytes may have unintended biological consequences that would require further
evaluation.
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Figure 5.1 Changes in aorta attenuation and biodistribution arising from injections of 5 x
106 AuNP labeled monocytes.
Atherosclerotic mice defined as ApoE-/- mice kept on western diet for 10 weeks. (a)
Atherosclerotic mice receiving gold labeled monocytes (AtT, n=4) show higher
attenuation in aortic plaques after 5 days as compared to wild-type mice receiving gold
labeled monocytes (WdT, n=3) and atherosclerotic mice receiving non-labeled
monocytes (AtN, n=3). (b) Biodistribution of gold labeled monocytes in organs.

Another approach to increase the CT attenuation in the scans is to increase the
number of recruited gold labeled monocytes to the plaques. In the current study, primary
monocytes were isolated based on the surface marker CD11b, a conserved monocyte
marker for all monocyte subtypes.28 As mentioned in Chapter 1, there are two distinct
monocyte populations conserved across species. In humans, classical “inflammatory”
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monocytes are described by the presence of CD14+ CD16- CCR2+ CX3CR1- surface
markers.29 These monocytes have phagocytic properties and known to migrate from the
circulation to inflamed tissue. The other “resident” monocyte is identified by CD14CD16+ CCR2- CX3CR1+ surface markers and participate more frequently in wound
healing.30 In mice, inflammatory monocytes can be identified by Ly6C+ and resident
monocytes by Ly6C- markers.31 In our studies, primary monocytes were isolated from
spleens of donor mice. Swirski et al. analyzed the population of monocytes in the spleen,
indicating that nearly 50% of the monocytes in the spleen were Ly6C+.32 By further
purifying primary monocytes for the Ly6C+ marker, we could isolate inflammatory
monocytes for gold labeling. Injecting only inflammatory monocytes may increase the
amount of gold labeled monocytes recruited to atherosclerotic plaques.
In addition to experimental changes, advances in CT technology are likely to
improve the detection of gold labeled monocytes for atherosclerosis. Photon-counting
CT presents the opportunity to use the k-edge of gold to improve detection of gold
labeled cells.33 This may also allow for better delineation between surrounding soft
tissue and gold labeled cells in CT scans.34-35 Advances in reconstruction methods are
also likely to improve detection of gold labeled cells with improved signal to noise (SNR)
in CT images. The development of iterative reconstruction methods have shown
improved SNR as compared to traditional back filtered projection algorithms.36 Iterative
reconstruction may also improve detection of contrast agents in CT scans. 37 Together,
the advances in CT technology are likely to improve the technology of cell tracking with
CT.

209

5.1.4 Modulation of monocyte recruitment
With improvement to the detection of monocytes in vivo, we hypothesize that the
technique can be used to both further assess mechanisms behind monocyte recruitment
and therapies aimed at decreasing monocyte recruitment. As described in Chapter 1,
monocytes play a crucial role in the progression of atherosclerosis through continued
recruitment to developing plaques. Monocyte recruitment involves a number of
processes including increased expression of adhesion molecules on endothelial cells
and chemokine gradients for transmigration. In the intima, monocytes differentiate in
macrophages and then foam cells, leading to the production of enzymes and cytokines
that promote plaque rupture. Due to the pivotal roles of monocytes and macrophages in
plaque progression, there has been significant interest in developing therapies that
target their recruitment and atherogenic functions.
In mice, a number of studies have sought to examine the impact of plaque
burden after the knocking down or therapeutically reducing the expression of key cell
adhesion molecules (VCAM, ICAM, P-selectin).38-41 For instance, Cybulsky et al.
generated an VCAM-1 knockdown mice model to evaluate plaque formation.42 The
group observed a significant decrease in plaque formation in the whole aorta and arch
(lesion area decreased by 31% and 45%, respectively) as compared mice expressing
VCAM-1. The group also noted an increase in overall circulating leukocytes, including
increased levels of circulating blood monocytes as compared to controls. Taken
together, the authors suggested that increased blood monocytes indicate less lesional
migration and therefore less plaque progression. With the development of cell tracking
for monocytes, the study may have been able to confirm and quantify the reduction of
monocyte recruitment in VCAM-1 knockdown mice. Interestingly in the study, the
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authors show that knock down of both ICAM-1 and VCAM-1 produced similar reductions
of plaque size to VCAM-1 knockdown alone. With comparing the significance of ICAM-1
versus VCAM-1 in plaque formation, the ability to quantify monocyte recruitment to
plaques in each case could help elucidate the importance of each.
With the success of VCAM-1 inhibition seen in mice, researchers have explored
VCAM inhibitors as possible therapeutics for coronary artery disease.43-44 Specifically,
groups have shown that natural antioxidants are able to inhibit VCAM-1 expression.43
The anti-oxidant Succinobucol (AGI-1067) was investigated in a double-blind placebo
trial for patients with acute coronary syndrome.45 In the study, 6144 patients with either a
recent myocardial infarction or unstable angina were split into Succinobucol receiving
and placebo groups. However, no significant improvements were identified in the
primary endpoints of severe cardiovascular events including death over 2 years. We
believe that cell tracking techniques such as those demonstrated in this thesis could
quickly determine the effectiveness of proposed drugs. In this study, monitoring
monocyte migration over time in vivo may have demonstrated the drug’s effectiveness or
non-effectiveness on monocyte recruitment to plaques as a VCAM-1 inhibitor before
launching a lengthy and costly primary outcome study.
Researchers continue to probe stages of monocyte recruitment to plaques as a
possible therapeutic target for atherosclerosis. A number of pre-clinical studies have
demonstrated the reduction of plaque formation in decreased expression of chemokine
receptors responsible for monocyte migration through plaques (CCR2, CX3CR1,
CCR5).46-49 Similarly, clinical trials have explored inhibitors of these chemokine receptors
as potential targets for plaque development. In a study with 243 patients, groups
received either MLN1202 (monoclonal anti-body inhibitor of CCR2 binding to MCP-1) or
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placebo.50 The study showed reduced concentrations of serum C-reactive protein in the
serum for treatment groups. C-reactive protein is a marker of inflammation and is
positively correlated to the progression of atherosclerosis. The study also found a
decrease in circulating monocytes with administration of MLN1202. The authors suggest
reduced emigration of monocytes from the bone marrow as the cause of this result but
no confirmatory data is shown. However, with real time monocyte tracking, the authors
would be able to confirm their hypothesis and possibility determine if MLN1202 reduces
monocyte recruitment to plaques.
In the monocyte recruitment pathway, additional potential targets continue to
emerge as areas of interest. Studies have explored the effects of inhibiting
transmigration targets such as junctional adhesion molecules (JAM-A) and connexins.5153

Monocyte-platelet interactions and macrophage migration inhibitory factor have also

been explored as possible drug targets.54-57 These studies aim to interfere with the
monocyte recruitment process, but not directly observe or quantify monocyte
recruitment. The monocyte cell tracking tool demonstrated in this thesis could enhance
similar studies in the future via observation of monocyte localization and migration.

5.1.5 Barriers to translation
Cell tracking presents an opportunity to observe cell migration in a variety of cell
based therapies. Currently, the state of cell tracking tools remains investigative with the
technology under development in a breadth of applications.58 While our technology of
monocyte cell tracking with CT is in the early stages of preclinical examination, the
capacity of translation into a clinical tool stands as a possibility. As mentioned in this
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chapter, monocyte cell tracking could be used to assess mechanisms of monocyte
recruitment or evaluate novel therapeutics targeting the recruitment pathway. In the work
presented, we demonstrated the feasibility of isolating monocytes with high purity from
donor animals. The cells were labeled with AuNP ex-vivo and delivered intravenously to
atherosclerotic mice. The mice were then scanned with a preclinical CT scanner and
monocytes localized to the plaques in the aorta were visualized. With the advances in
clinical CT scanners and clinical cell transfer technologies, adapting our work with
monocyte cell tracking to a clinical setting is a possibility.
In our studies, murine atherosclerotic plaques were visualized within the aorta
using a pre-clinical scanner at 80 kVp and reconstructed at 100 µm spatial resolution
(isotropic voxel). Modern clinical scanners are capable of spatial resolutions between
350 and 500 µm.59 For translation of our technology, monocyte recruitment would likely
be observed for plaque burden in the human coronary arteries. Current CT scanners are
capable of resolving the coronary arteries and assessing plaque burden, therefore
spatial detection of gold labeled cells in the human coronary arteries appears feasible.
Additionally, clinical CT scanners are capable operating at higher energies (100 kV, 120
kV, 140 kV), which would result in greater contrast since gold’s k-edge (80 keV) is within
those spectra, and likely improving detection of gold labeled cells with clinical CT
scanners.60
In a study by Dey et al., the plaque burden in the human coronary arteries were
quantified in patients with stable plaques and acute coronary syndrome.45 Plaque
volume was similar in both groups, 332.8 vs 334.3 mm3, respectively. For comparison,
the average volume of plaques measured in mouse aortas was 107.1 mm3 based on
estimations from our CT scans. In our mice, the average change in attenuation in the
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plaque was 15.3 HU. From our in vitro cell dispersions from Chapter 4, we correlated
this attenuation to approximately 15 cells/voxel (0.1 mm isotropic voxel). With
approximation of plaque size in the mice (107.1 mm3), we estimate that a change of 15.3
HU correlates to 1.07 x 103 gold labeled monocytes in the plaque. Theoretically for
human coronary plaques, a similar change in attenuation measurement would require
recruitment of 3.32 x 103 gold labeled monocytes based on coronary plaque volume
(332.8 mm3).
A significant barrier in the translation of this technology would be the isolation of
monocytes from the patient for labeling. In our study, 1.0 x 106 gold labeled monocytes
were delivered intravenously and localized to aortic plaques in mice. In mice,
approximately 1.0 x 106 monocytes are present in circulation.61 In humans, the number of
circulating monocytes range from 1.0 to 5.0 x 109 cells.62 For similar ratios as our mice
experiments, a cell delivery of 1.0 x 109 gold labeled monocytes may prove challenging.
However, with recent advancements in cell therapeutics, isolating and purifying this
magnitude of cells (109) has been demonstrated.63-64 Currently, dendritic cells are being
explored as clinical cell treatments for a number of diseases including cancer.65-67 The
process of acquiring dendritic cells for cell therapy begins with the isolation of monocytes
from patients through a process of leukapheresis.68-69 This process involves collecting
blood continuously, filtering out desired cells, and returning the remaining constituents to
the patient. Recent technology developments utilizing elutriation for purification have
yielded 109 monocytes in highly purified populations.70 The technologies show that
acquiring monocytes from patients for ex-vivo labeling is achievable.
After acquiring cells from the patient, the process of ex-vivo labeling with AuNP
could face challenges involving the cost of gold and scaled up manufacturing. For our
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current labeling experiments, we used a ratio of 0.5 mg of AuNP for 1 x 106 cells (0.5
mg:1 million cells). To label 1.0 x 109 cells under the same conditions, 500 mg of AuNP
would be required. Previously in our lab, we have synthesized large batches of AuNP
through the Turkevich method (1280 mg gold chloride trihydrate, HAuCl4). With 20%
efficiency from HAuCl4 to purified and capped AuNP, we can achieve approximately 250
mg of AuNP in a single batch. However, each batch requires 3 days to complete. As of
this writing, the cost of HAuCl4 is $1600 USD for 25 g (Gold(III) chloride trihydrate,
G4022-25G, Sigma-Aldrich, St. Louis, MO). Therefore, synthesis of AuNP for labeling of
1 x 109 cells, would require HAuCl4 costing approximately $160 and 6 days to complete.
These estimations are with the current procedures that would likely be refined for large
scale manufacturing as a clinical tool. The process of ex-vivo labeling with AuNP for
translation into the clinic appears feasible with these estimations.
With the current state of the CT scanners and technologies involved with
adoptive cell therapies, our technology appears to be translatable into clinical tool.
However, currently the cost and technical difficulty of the clinical procedures list above
constrain the realistic translational of our technology into a clinical tool. These
procedures continue to be reserved for experimental adoptive cell treatments and
determining their efficacy i.e. T-CAR cell immuno-therapy and dendritic cell vaccines.
With continued research and advancement, there may be a time where utility of
monocyte cell tracking to investigate the efficacy of atherosclerotic drugs outweigh the
challenges of these clinical procedures.
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5.2 Future directions
5.2.1 Overview
The ability to track the location and migration of cells in vivo is an emerging tool
of need, providing valuable information in the study of disease mechanisms and
assessment of treatment effectiveness. In our work, the successful tracking of
monocytes with CT opens a number of opportunities to not only study monocyte
behavior, but the possibility of additional cells in different applications. Here I discuss
future directions of the work and potential avenues for future projects. I will describe the
potential use of monocyte tracking to study their role in myocardial infarction wound
healing. I will examine alternative labeling strategies for monocytes and the potential
applications for these approaches. Additionally, I discuss other cell types that would be
interesting to track in atherosclerosis. Finally, I discuss the potential use of AuNP to
track other cell types in other disease applications.

5.2.2 Myocardial infarction
Monocytes have several functional roles in the progression of coronary artery
disease. In this thesis, we explored tracking the recruitment of monocytes to developing
plaques. In addition, monocytes play a large role in wound healing after a myocardial
infarct. Immediately following the infarct, monocytes are recruited from the circulation to
the injured tissue. Evidence has shown that this recruitment period for wound healing
consists of two overlapping phases.71 The first phase is dominated by the recruitment of
an inflammatory monocyte subset for phagocytosis and clearing of necrotic tissue,
lasting for 1-4 days post infarction. From day 4 onwards, the anti-inflammatory monocyte
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subset or “residential” monocytes are most present in the infarct. These monocytes are
necessary for wound healing and tissue repair. This phenomenon was demonstrated in
mice by Nahrendorf et al. with Ly-6c+ and Ly-6c- monocyte subsets.72 The authors
suggest that this bi-phasic recruitment of monocytes is due to shifts in chemokine
expression in the infarct tissue that favor each monocyte subtype at different times. The
release of MCP-1 (CCR ligand) promotes Ly-6c+ monocyte recruitment initially and a
subsequent shift to fractalkine (CX3CR1 ligand) release promotes Ly-6c- monocyte
recruitment. This bi-phasic monocyte recruitment has also been studied in human
myocardial

infarcts

with

CD14++CD16-

(inflammatory)

and

CD14+CD16+ (anti-

inflammatory) monocytes subsets. The recruitment of monocytes in both phases are
critical to proper wound healing as studies with increased inflammatory monocyte
recruitment have shown poorer outcomes in left ventricular remodeling.73-75 In our work,
the development of monocyte cell tracking can be directly applied to studying monocyte
recruitment after a myocardial infarction. There has been continued interest in
developing cell tracking methods for cell therapy for myocardial infarction.76
In preliminary studies, we labeled primary monocytes with AuNP via ex-vivo
incubation for 24 hours. Afterwards these cells were directly injected into the infarct
region of mice post myocardial infarction. After 5 days, the hearts were excised and
scanned with a microCT scanner. The results in Figure 5.2 show localized high CT
attenuation areas in the infarct region indicating the persistence of gold labeled
monocytes in the region. Further experiments could demonstrate the migratory process
of gold labeled monocytes to infarct regions after intravenous delivery. With this
development, monocyte tracking could potentially be used to study therapies that
modulate monocyte recruitment and may alter wound healing outcomes in the infarct.
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Figure 5.2 Gold labeled monocytes in myocardial infarct.
Monocytes were labeled with AuNP and directly injected into infarct region. Heart was
excised 5 days post-injection and scanned with CT.

5.2.3 In-situ spleen labeling
In our studies, cells are isolated from the spleens of donor mice and labeled with
AuNP ex-vivo. As mentioned, ex-vivo labeling remains a strategy that may procedurally
translate clinically for adoptive cell therapies. However, this procedure requires the
isolation of cells before labeling which can be technically challenging. A cell tracking
agent that could label specific cells in-situ would be advantageous.
For monocyte labeling, we observed the high trafficking of AuNP to the spleen
after intravenous delivery. The spleen has been shown as a major reservoir for
monocytes containing as much as 50% of the total monocyte population.32,

77
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monocytes are held in the red pulp with arterial access in the spleen. Studies have
demonstrated that upon significant injury, monocytes in the spleen are deployed into
circulation to address the wound.78-79 A study by van der Laan et al., studied the
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recruitment of monocytes after myocardial infarction in humans. 80 The group found an
abundance of CD14+CD16- cells (markers for inflammatory monocytes) in the border
zone during the inflammatory recruitment phase. During this inflammatory phase (>3 day
post infarct), the authors also found a decrease in CD14+ cells in the spleen and an
increase in the blood circulation. Taken together, the results suggest that early after a
myocardial infarction, monocytes are released into circulation and are recruited into the
surrounding infarct region for repair.
We hypothesis a cell tracking method could be developed to label monocytes in
the spleen before deployment to sites of inflammation. In preliminary studies, we
intravenously injected AuNP coated with methoxy-poly(ethylene glycol) (AuNP-MPEG,
250 mg/kg) into wild type mice. The mice were scanned with CT over 48 hours after
which they were dissected for biodistribution afterwards. The spleen was excised and
monocytes were purified through magnetic labeling for CD11b similar to methods in
Chapter 4. The monocytes were collected and ICP-OES was run to determine if AuNP
were present in the isolated monocyte fraction.
In Figure 5.3a, CT images are shown of the abdomen and thorax acquired over a
48 hour period pre- and post-injection of AuNP. There is a significant increase in
attenuation in the spleen over this time period. The scans also show initial increases in
attenuation in the vasculature and heart, reflection the presence of the AuNP in the
circulation. After 48 hours, the attenuation in the spleen remained high, indicating AuNP
accumulation. This organ was excised and monocytes were isolated. We found higher
gold uptake in the enriched monocyte population, as compared to the discarded cell
fraction (Figure 5.3b). This indicates that AuNP from intravenous injection were taken up
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by monocytes in the spleen. Figure 5.3c shows the biodistribution after 48 hours with
AuNP taken up to the greatest extent by the liver.
The uptake of AuNP in our purified monocyte population indicates that labeling of
monocytes in the spleen may be achievable. However, the uptake of approximately 4
pg/cell is considerably less than our ex-vivo labeling uptake values of 126 pg/cell.
Further experiments on different AuNP formulations may be explored to improve uptake
for the monocytes in the spleen. In this study, mPEG was used to provide long
circulation for the AuNP; however mPEG is well known to minimize cell uptake, which
may have contributed to low monocyte uptake values. Eventually, with adequate uptake
in monocytes for detection, we envision pre-labeling monocytes in the spleen.
Afterwards, we expect a significant injury leading to a strong inflammatory response will
allow for detection of monocytes migrating from the spleen to the site of injury, as in the
case of myocardial infarction. This cell tracking approach would open opportunities in
studying monocyte response to various inflammation reactions, including the timing and
magnitude of monocyte responses.
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Figure 5.3 In-situ labeling of monocytes in the spleen.
Wild-type mice received intravenous injections of AuNP-mPEG (250 mg/kg). (a) CT
scans of mice pre-injection, 5 minutes, 60 minutes, 4 hours, 24 hours, and 48 hours post
injection. Red arrows indicate the location of spleen. (b) ICP-OES quantification of gold
uptake in monocyte enriched populations versus discarded cell populations. (c)
Biodistribution of AuNP-mPEG after 48 hours.

5.2.4 Alternative cell tracking for atherosclerosis
In our work, we focused on the role of monocytes in the progression of
atherosclerosis. While monocyte recruitment contributes significantly to plaque
progression, it is only one part of the inflammation story in atherosclerosis. A number of
different cells, especially other leukocytes including neutrophils, dendritic cells, platelets
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and T-cells, have been found contribute to plaque progression due to their association
with inflammation.81-82 Similar to monocytes, the increase in expression of cellular
adhesion molecules on endothelial cells promotes the adherence and extravasation of
leukocytes into the vessel wall. The work with monocyte tracking with CT could be
expanded to other cells playing a role in atherosclerosis.
Neutrophils are essential to the innate immune system and typically are the
“first responders” to acute injury sites. More recently, the role of neutrophils in chronic
diseases have attracted attention due their ability to release a number of different cell
modulators including various cytokines.83-84 In atherosclerosis, neutrophil adherence and
rolling relies on several chemokine receptors on their surface including CCR2, CXCR2
and CCR5.85-86 Recent studies have shown that neutrophils play a role in recruiting
monocytes to atherosclerotic lesions. In Cramp (neutrophil secreted protein) deficient
mice, a reduction of early plaque formation was observed due to reduced monocytes
recruitment.87 Other neutrophil secreted factors including cathepsin G and α-defensins
also have shown to play role in driving monocyte recruitment into plaques.88-90
Neutrophils have also demonstrated compounding effects to atherosclerosis progression
including increasing endothelial dysfunction at plaque prone sites and promoting foam
cell formation of lesional macrophages.91-92 Neutrophils represent a possible candidate
for CT cell tracking to allow further elucidation of their role in plaque progression.
Along with monocytes, T-cells undergo recruitment to developing plaques
through adherence to VCAM-1 and migration through CX3CR1 cell surface marker.81 In
the plaque, with exposure to abundant low density lipids, T-cells differentiate into T-1
helper cells (TH1).93 TH1 cells have been shown to be atherogenic with release of proinflammatory cytokines including interferon-γ (IFN-γ), interleukin-12, and interleukin-
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18.94-96 Particularly, the release of IFN-γ can exacerbate plaque instability by further
amplifying macrophage/foam cell release of degradation enzymes and proteases.97-98
Also found in lesions were the presence of T-2 helper cells (TH2) and T-17 helper cells
(TH17). However, the atherogenic or atheroprotective roles of these cells remain
unclear.99 More recently, the role of T-regulatory (Treg) cells have become a point of
investigation in atherosclerosis due to their auto-immunity protective properties. Treg cells
have been found to have several functions in atherosclerosis including inhibiting foam
cell formation, inhibiting macrophage activation, and inhibiting atherogenic properties of
TH1 cells.100-103 The effects of Treg cells are mostly accomplished through the release of
anti-inflammatory cytokines, interleukin-10 and transforming growth factor-β.104-105
Inhibition of these cytokines has shown accelerated plaque progression. 106-107
Interestingly, Treg cells are found in low concentrations in plaques as compared to other
inflammatory diseases, implying a suppression of their presence under atherosclerotic
disease conditions.108-109 Therefore, there is considerable interest in utilizing T reg cells as
a potential cell therapy for atherosclerosis.110-111 Studies enhancing migration of Treg cells
to atherosclerosis may greatly benefit from similar cell tracking tools developed in our
work. Cell tracking may also help further elucidate the effects of T-helper cells by altering
their plaque migratory properties.

5.2.5 Alternative CT cell tracking applications
X-ray computed tomography with high spatial and temporal resolution allows for
imaging of the human coronary arteries and is therefore a preferred choice in developing
cell tracking tools for the study of atherosclerosis. However, with advances in photon
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counting CT, especially in material decomposition, the utility of cell tracking can be
further expanded.
In a collaboration with Marlène Wiart from the Center for National Research
(Lyon, France), we are exploring the use of our AuNP to track macrophages in the
treatment of stroke. The work entails utilizing a gadolinium labeled scaffold to deliver
AuNP labeled macrophages to the site of injury. The use of photon-counting CT allows
for the discrimination between gold labeled macrophages and the gadolinium scaffold.
This could provide information on cell migration from the scaffold to injured areas. While
studies are still preliminary, the successful labeling of macrophages and their detection
with photon-counting CT have been demonstrated (Figure 5.4).

Figure 5.4 Gold labeling of macrophages for stroke cell therapies.
(a) Labeling of primary macrophages with AuNP. (b) Detection of gold labeling
macrophages using single photon counting CT. 3D overlay of gold specific image
(yellow) on a conventional CT image (greyscale) with an injection of AuNP labeled
macrophages in the brain

5.3 Concluding remarks
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The work of monocyte cell tracking for CT, the improvement of labeling
techniques has the opportunity for this tool to be utilized to study atherosclerotic
mechanisms and therapies. The work reported in this thesis is the initial steps in using
CT cell tracking to study monocyte recruitment. Overall, I think this work is a significant
development in the use of CT as a cell tracking method, which has been relatively
unexplored compared to MRI and PET. Few studies have reported the use of CT for cell
tracking, but with rapidly improving CT technology, I believe that this field will grow,
especially with the use of photon counting CT and material decomposition. With further
research, I envisage that cell tracking will emerge as a valuable tool for the development
and implementation of clinical cell therapies.
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